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ii 
Abstract 
 
Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that is upregulated 
in a variety of human cancers. While there is evidence that FAK is implicated in 
a wide range of crucial cellular processes that are perturbed in malignancy 
including proliferation, cell cycle, adhesion and invasion, there is limited 
information regarding the role of FAK in radiation survival. We aimed to evaluate 
whether FAK is a novel radiosensitising target by studying clonogenicity in wt 
p53 FAK +/+ versus FAK -/- squamous cell carcinoma (SCC) cell lines generated 
in this laboratory. Surprisingly, the absence of FAK was associated with 
increased radioresistance. In this particular context, FAK indirectly inhibits p53 
mediated transcriptional regulation of p21 in response to ionising radiation. Why 
FAK should repress the pro-survival function of p53 is unclear, but this data 
indicates that inhibition of FAK in combination with radiation may not always be 
advantageous in the clinical setting and contributes to an increasing body of 
literature highlighting a close interaction between FAK and p53. 
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Chapter 1  2 
1 Introduction 
1.1 Radiotherapy in cancer management 
1.1.1 History of radiotherapy 
Radiotherapy, the medical application of ionising radiation, has been in clinical 
use for over a century, since the discovery of x-rays in 1895 (Rontgen 1895). The 
rapid development of normal tissue injuries in the first generation of scientists 
exposed to x-rays suggested that this form of radiation could have deleterious 
effects at the cellular level and prompted interest in manipulating this novel 
form of radiation in order to treat malignant lesions. Initial attempts at 
radiotherapy were extremely limited by the rather primitive nature of early x-
ray generators, which produced radiation that varied in energy and intensity, 
making reproducible administration of radiation impossible. Moreover, the low x-
ray energies available limited radiotherapy to the treatment of superficial 
lesions and the low dose rates necessitated protracted treatments. Anecdotal 
reports of cancer patients successfully treated with radiation began to emerge, 
however, and were sufficient to encourage development of the modality, but 
the limitations of the technology precluded routinely curative therapy.  
The field began to grow significantly in the early 1900s, largely due to Marie 
Curie and her groundbreaking work on the radioactive elements radium and 
polonium. Radium, in particular, was utilised in various forms for several 
decades until cobalt (60Co) and caesium (137Cs) units came into use. This method 
of radiotherapy delivery was relatively reliable and the machinery simple to 
maintain. However, the advent of megavoltage linear accelerators, which 
generate high energy therapeutic x-rays, in the 1950s, revolutionised 
radiotherapy treatment.  By obviating the need for an external radioactive 
source, treatment was much safer for both patient and medical staff.  This 
means of therapy also allowed a much higher and better directed radiation dose. 
Clinical (or radiation) oncology then rapidly evolved as a separate medical 
specialty.  
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1.1.2 Applications of radiotherapy 
Although radiotherapy can be useful in certain benign conditions, such as 
dysthyroid eye disease or pituitary adenomas, its predominant application is in 
the management of cancer and it has been estimated that 50% of all cancer 
patients will receive radiotherapy at some point in their care 
(http://info.cancerresearchuk.org/cancerstats/). While radiation undoubtedly 
has a major role in the palliation of cancer symptoms, for example the 
treatment of painful bone metastases, it also has a valuable role as an adjunct 
before or after surgery. Most importantly, radiotherapy can be used as first line 
management with radical (curative) intent, alone or in combination with 
chemotherapy, in a range of solid tumours, particularly cancers of the head and 
neck, cervix, prostate, and lung. 
1.1.3 Delivery of radiotherapy 
Radiotherapy can be administered by several routes: external beam radiotherapy 
(which usually implies the use of x-rays or γ-rays from a megavoltage unit); 
brachytherapy (use of a sealed radioactive source); and systemic radioisotope 
therapy (use of an unsealed radioactive source). The specific type of 
radiotherapy selected largely depends on tumour type and location. 
Brachytherapy, for example, can be very useful in the management of intra-
cavitary or intra-luminal malignancies whereas systemic radioisotope therapy 
may provide symptomatic relief in patients with disseminated bone metastases. 
External beam radiotherapy is the most commonly applied form of radiation 
treatment and unless otherwise specified the term radiotherapy refers to this 
form of treatment.  
Radiotherapy treatment requires careful planning in order to ensure not only 
adequate tumour coverage and dose, but also to minimise toxicity to normal 
tissue. Currently, most centres in the UK employ computed tomography (CT) 
based planning where the patient is simulated in the treatment position, which 
usually requires some form of immobilisation so that the same position can be 
maintained during the entire course of treatment.  
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The target volume is then delineated on the CT-acquired images, first taking 
into account visible macroscopic disease, which is referred to as the gross 
tumour volume (GTV).  A margin of normal tissue must be added to this volume 
to allow for subclinical tumour spread that is not visible on diagnostic imaging; 
this is known as the clinical target volume (CTV). Finally, a further margin is 
required to compensate for potential movements relating to respiration and/or 
digestion. Also, despite careful immobilisation, small errors in patient set-up are 
likely to occur from day to day, usually no more than a few millimetres, but this 
must be taken into account.  
The resultant planning target volume (PTV) can then be taken forward to beam 
direction and dose distribution studies. This is generally performed on dedicated 
computers using specialised planning software, and input is required from 
trained medicial physicists and dosimetrists. Depending on the radiation delivery 
method and target volume, it is likely that several x-ray beams will be required 
to deliver a uniform prescription dose to the tumour bed and minimise dose to 
surrounding healthy tissues.  The clinical oncologist must ensure that the 
delivery parameters of a prescibed dose are satisfactory and, where practicable, 
minimise the irradiation of critical structures, such as the spinal cord. Examples  
of planning target volumes and a dose distribution profile are shown in Figure 1 
and Figure 2, respectively. 
The amount of radiation used in radiation therapy is measured in gray (Gy), and 
varies depending on both the type and stage of cancer being treated. While 
lymphoma can be effectively treated with just 20 to 40 Gy, the radical dose 
required for a solid epithelial tumor ranges from 55 to 80 Gy. The total dose is 
fractionated, typically 2Gy per day, which means that a course of treatment is 
extended over a number of weeks.  One of the most important reasons for 
fractionation is that it allows normal cells time to recover between radiation 
doses. In some cancer types, however, prolongation of the treatment schedule 
over too long a period of time can permit repopulation of cancer cells, and for 
these tumour types, including squamous cell carcinomas of the head and neck 
and cervix, radiation treatment is preferably completed within a limited time 
frame. 
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Figure 1 - Delineation of radiotherapy target volumes 
The visible tumour or gross tumour volume (GTV) seen on diagnostic imaging is marked in yellow. 
A margin is added to allow for sub-clinical tumour spread into surrounding tissue (orange). These 
combined areas are known as the clinical target volume (CTV). Finally, a margin is applied to allow 
for day to day set-up errors and organ motion (red). Beams can then be directed at the resultant 
planning target volume (PTV). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 - Radiotherapy dose distribution profile 
The image depicted above represents the dose distribution profile for a patient being treated with 
radical radiotherapy for prostate cancer. Five beams are directed at the pelvis to encompass the 
PTV (shown in red). Ideally this area should receive 95-104% of the prescribed dose. Surrounding 
tissues receive a fall-off dose (green – blue) which reduces as distance from the target volume 
increases.   
visible tumourvisible tumour
(GTV)
CTV
PTV
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1.1.4 Radiotherapy related toxicity 
The majority of patients will experience some toxicity during radiotherapy 
treatment; this varies depending on the applied dose and area of treatment. In 
general, most of the acute effects are manifested in rapidly dividing epithelial 
tissues and can range from erythema to moist desquamation in the skin and 
mucous membranes, or diarrhoea if the gut is in the radiation field. These 
symptoms usually settle rapidly following treatment, often within a few weeks. 
More concerning is the potential for radiation to induce late effects in normal 
tissue. This is largely due to damage to connective tissue and small blood vessels 
and can result not only in cosmetic effects due to fibrosis, but also more 
problematic sequelae such as ulceration, fistula formation, and organ 
dysfunction. With modern planning techniques, it is possible to minimise but not 
eliminate the likelihood of these late effects and much of this is dependent on 
the size and position of the tumour. 
It is clear that some individuals are more susceptible to normal tissue damage.  
One of the reasons for this is the tendency to mount an excessive inflammatory 
response. Ionising radiation triggers the production of inflammatory cytokines in 
a number of cell types, such as macrophages, epithelial cells, and fibroblasts. 
This contributes to increased collagen production and the development of 
fibrosis. In some cases, the inflammatory reaction is more pronounced, leading 
to the expression and maintenance of a perpetual cytokine cascade, and 
ultimately increasing the severity of the late reaction. Transforming growth 
factor-beta-1 (TGF-β1) is one such cytokine that has been implicated in 
mediating radiation related fibrosis (Anscher, Kong et al. 1997; Anscher, Marks 
et al. 2001). It is likely that the regulation of cytokines, including TGF-β1, in 
response to radiation is controlled at the genetic level. Hence, there is currently 
interest in trying to use inflammatory and/or genetic profiling in order to 
identify those individuals at greater than normal risk of toxicity  (reviewed by 
(Okunieff, Chen et al. 2008)). If so, at some point in the future it may be 
possible to consider limiting the total radiation dose in these patients and/or 
attempt to modulate their immune response in some way in order to minimise 
the late effects of radiotherapy treatment. 
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As well as the effects of radiation on tissue integrity and organ function, it is 
important to note that ionising radiation can itself induce cancer. The risk of 
malignancy from radiation exposure is well documented. However, this data is 
largely based on atomic bomb survivors (Little 2001) and it is difficult to 
accurately extrapolate the relative risks in this cohort to those of medically 
exposed individuals. Nonetheless, a treatment course of radiotherapy does 
induce a risk of second malignancy (Curtis 2006). This risk is typically very small 
and it can take many years for such cancers to develop.  
1.2 Radiobiology 
1.2.1 Radiation induced subcellular damage 
It has been widely recognised for decades that ionising radiation exerts its effect 
by damaging cellular DNA. While the ability of radiation to induce DNA damage is 
unquestionable, the field of radiobiology has grown extensively over the past   
10 – 15 years as it is becoming clear that the cellular response to ionising 
radiation is extremely complex. Indeed, it has already been mentioned that 
radiation can trigger an inflammatory response. More importantly, it has now 
been acknowledged that radiation can actively encourage cell preservation 
mechanisms. This ability of radiation to promote cell survival will be discussed in 
later sections. At this point, the traditional view of radiation induced DNA 
damage will be discussed in more detail. 
Cellular DNA damage following exposure to radiation is sustained as a result of 
either direct or indirect ionisation. The latter is due to the ionisation of water, 
which forms free radicals, notably hydroxyl radicals, which are highly toxic. In 
the most common forms of radiation therapy, including traditional external 
beam radiotherapy, most of the damage is induced indirectly by free radicals, as 
opposed to direct ionisation. However, the vast majority of these molecules do 
not produce significant injury. The effect of ionisation is strongly influenced 
geographically by proximity to DNA and biologically by free-radical scavenging 
processes and cellular repair abilities. In addition, some lesions are more 
important than others and although radiation can cause a wide range of DNA 
damage as outlined in Table 1, radiation lethality appears to correlate most 
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significantly with the number of residual, unrepaired double-strand breaks (DSB) 
present several hours after radiation. The precise location and extent of these 
DSBs has a significant impact on whether a cell lives or dies following a radiation 
insult.  
Table 1 - Types and frequency of radiation induced damage 
 
Type of damage Number per Gy per cell 
DNA double-strand breaks 
DNA single-strand breaks 
DNA – protein crosslinks 
DNA – DNA crosslinks 
Base damage 
Sugar damage 
40 
1000 
150 
30 
2000 
1500 
             
This table was adapted from (Steel, 2002). 
 
1.2.2 Radiation induced cell kill 
An important product of DNA damage is observed as chromosome aberrations 
when cells are irradiated in the G1 phase of the cell cycle or chromatid 
aberrations when cells are irradiated after the DNA replication phase. The 
amount of chromosome or chromatid damage observed at the first mitosis after 
irradiation is perhaps the subcellular endpoint that correlates best with cell kill 
for most cell types. This has encouraged the view that the major cause of cell 
death after irradiation is physically aberrant mitosis leading to uneven 
distribution of chromsomes fragments, known as mitotic catastrophe. Such large 
scale loss of DNA probably leads to metabolic imbalance that is incompatible 
with further proliferation.  
Not all irradiated cells enter mitosis before they begin to degenerate and in this 
case, apoptosis appears to be a significant cell death mechanism. Interestingly, 
radiation induced apoptosis is not necessarily explained by effects on DNA as it 
has been shown that ionising radiation can effect changes in the cell membrane 
that trigger apoptosis (reveiwed by (Verbrugge, de Vries et al. 2008)). The role 
that each form of cell death contributes to clinical radiosensitivity has been the 
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subject of much discussion for many years and is still controversial (reviewed by 
(Eriksson and Stigbrand 2010)). 
1.2.3 Clonogenicity 
To complicate matters, cells often do not die rapidly in response to radiation but 
typically sustain damage that impedes further proliferation after several cell 
divisions. Indeed, it is this loss of reproductive integrity or clonogencity that 
underpins the biological effects of ionising radiation. In normal tissues the key 
determinant of growth is the stem cell population which forms the proliferative 
driving force due to an unlimited ability to divide. Similarly, in tumours there 
appears to be a subset of cells that make the major contribution to tumour 
growth – whether this population is composed of “cancer stem cells” is open to 
debate. It is essential to sterilise this subset of cells during a course of 
radiotherapy in order to minimise the risk of local or distant treatment failure. 
The evaluation of the reproductive capacity of these cells in the laboratory is 
best made using clonogenic assays, where the surrogate of a stem cell is the 
clonogenic cell. This is defined as a cell that will produce a colony of 50 cells or 
more under defined experimental conditions. This threshold represents the 
ability to undergo 5 – 6 cell divisions and is chosen in order to exclude cells that 
have a limited growth potential as a result of sublethal radiation damage, or 
having embarked on differentiation. The basic experimental procedure is to 
prepare a single cell suspension, irradiate the cells with a range of radiation 
doses, and allow them to proliferate in appropriate growth conditions for a 
suitable period of time (usually 7 – 21 days). The number of visible colonies are 
then scored and the plating efficiency of each group determined by simply 
calculating the ratio of the number of colonies formed and the number of cells 
seeded. The efficacy of each radiation dose is then related to the untreated 
cells by the surviving fraction,  which is defined by: 
Surviving fraction (SF) = Plating efficiency of treated cells 
Plating efficiency of untreated cells 
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Radiation induced cell kill is exponential so the surviving fractions are plotted on 
semilogarithmic axes to produce cell survival curves, examples of which are 
shown in Figure 3. For some very radiosensitive cell types, for example 
lymphoma or seminoma, the cell survival curve is linear. However, for most cell 
types there is either a shoulder on the curve (that is, a region at low dose where 
an increment of radiation dose has little or no effect on cell kill) or the curve 
may be continuously bending. Several mathematical equations exist to describe 
these curves, including the multi-target equation, the multi-target with single 
hit equation, and the linear quadratic equation. As the latter most accurately 
describes the data from collective experiments on both normal tissue and human 
tumour cells, this is the most commonly used model.  
For the purposes of laboratory studies, it is important to carefully consider the 
endpoint when designing radiation experiments. While it is acceptable to 
perform short term assays of cell survival or viability, it is good practice to 
compare these results against the more laborious and time consuming, but 
generally more reliable, clonogenic assay. Similarly, due to the controversy over 
apoptosis and whether the level detected truly reflects cellular radiosensitivity, 
apoptosis assays should be carried out in parallel with an assessment of 
clonogenicity. Often, surrogates of cell death are used such as the comet assay, 
which is designed to quantify the number of strand breaks, and can be adapted 
to measure either single- or double-strand breaks. However, it is important to 
point out that this assay does not take into account either the rate or fidelity of 
DNA repair. To some extent, this can be assessed by the appearance of 
phosphorylated histone H2AX (γH2AX) foci formation in the nucleus and their 
subsequent clearance. Phosphorylation on the serine 139 site of the histone 
γH2AX occurs in response to ionising radiation (Rogakou, Pilch et al. 1998) and is 
generally considered to be a reliable surrogate of DSB repair. Although these 
DNA damage based assays can provide useful information on the extent of DNA 
damage and the kinetics of DNA repair, it is essential to support the findings 
from these assays with clonogenicity experiments. 
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Figure 3 - Radiation survival curves vary in different cell lines 
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1.2.4 Radiosensitivity 
The efficacy of a course of fractionated radiotherapy is determined by both the 
physical and technical aspects of radiation delivery, and the biological effects on 
the tumour and normal tissue. There are five factors that are highly influential 
in dictating the biological response – the “5Rs of radiotherapy”. Two of these, 
recovery and repopulation, lead to a decrease in response when treatment is 
prolonged, while two, reassortment and reoxygenation, are beneficial in a 
fractionated regimen. The fifth, intrinsic radiosensitivity, is the baseline on 
which the other modifications work. 
1.2.4.1 Reassortment 
Cells alter their sensitivity to radiation as they progress through the cell cycle. 
Cells in mitosis, for example, can be twice as sensitive as those at the end of the 
DNA synthesis phase. A single dose of radiation therefore preferentially kills cells 
at particular stages of the cell cycle. Although cells do not progress normally 
through the cell cycle after exposure to radiation due to checkpoint activation, 
there is usually some progression between fractions, such that cells in a resistant 
phase may be reassorted into a more sensitive phase of the cycle.  
1.2.4.2 Reoxygenation 
Oxygen is critical to the effects of radiation. Cells that are irradiated in hypoxic 
environments are much more resistant to radiation compared with their well 
oxygenated counterparts. This is largely because oxygen reacts with free radicals 
to produce chemically unrepairable peroxy radicals (R· + O2    RO2), hence oxic 
cells sustain more DNA damage. The degree of sensitisation by oxygen is often 
quoted as the oxygen enhancement ratio (OER), which is the ratio of doses 
needed to produce a given biological effect in the presence or absence of 
oxygen. For most cells and tissues the OER has a value of 2.5 – 3 (Chapman, 
Dugle et al. 1974; Hall and Chapman 1974). The decrease in sensitivity depends 
on the partial pressure of oxygen, which means that most well vascularised 
normal tissues are not affected by the oxygen effect. However, the vascular 
supply in tumours is often not adequate to maintain sufficient partial pressure of 
oxygen for all cells.  This is due to insufficient vessel production which results in 
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chronic hypoxia, and is compounded by the abnormal, inefficient nature of these 
new vessels which can constrict causing acute hypoxia. The proportion of the 
tumour that is deficient in oxygen can have an important influence on the 
success of radiotherapy. As it is not unusual to find hypoxic fractions of 10-20% 
in solid tumours, this can pose a series threat to treatment outcome.  
A number of approaches have been considered in an attempt to overcome this 
problem in clinical practice. One simple measure for certain tumour types is to 
correct anaemia with a blood transfusion prior to treatment. More technical 
advances such as the use of hyperbaric oxygen during radiotherapy, although of 
proven benefit, are difficult to implement. The prospect of introducing drugs 
that can radiosensitise hypoxic cells was very popular in the 1980s. The most 
widely studied group consisted of the nitroimidazoles which in principle mimic 
the effect of oxygen and have no sensitising effect on normal tissue. However, 
the validity of this approach was called into question due to concerns over dose 
limiting neurotoxicity.  
There is renewed interest in tackling hypoxia following the recognition that cells 
react to hypoxia by switching on certain genes. This may allow not only the 
identification of hypoxic cells, but may lead to specific targeting of hypoxic 
cells. Targeting the vasculature itself as means of combating tumour cell 
hypoxia has come under scrutiny recently and will be discussed in more detail in 
Section 1.4.2.  
1.2.4.3 Repopulation 
During a course of radiotherapy, cells that survive irradiation may proliferate. 
Even if this occurs at the tumour’s normal doubling rate, this can lead to an 
increase in the number of cells that must be killed. However, there is evidence 
that repopulation can actually be stimulated to a significant extent in certain 
tumour types, particularly in head and neck cancer. Accelerated radiotherapy 
protocols, in which the overall treatment time is reduced by giving multiple 
fractions on a daily basis, have been developed to address this issue, and in 
some cases this is proving effective (Hatton and Martin 2010; Saunders, Rojas et 
al. 2010). 
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1.2.4.4 Recovery / repair 
Most of the damage induced in cells by radiation is satisfactorily repaired. 
Evidence for this comes from studies of strand breaks in DNA, the vast majority 
of which disappear within hours after irradiation. Therefore, between 
radiotherapy fractions, the cell may have sufficent time to reduce the extent of 
radiation damage, hence the term recovery. This can promote tumour cell 
survival, which is unfavourable, but this repair period is obviously crucial for 
normal cells as well as cancer cells; otherwise early and late radiotherapy 
related toxicity may be a major problem. Accelerated radiotherapy regimens 
mentioned above can impact on recovery time as well as repopulation. This is 
because the multiple fractions given each day have only 6 or 8 hours in between 
as opposed to the standard 24 hour gaps in treatment. While this approach can 
increase tumour cell kill, it does not lead to a significant exacerbation in normal 
tissue toxicity as the dose of radiation per fraction is typically much smaller. 
1.2.4.5 Intrinsic radiosensitivity  
Intrinsic radiosensitivity is the relative susceptibility of cells, tissues, or organs 
to the harmful effects of radiation. It is well recognised that the inherent 
sensitivity of tumour cells varies between tumours of different pathological type 
and between tumours of the same type taken from different patients. In 
addition, there are discrepancies in radiosensitivity in cells within a single 
tumour. There are also differences in the susceptibility of normal cells between 
individuals. While there are some genetic syndromes, such as ataxia 
telangectasia, that can explain the significant tissue toxicity in certain 
individuals exposed to ionising radiation, these syndromes are rare. The reasons 
for marked variation in the non-syndromic population are largely unknown, but it 
is likely that DNA repair capabilities play a significant role with each individual 
possessing a pre-determined ability to control the rate, extent, and fidelity of 
DNA repair. The mechanisms underlying the variation in tumour cell 
radiosensitivity are probably even more diverse. On top of the intrinsic 
radiosensitivity acquired from the tissue of origin, cancer cells will have amassed 
a range of molecular aberrations such as gene amplifications and/or mutations 
that are likely to influence DNA repair, cell cycle control and cell survival 
pathways. 
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1.3 Advances in radiotherapy delivery and dosimetry 
The greatest challenge for radiotherapy (or any cancer therapy for that matter) 
is to increase the therapeutic ratio, that is, to attain the highest probability of 
cure with the least morbidity. The simplest way in theory to achieve this with 
radiation is to encompass all cancer cells with sufficient doses of radiation 
during each fraction, while simultaneously sparing surrounding normal tissues. In 
practice, however, it is not always straightforward to identify the cancer cells or 
target them adequately with radiation. Over the past decade, enormous progress 
has been made on both fronts. Technical improvements in the application of x-
rays, computed tomography scans, magnetic resonance imaging with and without 
spectroscopy, ultrasound, positron emission tomography scans, and electronic 
portal imaging — and a clearer understanding of their limitations — have greatly 
improved the ability to identify the tumour volume.  
1.3.1 Conformal radiotherapy 
For almost a century, radiotherapy planning of deep seated tumours was based 
on the use of co-planar, regularly shaped symmetrical fields, with the result that 
the treated volume approximated a simple geometric box, a distinct 
disadvantage being the inclusion of much adjacent healthy tissue.  Nowadays the 
x-ray beams are shaped with lead to conform to the size and shape of the target 
volume, hence the term conformal radiotherapy. The advent of three-
dimensional (3D) CT based planning has greatly assisted conformal treatment. 
Because it takes into account axial anatomy and complex tissue contours, as well 
as irregular beam shape, it can provide a reasonably accurate assessment of 
dose distribution across the target volume.  
1.3.2 Intensity modulated radiotherapy 
While CT based planning has revolutionised the field of clinical oncology, it does 
have limitations. As its name implies, intensity modulated radiotherapy (IMRT) 
permits modulation of the intensity of each radiation beam, so each field may 
have one or many areas of high intensity radiation and any number of lower 
intensity areas within the same field, thus allowing for greater control of the 
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dose distribution within the target. By modulating both the number of fields and 
the intensity of radiation within each field, it is possible to sculpt radiation dose. 
Advanced treatment planning software has furthered the ability to modulate 
radiation dose. Instead of the clinician or physicist choosing every beam angle 
and weighting, computer optimisation techniques can now help determine the 
distribution of beam intensities across a treatment volume. This form of 
radiotherapy can be very useful in situations where the tumour is lying very 
close to an important structure such as the spinal cord, but is not widely 
available as yet. 
1.3.3 Image guided radiotherapy 
Image guided radiotherapy (IGRT) is a novel array of techniques designed to 
minimise the discrepancies which occur due to variations in patient and/or 
tumour position. Strictly speaking, IGRT is the use of imaging to monitor or 
modify the delivery of radiotherapy treatment. However, the term IGRT is often 
used to encompass three broad categories of image-based innovations: (1) the 
integration of functional and biological imaging into the treatment planning 
process to improve tumour contouring (or target delineation), (2) the use of 
various imaging modalities to adjust for tumour motion and positional 
uncertainty, and finally (3) the adaptation of treatment planning based on 
tumour response and changes in normal tissue anatomy (Nath, Simpson et al. 
2009).  
A key innovation in the first category of IGRT is the use of 18-F-
Flurodeoxyglucose (FDG)-PET, a radio labelled analogue of glucose that is 
selectively absorbed in tumour cells more than normal tissues. Hence, it can be 
effective in highlighting the presence of neoplastic growth in tissues that appear 
radiologically normal. As such, FDG-PET now has an established role in oncology 
and is a useful tool in the staging process of several common cancers, including 
lung (Lardinois, Weder et al. 2003; Halpern, Schiepers et al. 2005) and 
colorectal cancer (Tutt, Plunkett et al. 2004; Rosenbaum, Stergar et al. 2006; 
Israel and Kuten 2007). However, there is now increased focus on the value of 
FDG-PET in target delineation for radiotherapy. Sophisticated software can   
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perform an accurate overlay of PET and CT images and these fused images can 
guide the contouring of tumour margins and extended fields.  
The second type of IGRT involves the use of modern imaging modalities to assist 
in daily patient positioning. Most radiotherapy protocols involve several weeks of 
sequential daily treatment, and each day the patient needs to be repositioned 
into the exact position obtained during the initial planning CT. Despite the use 
of immobilisation devices, there is considerable potential for setup variability. A 
common way to verify patient positioning is through the use of two-dimensional 
(2D) portal film imaging. This is done using devices attached to the treatment 
machine that are capable of taking radiographs. However, the image quality is 
usually quite poor. Improved means of imaging are now being introduced, but 
there are concerns that the increased radiation dose may correspond with a 
higher risk of second malignancy (Kan, Leung et al. 2008), although this has yet 
to be established. 
The final form of IGRT is known as adaptive radiotherapy. This is a new, and still 
evolving, concept with the potential to greatly improve the delivery of 
radiotherapy.  As there can be significant changes in patient anatomy during a 
course of treatment due to tumour shrinkage or weight loss, the premise of 
adaptive radiotherapy is to alter the treatment plan in response to these 
changes. Research in this field is quite preliminary so it is currently unclear 
when and how often re-planning should be done and how this will impact on the 
available resources.  
1.3.4 Intra-operative radiotherapy 
A standard course of traditional external beam radiotherapy lasts for several 
weeks. This may have financial implications for the patient and can significantly 
impact on healthcare resources.  In the post-operative or adjuvant setting, the 
possibility of applying a single fraction of radiation immediately after surgery 
has been suggested. This practice is already performed at a number of cancer 
centres in the US, but only in selected tumour types. In general, the numbers of 
patients accrued for each tumour type are insufficient to draw definitive 
conclusions (Beddar, Biggs et al. 2006; Skandarajah, Lynch et al. 2009). Perhaps 
the one major exception is breast cancer, where a large international study is 
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directly comparing a standard course of post-operative radiotherapy with a 
single fraction of radiotherapy given intra-operatively. If this is equivalent in 
terms of local disease recurrence, the obvious question is whether a single 
fraction will lead to increased late toxicity. So far, this does not seem to pose a 
particular threat (Holmes, Baum et al. 2007; Baum and Vaidya 2008; Kimple, 
Klauber-DeMore et al. 2010) but long term follow up will be required. 
1.3.5 4D radiotherapy planning  
Recently, a new technology has been developed; four-dimensional (4D) 
radiotherapy planning. This can add the dimension of time to conventional 
spatial (3D) planning. A technique such as this may prove to be particularly 
useful in the treatment of lung cancers where tumours may move up to 4cm 
during inspiration and expiration. If organ motion can be recorded, this 
information may be used to better define the radiotherapy treatment volume. 
For instance, the target could be defined as the volume that encompasses the 
tumour throughout the breathing cycle, so that the tumour always stays within 
the radiation field. In addition, separate treatment plans may be created for 
different phases of motion and the best one selected for “gated” delivery. To 
achieve this, it would be necessary to synchronise the delivery of radiation with 
the target motion so that the dose is only delivered when the tumour is in a 
certain position. While this form of radiotherapy is an exciting step forward, it 
does require significantly more input and expertise from radiation physics 
departments, and both treatment planning and treatment delivery times are 
longer. 
1.3.6 Particle therapy 
As already outlined, most solid tumours are treated with traditional external 
beam radiotherapy from megavoltage linear accelerators which produce high 
energy x-rays. However, there is interest in exploiting forms of radiation other 
than x-rays for therapeutic use. Particle therapy is a form of external beam 
radiation that takes advantage of the biological properties of protons, fast 
neutrons or heavy ions.   
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1.3.6.1 Protons 
Although protons have a similar biological effect to x-rays, they have superior 
dose distribution properties, which allow the production of a highly focused, 
high energy peak in otherwise inaccessible sites. The major limitation in the 
routine use of proton beams is the expensive and complex cyclotron technology 
required to produce a beam for medical use; at present only a few centres 
worldwide offer this form of treatment. 
1.3.6.2 Neutrons 
Unlike protons, neutrons do not have dose distribution advantages over x-rays. 
However, they do offer a biological advantage. Both x-rays and protons are 
forms of low energy transfer radiation as they are sparsely ionising, whereas 
neutrons are more densely ionising and are therefore considered to be high 
energy transfer radiation. The latter are biologically more effective per unit 
dose and have less dependence on oxygen for cell kill. Neutrons have been more 
extensively studied than protons but the clinical results obtained are 
controversial due to unacceptably high levels of normal tissue toxicity. To some 
extent these findings probably reflect the poor dose distributions and beam 
delivery systems of early experimental neutron facilities.  The precise role of 
neutron beams in radiotherapy continues to be investigated, but this form of 
treatment is certainly not standard practice at the moment. 
1.3.6.3 Heavy ions 
Heavy ion therapy is the use of particles more massive than protons or neutrons, 
such as carbon ions. Similar to neutrons, heavy ions have a higher density of 
ionisation compared with x-rays. The experience in this type of therapy is 
restricted to less than a handful of centres worldwide (reviewed by (Kitagawa, 
Fujita et al. 2010)), but a number of new facilities are under construction. Work 
is also underway to improve the stability and reproducibility of heavy ion beams. 
This form of treatment may be of value in selected patients but is unlikely to be 
routinely employed in clinical oncology practice. 
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1.4 Novel targets in radiation research 
As outlined in the previous section, the planning and delivery of radiotherapy is 
becoming ever more complex, with the ultimate aim of achieving increased 
tumour cell kill with minimal normal tissue toxicity. However, it is also possible 
to augment tumour cell kill by biological means. Cytotoxic chemotherapy, for 
example, has long been used in combination with radiotherapy. Theoretically, 
there is an advantage to combined modality treatment as the total cell kill 
should be greater than that achieved with either agent alone (independent cell 
kill). In addition to this, chemotherapy can enhance the activity of radiotherapy 
(synergistic cell kill). Certain drugs can inhibit the repair of radiation damage 
such as cisplatin, doxorubicin and bleomycin. In addition, cisplatin can increase 
the number of radiation induced strand breaks. Some drugs, such as taxanes, can 
also influence radiation response by increasing the proportion of cells in a more 
radiosensitive phase of the cell cycle. For these mechanisms to be exploited, the 
two modalites should have non-overlapping toxicities and the chemotherapy 
should not enhance normal tissue damage. Even so, this is likely to have a wider 
range of toxicity which must be taken into account.                                          
The combination of chemotherapy and radiotherapy has led to improved 
treatment results in patients with locally advanced solid tumours. In particular, 
the concurrent application of both modalities has proven efficacy and resulted in 
lower recurrence rates and improved survival in several tumour types, such as 
head and neck cancer (Calais, Alfonsi et al. 1999) and cervical cancer (Rose, 
Bundy et al. 1999). More recently, it has been shown that the addition of 
chemotherapy in notoriously radioresistant tumours such as glioblastoma, can 
improve outcome (Stupp, Hegi et al. 2009).  
An exciting development in cancer therapy in the last 20 years, however, is the 
increased understanding of oncogenes, cellular growth factors and signal 
transduction pathways that control cell proliferation, differentiation, invasion, 
and angiogenesis. This has led to the development of targeted agents to use 
alone or in combination with cytotoxic chemotherapy. Similarly, radiation 
biology has advanced over this time. It has already been highlighted that 
radiotherapy exerts its effect by inducing DNA damage, and recent years have 
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seen much progress in dissecting out the various mechanisms responsible for 
controlling DNA repair. Furthermore, it is becoming clear that radiation does not 
always induce cell death or a proliferative block. Conversely, ionising radiation 
can inhibit cell death and /or stimulate cell survival pathways. Many of these 
effects have been linked to the induction of growth factor receptors, although 
there are likely to be other factors involved.  
This section will focus on combination strategies with proven clinical efficacy 
and on approaches that are highly promising for combined use with radiotherapy 
based on their underlying mode of action. 
1.4.1 EGFR signalling pathway 
To date, much of the preclinical and clinical experience combining molecularly 
targeted agents with radiation has involved inhibiting signalling through the 
epidermal growth factor receptor (EGFR) pathway. EGFR is a member of the 
receptor tyrosine kinase family of growth factor receptors that are activated 
under normal circumstances by ligand binding to transmit mitogenic signals to 
the nucleus. On binding to its ligand, EGF, or transforming growth factor-α 
(TGFα), EGFR dimerizes and the intracellular domain becomes phosphorylated 
on tyrosine residues, thereby initiating a cascade of signals from the cytoplasm 
to the nucleus, predominantly through the activation of the Ras/MAPK and PI3K/ 
Akt/mTOR pathways, that control a variety of cellular responses modifying cell 
growth and survival (Ullrich and Schlessinger 1990). An overview of the EGFR 
signalling cascade is provided in Figure 4. 
EGFR is often expressed at high levels in human cancer; typically mediated by 
gene amplification or mutation. Upregulation of this protein has been associated 
with more aggressive tumours and poor prognosis in a range of tumour types 
(reviewed by (Hale, Buckley et al. 1993)). The first indication that EGFR was 
involved in radioresistance was documented over 15 years ago when the addition 
of exogenous EGF rendered MCF-7 breast cancer cells radioresistant (Wollman, 
Yahalom et al. 1994). This effect was abrogated by exposure to EGFR antibody. 
It has since been shown that EGFR tyrosine phosphorylation is stimulated by 
radiation (Dent, Reardon et al. 1999) and the subsequent activation of the signal             
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Figure 4 - Simplified model of signalling through the EGFR pathway 
The stimulation of the epidermal growth factor receptor (EGFR) results in the assembly of multi-
molecular complexes (e.g. SHC, Grb2 and SOS) that interact with Ras at the plasma membrane. 
Activated Ras then participates in a cascade of signalling events, including Raf/MEK/ERK. The end 
product of ERK activation is the phosphorylation of cytoplasmic and nuclear targets, such as the 
Elk1 transcription factor, which regulates transcription of genes involved in crucial cellular 
processes including cell cycle progression, survival, invasion, and angiogenesis. Activation of PI3K 
leads to activation of Akt and mTOR, which play critical roles in the control of apoptosis and protein 
synthesis. Downstream of PI3K, the tumour suppressor genes PTEN and TSC also contribute to 
the regulation of Akt and mTOR. RalGDS is a guanine nucleotide exchange factor (GEF) for Ral, 
which has roles in regulating gene transcription and vesicle transport. Phospholipase C (PLC) 
mediates cross talk between small GTPase signalling pathways and activates protein kinase C 
(PKC), which has numerous effects on tumour cells including stimulation of proliferation. 
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transduction pathways outlined in Figure 4 mimics ligand binding. Consequently, 
this results in a proliferative response after radiation and counteracts radiation 
induced growth arrest and cell kill. In addition, it has been reported that 
radiation induces nuclear translocation of EGFR. This allows DNA-dependent 
protein kinase (DNA-PK) complex formation which is an important factor in DNA 
DSB repair (Dittmann, Mayer et al. 2005). 
These processes can be inhibited by small molecule inhibitors of EGFR 
autophosphorylation, such as gefitinib (iressa) and erlotinib (tarceva), or by anti-
EGFR antibodies, such as cetuximab. Both modalities have been shown to 
increase radiosensitivity in a wide range of cancer cell lines (Bianco, Tortora et 
al. 2002; Shintani, Kiyota et al. 2003; Stea, Falsey et al. 2003; Eller, Longo et al. 
2005; Raben, Helfrich et al. 2005; Taira, Doihara et al. 2006; Colquhoun, McHugh 
et al. 2007). While some of the effects are due to DNA repair, certainly cytosolic 
sequestration of DNA-PK by cetuximab is thought to impair DSB repair (Dittmann, 
Mayer et al. 2005; Dittmann, Mayer et al. 2008), changes in cell cycle have also 
been reported, typically a reduction in the proportion of cells in S phase, which 
is generally regarded as the most radioresistant phase of the cell cycle. 
The use of tumour growth delay experiments in human tumour xenografts 
treated with either EGFR antibodies or tyrosine kinase inhibitors (TKIs) in 
combination with radiation have also shown positive results, usually an additive 
effect although some instances of synergistic cell kill have been reported (Saleh, 
Raisch et al. 1999; Milas, Mason et al. 2000; Williams, Telfer et al. 2002; She, 
Lee et al. 2003; Milas, Fan et al. 2004; Nyati, Maheshwari et al. 2004; Krause, 
Schutze et al. 2005; Colquhoun, McHugh et al. 2007; Feng, Lopez et al. 2007; 
Geoerger, Gaspar et al. 2008). Effects on cell proliferation seem to be important 
in vivo, at least in single fraction studies. In fractionated studies, decreased 
repopulation and increased reoxygenation contribute to the outcome. The latter 
is likely due to an effect on tumour vasculature as EGFR blocking agents have 
been shown to enhance flow perfusion and reduce hypoxia, ultimately improving 
tumour response (Qayum, Muschel et al. 2009).  
In the clinical setting, the benefit of anti-EGFR treatment in combination with 
radiotherapy has been demonstrated in locally advanced head and neck cancer. 
The addition of cetuximab led to increased local disease control and, more 
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importantly, overall survival (Bonner, Harari et al. 2006; Bonner, Harari et al. 
2009). However, this study was initiated before chemoradiotherapy became 
standard of care in head and neck cancer, so it remains to be seen whether 
cetuximab can replace chemotherapy in combination schedules or whether 
cetuximab should be given alongside chemoradiotherapy. While there is some in 
vitro and in vivo data (Feng, Lopez et al. 2007; Zhang, Erjala et al. 2009) to 
support the latter, this may induce considerable toxicity (Pfister, Su et al. 2006). 
Another interesting question that has yet to be answered is whether the level of 
EGFR overexpression in tumours is critical in terms of predicting response to 
combination therapy. While this does seem to be significant in vitro, and 
certainly EGFR is often overexpressed in head and neck cancer (Kalyankrishna 
and Grandis 2006; Temam, Kawaguchi et al. 2007), the Bonner study did not 
differentiate between low and high expressors. It is important to point out, 
however, that based on the evidence from single agent or chemotherapy 
combination studies in other tumour types, the response to EGFR inhibition is 
not necessarily dependent on EGFR overexpression, but is influenced by the 
presence of activating EGFR mutations (Lynch, Bell et al. 2004) or K-Ras status 
(Ibrahim, Zekri et al. 2010). It has yet to be established whether this type of 
mutation analysis can be used to select patients who will be most likely to 
benefit from a combination approach involving radiotherapy. The role of 
cetuximab (and newer second generation monoclonal antibodies) and various 
EGFR TKIs in combination with radiotherapy / chemoradiotherapy in other 
cancers, particularly rectal, pancreas and glioblastoma is currently under 
investigation and it is likely that future Phase III trials will attempt to address 
the issue of patient selection / prediction.  
Although most of the experience to date has involved targeting EGFR itself in 
combination with radiation, the constituent components of the downstream 
signalling pathways are also potential targets. In fact, one of the first attempts 
at combining targeted agents with radiation concentrated on Ras. This was 
based on work in the 1990s which demonstrated that constitutive Ras activation 
promoted radioresistance (Ling and Endlich 1989; McKenna, Weiss et al. 1990; 
McKenna, Weiss et al. 1990; Samid, Miller et al. 1991; Bernhard, Stanbridge et 
al. 2000), although in retrospect some of this data is difficult to interpret and 
confounded by the presence of other oncogenes, such as myc, which can also 
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influence radiosensitivity. The development of farnesyl transferase inhibitors 
(FTIs), which prevent membranous localisation of Ras and hence its full 
biological activity, led to much excitement as Ras mutations are very common in 
human cancers (Bos 1989). However, these agents failed to meet expectations in 
the clinical setting, probably because much of the dramatic effects of FTIs 
observed in early experimental systems were predominantly based on H-Ras 
induced cancer model systems (Kohl, Mosser et al. 1993); H-Ras mutations being 
far less frequent than either K-Ras or N-Ras mutations in human cancers. In 
addition, it is now clear that K-Ras and N-Ras proteins undergo alternative 
means of modification in the context of farnesyl transferase inhibition (Whyte, 
Kirschmeier et al. 1997). What is more, the exact mechanism of these agents has 
been called into question as many intracellular proteins are farnesylated and it 
has been proposed that alternative targets may be responsible for the anti-
tumour effects of FTIs (Clark, Kinch et al. 1997; Lebowitz, Casey et al. 1997; 
Ashar, James et al. 2000; Zeng, Si et al. 2000). In keeping with this, some wild-
type (wt) Ras cell lines exhibited increased radiosensitivity when treated with 
FTIs (Cohen-Jonathan, Toulas et al. 1999; Delmas, Heliez et al. 2002), although 
it should be pointed out that these findings have not been completely replicated 
(Bernhard, McKenna et al. 1998). While there is still some interest in combining 
these agents with radiotherapy, there is no conclusive evidence as yet from 
clinical studies to support this. 
There are agents available which target Raf and MAPK (MEK) in various stages of 
clinical development and some pre-clinical data to suggest a possible benefit in 
combination with radiation. Therapeutic targeting of PI3K and Akt has proved 
more difficult and the progress of a number of compounds has been limited by 
specificity and / or toxicity. This is disappointing as Akt is often activated in 
response to radiation in the in vitro setting and inhibiting this pathway with the 
laboratory based agents wortmannin and/or LY294002 has been shown to have a 
beneficial effect in combination with radiation in many cell systems (reviewed 
by (Graham and Olson 2007)).  mTOR, however, which is downstream of Akt, and 
controls the translation of proteins for cell cycle progression and cell 
proliferation, is perhaps a more promising target.  mTOR inhibitors are currently 
under evaluation, particularly in endometrial cancer and glioblastoma, both of 
which commonly possess mutations in PTEN (Sansal and Sellers 2004). There is 
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certainly in vitro and in vivo data in support of a combination approach with the 
latter (Eshleman, Carlson et al. 2002) so it will be of interest to see if the 
proposed clinical studies corroborate this. 
1.4.2 Angiogenic factors 
Blood vessels are essential for tumour growth and metastasis. Hence, this has 
prompted interest in therapeutic targeting of the tumour vasculature. The major 
strategy to date in this endeavour has involved inhibition of vascular endothelial 
growth factor (VEGF) signalling. VEGF, the key pro-angiogenic growth factor, is 
secreted by almost all solid tumours (Leung, Cachianes et al. 1989), and acts 
through VEGFR1, VEGFR2, or VEGFR3 receptors on endothelial cells (Millauer, 
Wizigmann-Voos et al. 1993), and disruption of this signalling pathway can lead 
to interference with the formation of new blood vessels.   
While preclinical data has suggested that VEGF is upregulated in tumours in 
response to radiotherapy and that this might be a cause of radioresistance 
(Gorski, Beckett et al. 1999),  VEGF inhibition did not have a radiosensitising 
effect on cancer cells grown in culture (Gorski, Beckett et al. 1999), although 
testing this hypothesis was not particularly straightforward as VEGFR is often not 
expressed on cell lines in vitro. However, VEGF inhibition did sensitise 
endothelial cells, such as HUVECs (which do express VEGFR), to radiation 
(Gorski, Beckett et al. 1999; Geng, Donnelly et al. 2001). Whether this in vitro 
effect would translate into tumour growth delay in vivo was an important 
question, since an effect on the tumour vasculature could potentially render 
cells more radioresistant as a result of hypoxia. It has already been highlighted 
that the generation of highly reactive oxygen intermediates is critical to 
radiation induced DNA damage and that reduced oxygen levels limit the 
damaging effect of radiation. Another important consideration that must be 
taken into account is that the late toxicity from radiotherapy treatment is often 
attributed to small vessel ischaemia and/or necrosis.  
Based on these aspects of tumour microenvironment, the combinaton of anti-
angiogenic agents and radiation would seem to be counter-intuitive. However, 
the concept of a “normalisation window” has been raised as a potential 
sensitising mechanism (Jain 2005). Essentially, in normal cells there is a balance 
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between pro- and anti- angiogenic factors resulting in an organised and efficient 
vascular network and blood supply. In tumours this balance is shifted towards 
pro-angiogenic factors that promote the formation of an abnormal vasculature 
with an inefficient supply of oxygen and nutrients. Then, after administration of 
anti-angiogenic agents, the balance is restored allowing the normalisation of the 
vascular network with improved perfusion and oxygen delivery. An outline of the 
connection between radiation and the vasculature is shown in Figure 5. 
Accordingly, the use of anti-angiogenic agents increased radiosensitivity in a 
variety of tumour xenograft models such as colon, lung, prostate, breast and 
ovary (Lee, Heijn et al. 2000; Cao, Albert et al. 2006; Williams, Telfer et al. 
2007) (Nieder, Wiedenmann et al. 2007). Most of these studies used fractionated 
radiotherapy combined with a VEGFR antibody and radiosensitivity was assessed 
by tumour growth delay experiments. In some cases, the researchers specifically 
examined the vasculature and found that hypoxia levels decreased after VEGFR 
inhibition due to vessel regression and reorganisation, primarily as a result of 
reduced vascular permeability and interstitial fluid pressure (Lee, Heijn et al. 
2000). It has been proposed that the “normalisation window” may only be 
temporary and therefore the timing or sequencing of VEGFR inhibition and 
radiation may be critical. While some xenograft studies have demonstrated that 
sequencing can influence the outcome of combined treatment (Williams, Telfer 
et al. 2004), this does not always appear to be the case, although it is important 
to remember that the vasculature and tumour environment in a simplified 
xenograft model is likely to be very different from that of an established more 
complex human malignancy.  
Several Phase I and II trials have been reported detailing the combination of 
radiotherapy with bevacizumab (avastin), a recombinant humanised monoclonal 
antibody that binds to and inhibits the biological activity of VEGFR, with some 
promising results. Cediranib (recentin), a potent orally active tyrosine kinase 
inhibitor which targets all three VEGF receptors, is also under investigation. As 
yet, there is no Phase III data on either drug available, so the role of anti-
angiogenesis agents in combination with ionising radiation has still to be 
established. If there is a proven benefit, it will be some time before there is    
mature data available on the potential long term toxicity.   
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Figure 5 - Mechanistic interaction of radiotherapy and VEGF inhibition 
VEGF inhibition enhances radiothearpy induced endothelial cell death. It can also induce “vascular 
normalisation”, leading to improved tumour oxygenation and sensitisation to radiation. 
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1.4.3 DNA damage response proteins 
Radiotherapy and many anti-cancer chemotherapeutic agents cause cell death 
by inducing DNA damage and it is recognised that functioning DNA repair 
pathways can act as mechanisms of radioresistance or drug resistance (Gatti and 
Zunino 2005; Borst, Rottenberg et al. 2008). In addition, over-expression of 
these repair pathways has been reported in tumours (Wharton, McNelis et al. 
2000; Staibano, Pepe et al. 2005). Thus the potential to inhibit DNA repair 
enzymes as a means of improving existing cancer treatments has been the focus 
of drug development programmes. Recent attention has been directed at the 
poly(ADP-ribose)polymerases (PARPs), a family of highly conserved enzymes 
found in plants and animals, that were first described over 40 years ago 
(Chambon, Weill et al. 1963). PARP-1 is the most abundant form of the enzyme 
and is found in the nucleus, acting as a “molecular nick sensor” to signal DNA 
single strand breaks (SSBs) and assist in their repair (de Murcia and de Murcia 
1994). Commonly used chemotherapeutic agents, such as alkylating agents and 
camptothecins damage DNA by causing SSBs and for this reason PARP inhibitors 
were first developed as chemopotentiating agents. 
The publication of paired Nature papers in 2005 has revolutionised the clinical 
research approach to PARP inhibitors (Bryant, Schultz et al. 2005; Farmer, 
McCabe et al. 2005). These preclinical cell line and xenograft experiments 
demonstrated that cells with loss of the homologous recombination DSB repair 
pathway were hypersensitive to blockade of SSB repair with a PARP inhibitor. 
The proposed mechanism of cytotoxicity is that blocking SSB repair leads to the 
formation of DSBs at the replication fork. In normal or heterozygote cells the 
DSB mechanisms can repair the lesion and DNA replication and cell division 
continues. However, in cells where DSB repair is not functional, such as those 
with a homozygous mutation in BRCA1 or BRCA2, the loss of two DNA repair 
pathways causes synthetic lethality and cell death (Evers, Drost et al. 2008). 
This observation was then tested clinically in Phase II studies in BRCA1 or BRCA2 
mutant carriers with breast and ovarian cancer, respectively, with promising 
results (Audeh, Penson et al. 2009; Tutt, Robson et al. 2009). Although these 
findings from small non-randomised studies require confirmation in a phase III 
trial, they do suggest that PARP inhibitors may be useful not only as 
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chemopotentiators, but they may have an additional exciting role as single 
agents in appropriately molecularly profiled patients. 
Over 20 years ago, tests with early experimental drugs capable of affecting PARP 
activity showed that addition of PARP inhibitors resulted in enhancement of 
radiation cell kill in vitro (Thraves, Mossman et al. 1985; Kelland, Burgess et al. 
1988) and that this was based on DNA repair inhibition (Bowman, White et al. 
1998; Veuger, Curtin et al. 2004). Further development of these agents was 
limited by concerns over excessive toxicity but interest in combining radiation 
with PARP inhibitors has resurfaced again based on both the general excitement 
currently surrounding these agents and the introduction of more specific and 
well tolerated compounds. In keeping with earlier observations, an increase in 
radiosensitivity has again been demonstrated with these newer agents in both 
the in vitro and in vivo settings (Veuger, Curtin et al. 2003; Brock, Milas et al. 
2004; Calabrese, Almassy et al. 2004; Albert, Cao et al. 2007; Donawho, Luo et 
al. 2007; Thomas, Calabrese et al. 2007; Clarke, Mulligan et al. 2009). Clinical 
trials are now underway investigating the use of PARP inhibitors in combination 
with radiotherapy so it will be of interest to see if this approach is of clinical 
benefit. It will also be important to ascertain whether normal tissue toxicity 
varies depending on the site treated. As the effects of PARP inhibition are more 
profound in proliferating cells (underlining the model that secondarily induced 
DSBs resulting from conversion from SSBs are responsible for much of the cell kill 
as shown in Figure 6), organs where there is continuous cell turnover for normal 
function such as the bowel may be more susceptible than, for example, the 
brain with its much slower proliferative index. Hence, it may be necessary to 
select target sites carefully. A further cautionary note is that it has been 
suggested that blocking a DNA repair pathway may lead to the accumulation of 
DNA damage. This stems largely from pharmacodynamic data in a Phase I study 
where the authors found an increase in γH2AX foci in sampled surrogate tissue 
from patients (Fong, Boss et al. 2009). It is likely that any excess damage could 
be repaired when pharmacological inhibition is removed but it must be borne in 
mind that long-term use of a PARP inhibitor could lead to secondary harmful DNA 
lesions, and possibly further malignancy. Although this is unlikely to significantly 
impact on a course of radiotherapy lasting a number of weeks, the precise risk 
has yet to be quantified. 
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Figure 6 - DNA repair mechanisms in response to ionising radiation 
Ionising radiation induces DNA damage, including double strand breaks (DSBs) and single strand 
break (SSBs) which need to be repaired to maintain genomic integrity and prevent cell death. 
DSBs are detected by the ataxia telangectasia mutated (ATM) kinase (in conjunction with other 
molecules), which phosphorylates a series of downstream effectors in a signalling cascade that 
coordinates cell cycle arrest and DNA repair. In cells with functional p53 tumour suppressor 
protein, G1 cell cycle arrest may occur. In cells where p53 is dysfunctional, ATM acts through 
checkpoint kinase-1 (Chk1) to induce a G2/M arrest. The repair of DSBs occurs predominantly 
through the process of non-homologous end-joining (NHEJ) mediated by the catalytic subunit of 
the DNA-dependent protein kinase (DNA-PK). Alternatively, DSBs may be repaired by homologous 
recombination (HR). The repair of SSBs occurs principally through the process of nucleotide 
excision repair (NER). The poly(ADP-ribose)polymerase (PARP) family of enzymes regulate this 
process. However, if PARP is inhibited, then SSBs that persist at the time of cell replication will be 
converted to DSBs, increasing the total number of DSBs that must be repaired.  
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1.4.4 Apoptosis modulating proteins 
The inherent or acquired capacity of tumour cells to resist apoptosis is one of 
the hallmarks of cancer, and is considered to be an important factor in 
determining treatment resistance. Even though radiation can induce apoptosis  
in cancer cells, the significance of apoptosis in terms of tumour response and 
clonogenicity has yet to be fully elucidated, as already mentioned in Section 
1.2.2. Nevertheless, it is clear that in some cases the active modulation of 
apoptosis can influence radiation reponses to a substantial degree.  
Apoptosis can be triggered by either intrinsic or extrinsic pathways as shown in 
Figure 7.  Most apoptotic stimuli, including ionising radiation, depend on the 
intrinsic mitochondrial pathway. DNA damage sensors, such as p53,  induce 
permeability of the mitochondrial outer membrane permitting the release of 
pro-apoptotic factors into the cytosol (reviewed by (Wang, 2001)). The Bcl-2 
protein family mediates mitochondrial permeability and is therefore the key 
regulator of most apoptotic pathways. Anti-apoptotic Bcl-2 and its family 
members are frequently overexpressed in a variey of cancers and increased 
levels often correlate with radio and chemoresistance (Belka and Budach 2002; 
Wang, Yang et al. 2003; Hara, Omura-Minamisawa et al. 2005). Despite this, and 
the availability of anti-Bcl-2 agents, the number of clinical trials exploring 
knockdown of Bcl-2 in combination with radiation has been limited so far. 
In contrast to Bcl-2 family members which control the intrinsic pathway, death 
receptors such as TRAIL activate the extrinsic apoptosis pathway.  This receptor 
is of particular interest because of its proven capacity to induce apoptosis in 
cancer cells, but relative lack of normal tissue toxicity in preclinical animal 
models (Ashkenazi, Pai et al. 1999; Walczak, Miller et al. 1999). While of 
potential value as a therapeutic modality in itself, TRAIL is an excellent 
candidate for combination therapy, since TRAIL and radiation are known to 
activate distinct apoptosis signalling pathways. Intriguingly, however, it has 
been proposed that DNA damage can lead to upregulation or sensitisation of the 
TRAIL complex, which may explain the synergistic effects seen in experimental 
systems when TRAIL activation is combined with radiation (Belka, Schmid et al. 
2001). The two main approaches involve recombinant human TRAIL ligand or 
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agonistic TRAIL receptor antibodies. Phase I/II trials with the former are now 
ongoing. It will be fascinating to determine whether the promising in vitro and 
in vivo results of TRAIL modulating agents combined with radiation are 
reproduced in the more complicated setting of human malignancies. 
1.4.5 Other potential radiosensitising targets 
In recent years, an increasing number of targeted agents have become available 
for preclinical evaluation as radiosensitisers. Histone deacetylase inhibitors, for 
example, which regulate chromatin structure and gene expression, appear be 
useful in combination with radiotherapy (Camphausen and Tofilon 2007). This 
may be mediated by effects on DNA repair as well as gene transcription. DNA 
repair may also be modulated by targeting checkpoint kinases (Chk) such as Chk1 
and Chk2. These kinases are activated in response to ionising radiation and 
result in cell cycle block, which allows time for effective DNA repair. Inhibiting 
Chk1 and/or Chk2 can promote premature progression through the cell cycle, 
minimising the time available for DNA repair. The loss of adequate checkpoint 
control may also lead to increased cell death by mitotic catastrophe (Riesterer, 
Matsumoto et al. 2009). Full discussion of all the remaining potential 
radiosensitising targets, including growth factor receptors other than EGFR, is 
beyond the scope of this review.  
One final point on this subject, however, is that the cellular response to 
radiation is highly complex. As yet, it is unclear which targeted approach is 
likely to be most successful in combination with radiation in the clinical setting 
and which patients are most likely to respond to specific targeted agents. 
Clinical trials must be rationally designed and ideally incorporate the use of 
biomarkers or predictive assays in order to select out those individuals most 
likely to benefit. In addition, although there are numerous options for 
developing novel therapeutics, the potential input from cross talk and alternate 
signalling mechanisms, many of which are not fully recognised or fully 
understood, may lead to substantially reduced efficacy. One way of combating 
this particular problem might be to employ therapeutic agents with a wide range 
of targets. Heat shock proteins, which act as molecular chaperones for a variety 
of essential proteins, may be a useful target in this regard. 
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Figure 7 - Ionising radiation induces apoptosis via intrinsic and extrinsic pathways 
Induction of apoptosis by ionising radiation may proceed through the intrinsic or extrinsic pathway. 
In the intrinsic pathway DNA damage is sensed by either p53-dependent or p53-independent 
pathways. This leads to altered mitochondrial permeabilisation and the release of cytochrome C, 
which induces caspase activity. Alternatively, ionising radiation may trigger death ligand binding to 
death receptors, such as the TRAIL family, which sets in motion a caspase cascade. Interestingly, 
DNA damage may lead to upregulation of death receptors which may sensitise cells to radiation. 
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1.5 Focal adhesion kinase (FAK) 
Focal adhesions are sites where cells contact the extracellular matrix (ECM). 
These sites are enriched in integrins and in various cytoskeletal and signalling 
proteins, including talin, vinculin, and paxillin (Figure 8). As such, focal 
adhesions are thought to function as connections between the actin cytoskeleton 
and the ECM thereby conferring structural integrity as well as transmitting 
critical signals from the external environment to the nucleus. Following its 
discovery as a focal adhesion protein that was phosphorylated in response to Src 
transformation (Hanks, Calalb et al. 1992; Schaller, Borgman et al. 1992), focal 
adhesion kinase (FAK) has emerged as a key signalling component at these 
complex dynamic sites. Since then, extensive research has revealed that FAK 
plays an integral role in normal development and FAK has been implicated in 
cancer. 
 
1.5.1 FAK structure and function 
FAK is a 125 kDa non-receptor protein tyrosine kinase that does not span or 
associate directly with the plasma membrane. It is structurally distinct from 
most other non-receptor tyrosine kinases,  which generally consist of a tyrosine 
kinase domain, protein-protein, protein-lipid and other interaction domains; the 
most common protein-protein interaction domains being SH2 and SH3 domains 
(reviewed by (Hubbard and Till 2000)).  FAK contains a central catalytic domain 
flanked by an amino-terminal functional ezrin radixin myosin (FERM) domain and 
a carboxy-terminal Focal Adhesion Targeting domain (FAT) (Figure 9), but unlike 
other non-receptor tyrosine kinases, FAK does not contain SH2 or SH3 domains 
and only the catalytic domain shows significant homology to any other protein 
tyrosine kinase. 
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Figure 8 - Schematic diagram of focal adhesion components 
Transmembrane integrin receptors transduce signals from the extracellular matirx leading to 
recruitment of large multi-protein complexes.  These complexes contain key signalling proteins 
such as FAK (shown in red), Src, paxillin and talin and provide a link between integrin receptor 
signalling and the actin cytoskeleton. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 - Schematic representation of FAK structure 
FAK contains a central catalytic domain flanked by a large amino-terminal domain and a carboxy-
terminal portion. These contain multiple binding sites for proteins such as Src, paxillin and talin. 
FAK contains six sites of tyrosine phosphorylation with the major site of autophosphorylation at 
FAK-Y397 highlighted in red. The focal adhesion targeting (FAT) domain is located in the carboxy-
terminus and is common to both FAK and FRNK.  
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1.5.1.1 FAK phosphorylation 
Six sites of tyrosine (Y) phosphorylation have been identified on FAK, namely 
Y397, Y407, Y576, Y577, Y861 and Y925 (Figure 9) (Schaller, Hildebrand et al. 
1994; Calalb, Polte et al. 1995; Schlaepfer and Hunter 1996).  Upon adhesion to 
the ECM, these sites are phosphorylated in cells, leading to the recruitment of 
various adaptor molecules and protein kinases, which form complexes with FAK.              
FAK-Y397 and FAK-Y407 lie within the amino-terminal half of FAK, and by the 
use of recombinant FAK protein, FAK-Y397 has been identified as the major site 
of autophosphorylation (Calalb, Polte et al. 1995).  After integrin engagement, 
phosphorylated FAK-Y397 forms an SH2 binding site for several proteins such as 
Src family kinases, the regulatory p85 subunit of phosphoinositide (PI) 3-Kinase, 
the Src homologous and collagen-like protein (Shc), and phospholipase C gamma 
(PLCγ) (Schaller, Hildebrand et al. 1994; Xing, Chen et al. 1994; Chen, Appeddu 
et al. 1996; Schlaepfer, Jones et al. 1998; Schaller 2001).  Recruitment of Src to 
phosphorylated FAK-Y397 promotes Src dependent phosphorylation of the 
remaining tyrosine residues of FAK (reviewed in (Schlaepfer, Hauck et al. 1999)).  
The resultant increase in phosphorylation further enhances FAK activity, placing 
FAK at the central hub of multiple signalling pathways.    
FAK-Y576/7 lies within the kinase activation loop and phosphorylation of both of 
these residues is required for maximal FAK kinase activity.  However, 
mutagenesis studies in which FAK-Y397 has been replaced by a phenylalanine 
(FAK-Y397F) demonstrated that this site is also essential for maximum FAK 
kinase activity and downstream signalling (Calalb, Polte et al. 1995). To further 
complicate matters, in vitro kinase assays have demonstrated a role for FAK-
Y576/7 in the regulation of transphosphorylation of FAK on Y397, with mutation 
of these residues impairing FAK-Y397 autophosphorylation (Leu and Maa 2002).  
The same study also highlighted that FAK-Y861 contributes to the activation of 
FAK-Y397 by regulating its cis-phosphorylation (Leu and Maa 2002).  Collectively, 
this data suggests that FAK-Y397 phosphorylation may be differentially regulated 
by phosphorylation of distinct tyrosine sites within FAK.  FAK-Y861 is heavily 
phosphorylated in cells by Src family kinases and in vitro by c-Src (Brunton, 
Avizienyte et al. 2005) and is thought to be important in mediating the anti-
apoptotic activity of FAK (Abu-Ghazaleh, Kabir et al. 2001).  FAK-Y925 is also 
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phosphorylated by Src upon integrin stimulation. This creates an SH2 binding site 
for the small adaptor protein Grb2, which links FAK signalling to the MAPK 
pathway (Schlaepfer, Hanks et al. 1994; Schlaepfer, Hauck et al. 1999).   
In addition, FAK can be phosphorylated on multiple serine residues located 
within the carboxy-terminal domain (S732, S840, S843 and S910), in response to 
various stimuli (Ma, Richardson et al. 2001). Despite being less well studied than  
tyrosine phosphorylation, there is evidence which implicates FAK serine 
phosphorylation in both FAK regulation and the control of biological processes 
such as microtubule organisation (Xie, Sanada et al. 2003). 
1.5.1.2 FAK amino-terminal (FERM) domain 
The functional ezrin radixin myosin (FERM) domains serve as a link between the 
actin cytoskeleton and the plasma membrane and they are primarily involved in 
mediating both intra-molecular and inter-molecular protein-protein interactions 
(reviewed by (Sun, Robb et al. 2002)). The FAK FERM domain, for example, links 
FAK to growth factor receptors at the plasma membrane. However, the FERM 
domain also regulates FAK activity and phosphorylation. Early studies found that 
FERM domain truncations of FAK yield proteins with increased tyrosine 
phosphorylation and associated activity (Chan, Kanner et al. 1994; Schlaepfer 
and Hunter 1996), thus supporting a negative regulatory role in FAK activation. 
As the FAK FERM domain can bind the FAK kinase domain and inhibit FAK activity 
in-trans, a direct auto-inhibitory mechanism for FAK regulation was proposed. 
Structural data was recently published confirming this (Lietha, Cai et al. 2007). 
However, the precise mechanisms which drive FAK-FERM-protein interactions 
have yet to be elucidated. Intriguingly, it seems that the FAK FERM domain has 
yet another function. Under conditions of cellular stress, the FERM domain can 
facilitate nuclear translocation of FAK and promote binding to p53 and MDM2 
(Lim, Chen et al. 2008). As p53 can inhibit transcription of FAK (Golubovskaya, 
Finch et al. 2008), this newly described property of the FAK FERM domain may 
have profound consequences on the level of FAK within the cell. The subject of 
the FAK–FERM–p53 interaction will be revisited in Section 1.5.3. 
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1.5.1.3 FAK kinase domain 
The activation of FAK requires autophosphorylation of FAK-Y397, recruitment 
and binding of Src, and subsequent Src induced phosphorylation of FAK-Y576/7 
(Calalb, Polte et al. 1995; Schlaepfer, Hauck et al. 1999). Autophosphorylation 
has been shown to be temporally related to the clustering of integrin receptors 
in the cell membrane that occurs when these receptors bind their ligand. The 
integrin receptor clustering triggers a conformational change in FAK that alters 
the interaction of the FERM domain with the kinase domain. FAK also undergoes 
autophosphorylation in response to activation by certain growth factor receptors 
in adherent cells. A number of studies have demonstrated that point mutations 
within the kinase domain may lead to FAK activation, for example, mutation of 
residues FAK-K578 and FAK-K581 to a glutamic acid (E) result in a “super-FAK” 
protein which displays adhesion independent kinase activity (Gabarra-Niecko, 
Keely et al. 2002).  Although mutagenesis experiments are of interest in the 
laboratory setting, it is notable that spontaneous mutations in FAK have not 
been reported in any species. While there is evidence that FAK may be 
upregulated by gene amplification, often the precise mechanism underlying 
elevated FAK expression and/or activity is unknown. What is known is that the 
kinase activity of FAK can be regulated in many different ways. These include 
direct binding of the negative regulator FAK-interacting protein of 200kDa 
(FIP200) to the kinase domain (Abbi, Ueda et al. 2002) and an intra-molecular 
interaction involving the FAK-FERM domain and the kinase domain (Lietha, Cai et 
al. 2007), as outlined above in Section 1.5.1.2.  FAK activity can also be 
regulated by protein tyrosine phosphatases (PTPs) which act upstream to 
regulate FAK-Y397 phosphorylation in response to integrin stimulation (Zheng, 
Xia et al. 2009).   
1.5.1.4 FAK carboxy-terminal portion 
The carboxy-terminal portion of FAK contains two proline rich regions, two 
paxillin binding sequences, a talin binding sequence, the focal adhesion 
targeting domain (FAT) and FAK-Y861 and FAK-Y925 (Figure 9).  The first proline 
rich region was identified as a binding site for the adaptor protein p130 v-Crk 
associated tyrosine kinase substrate (p130cas) (Polte and Hanks 1995) and c-Cbl-
associated protein (CAP) (Ribon, Herrera et al. 1998).  The second was identified 
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as a binding site for the GTPase-activating protein for rho associated with focal 
adhesion kinase (GRAF) (Hildebrand, Taylor et al. 1996).  These proteins are 
thought to play important roles in the formation of actin stress fibres and 
cytoskeletal organisation (Hildebrand, Taylor et al. 1996; Honda, Oda et al. 
1998; Ribon, Herrera et al. 1998). Binding of this domain to paxillin and talin 
(Chen, Appeddu et al. 1995; Tachibana, Sato et al. 1995), on the other hand, 
aids in the recruitment of FAK to adhesion complexes (Tachibana, Sato et al. 
1995; Hagel, George et al. 2002). 
1.5.1.5 FAK isoforms 
An amino-terminally truncated form of FAK, known as the FAK related non-
kinase domain (FRNK), can be expressed independently of the entire FAK protein 
through alternative splicing of the fak gene (Schaller, Borgman et al. 1993).  
FRNK has been shown to function as a physiological dominant negative inhibitor 
of FAK (Richardson and Parsons 1996).  Other isoforms of FAK created by 
alternative splicing have also been identified, mainly in rat brain tissue 
(Burgaya, Toutant et al. 1997). Some of these proteins have increased 
autophosphorylation activity, suggesting that FAK may have specific properties 
in neurones.  
1.5.1.6 FAK family members 
Pyk 2, also referred to as cell adhesion kinase-beta (CAK-β), related adhesion 
focal tyrosine kinase (RAFTK), or calcium dependent protein tyrosine kinase 
(CADTK), is the only other FAK family member to be identified (Lev, Moreno et 
al. 1995). FAK and Pyk2 share significant sequence homology, the majority of 
which comprises the kinase domain, the conserved tyrosine residues in the 
surrounding region responsible for binding SH2 containing proteins, the proline 
rich regions responsible for binding SH3 containing proteins and the paxillin 
binding sequences (reviewed by (Lipinski and Loftus 2010)). Pyk2 has four 
tyrosine phosphorylation sites (Y402, Y579/80 and Y881) at analogous positions 
to that of FAK (Y397, Y576/7 and Y925), and upon phosphorylation recruits Src 
family kinases. Although Pyk2 is stimulated by cell adhesion, it can also be 
activated in response to ultra violet (UV) light, hyper-osmotic shock, and 
changes in intracellular calcium levels (reviewed by (Lipinski and Loftus 2010)). 
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Interestingly, while FAK is ubiquitously expressed, Pyk2 is often highly expressed 
in cells of the haemopoetic and nervous system. What is more, Pyk 2 is not 
typically associated with focal adhesions, and instead is often localised in 
punctate spots in the peri-nuclear region.  The altered distribution and 
localisation of FAK and Pyk2 at both tissue and cellular levels would suggest that 
they perhaps have alternate properties. However, in mouse embryo fibroblasts 
genetically deficient for FAK, Pyk2 can compensate for certain aspects of FAK 
signalling.  
1.5.2 FAK is involved in multiple intracellular processes 
By virtue of its scaffolding and kinase domains, FAK interacts with an array of 
cellular proteins and is involved in a myriad of crucial cell signalling pathways. 
Work from the FAK knockout mouse model, for example, has demonstrated that 
FAK is necessary for vascular development and gastrulation in early embryonic 
life (Ilic, Furuta et al. 1995). In addition, FAK has been implicated in cancer. 
This is not surprising as an accumulating body of data links FAK with processes 
that are perturbed in malignancy, such as proliferation, migration, invasion, and 
angiogenesis. In this section the evidence associating FAK with these processes 
will be discussed, with emphasis on the relevance to human cancer. 
1.5.2.1 Proliferation and cell cycle 
FAK has been implicated in the control of cell proliferation where it is thought to 
mediate signals from growth factor receptors and integrins to regulate cell cycle 
progression. In fibroblasts it has been shown that FAK controls the G1-S 
transition and this is linked to its ability to regulate transcription of cyclin D1 
(Zhao, Pestell et al. 2001; Zhao, Bian et al. 2003). There is also evidence that 
FAK can regulate proliferation in cancer cells. In glioblastoma, for example, FAK 
controls exit of cells from G1 phase of the cell cycle via a mechanism involving 
cyclin D1 and p27 (Ding, Grammer et al. 2005). This property of FAK appears to 
be cell line dependent as FAK is often dispensable for proliferation, at least on 
tissue culture plastic. This does not mean that FAK will be dispensable for 
anchorage – independent proliferation in the same cell line. In fact, in this thesis 
we will show that FAK is a prerequisite for 3D, but not 2D, proliferation in a 
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murine squamous cell carcinoma cell line, and that the kinase activity of FAK is 
integral to this phenomenon.  
1.5.2.2 Migration 
Cell migration is central to many processes such as embryonic development, 
wound healing and cancer invasion and metastasis.  Initial studies in FAK 
deficient mouse embryo fibroblasts (MEFs) illustrated that loss of FAK led to 
impaired focal adhesion turnover and cell migration (Ilic, Furuta et al. 1995). 
Subsequently, specific loss of FAK from mouse keratinocytes was also shown to 
result in impaired migration (McLean, Komiyama et al. 2004). Re-introduction of 
kinase dead FAK (FAK-KD) into FAK deficient MEFs was not able to restore 
migration on fibronectin (Sieg, Hauck et al. 2000), indicating that the kinase 
activity of FAK is required. In contrast, growth factor stimulated migration was 
not dependent on the kinase activity of FAK, but was instead dependent on 
interactions within the N-terminal domain of FAK (Sieg, Hauck et al. 2000). 
Further work suggested that the ability of FAK to control cell migration was 
related to regulation of cell polarity (Tilghman, Slack-Davis et al. 2005), 
although this did not specify whether the effect was kinase-dependent or 
independent.  Recent data produced in this laboratory indicates that the ability 
of FAK to control directional cancer cell migration is indeed mediated via cell 
polarity. However, this is a complex process that involves both FAK kinase 
activity (personal communication – Valerie Brunton) and FAK adaptor functions 
(Serrels, Sandilands et al, submitted).  Interestingly, these processes can be 
overcome by inhibition of FAK kinase activity (personal communication – Valerie 
Brunton). This finding is significant as it may support the potential use of FAK 
kinase inhibitors to prevent tumour spread. 
1.5.2.3 Invasion 
Cell invasion through matrix and tissue barriers requires increased cell motility 
and usually also regulated proteolytic degradation of the matrix. FAK has been 
shown to mediate the invasive activity of both normal and v-Src transformed 
fibroblasts through reconstituted 3D matrix (Hauck, Hsia et al. 2002; Hsia, Mitra 
et al. 2003). While v-Src can promote transformation in FAK -/- cells  and 
overcome the motility defects associated with FAK deficiency (Hsia, Mitra et al. 
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2003; Moissoglu and Gelman 2003), these cells are defective in invading 3D 
matrices in vitro compared with v-Src transformed FAK containing cells (Hsia, 
Mitra et al. 2003). Moreover, dominant-negative inhibition of FAK activity 
blocked v-Src stimulated cell invasion and experimental metastases in nude mice 
without effects on in vitro motility (Hauck, Hsia et al. 2002). This was associated 
with decreased levels of matrix metalloproteinase (MMP) expression and activity. 
Further studies using either dominant negative or anti-sense inhibition of FAK 
have also shown reduced expression of MMPs in a range of carcinoma cell lines 
(Shibata, Kikkawa et al. 1998; Hauck, Hsia et al. 2002; Zhang, Thant et al. 
2002), implying a general requirement for FAK for the production and activity of 
MMPs that have cancer-associated matrix-degrading activities.  
Taken together, it appears to be the case that FAK regulates cell motility and 
invasion by distinct pathways; that is, by promoting the dynamic regulation of 
focal adhesions and peripheral actin structures during migration, as well as by 
MMP-mediated matrix degradation (reviewed by (Tomar and Schlaepfer 2009)). 
Interestingly, it is now quite well recognised that cancer cells can invade a 3D 
matrix by both MMP-dependent and MMP-independent mechanisms – referred to 
as mesenchymal-like and amoeboid-like invasion, respectively (reviewed by 
(Tomar and Schlaepfer 2009)). The precise function(s) of FAK during these 
specific mechanisms of invasion have yet to be elucidated. Since FAK has been 
implicated in MMP expression, and in the transition from an epithelial to  a 
mesenchymal phenotype in cancer cells (Avizienyte, Wyke et al. 2002), it is 
likely that FAK is required for mesenchymal-like invasion. By contrast, the 
amoeboid form of invasion, which does not seem to be dependent on integrin-
mediated adhesions within the matrix, may not critically depend on the 
presence of FAK. However, it has recently been suggested that there is a 
significant degree of overlap and that aspects of both forms of invasion may be 
required for sufficient execution of the metastatic process (Sanz-Moreno, Gadea 
et al. 2008). Exactly how FAK would fit into this model has yet to be 
determined. 
1.5.2.4 Angiogenesis 
The importance of angiogenesis in tumour growth and metastasis has already 
been outlined in Section 1.4.2. Development of blood vessels requires FAK 
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expression, especially in endothelial cells. This is clear from work in the FAK 
knockout mouse model, where endothelial cell dysfunction contributed to the 
embryonic lethal phenotype (Ilic, Furuta et al. 1995). Similarly, conditional 
knockout of FAK in mouse endothelial cells led to impaired angiogenesis (Shen, 
Park et al. 2005). It has been shown that FAK expression in endothelial cells is 
not only necessary for the process of formation of new vessels, but is also 
required for the stability of vascular networks and survival of endothelial cells 
(Shen, Park et al. 2005; Braren, Hu et al. 2006). In contrast, overexpression of 
FAK in vascular endothelial cells directly promotes angiogenesis in transgenic 
mice (Peng, Ueda et al. 2004). In support of a role for FAK in promoting 
angiogenesis in human cancer, a positive correlation between microvascular 
density in tumour specimens and level of FAK expression was found in a clinical 
study of breast cancer patients (Huang, Khoe et al. 2007). Interestingly, it has 
been shown that FAK regulates VEGF expression and induces an angiogenic 
switch in cancers (Mitra, Mikolon et al. 2006). This property of FAK was 
mediated via FAK-Y925 signalling through the MAPK pathway. This suggests that 
FAK kinase activity is important in mediating tumour angiogenesis. In keeping 
with this data, there is some evidence from in vivo studies that small molecule 
inhibitors of FAK activation cause a reduction in the microvascular network 
(Halder, Lin et al. 2007; Roberts, Ung et al. 2008), suggesting that FAK kinase 
inhibitors may be useful anti-angiogenesis agents.  
1.5.2.5 Cell survival 
FAK was first linked to cell survival by Frisch et al., who reported that FAK was 
able to suppress suspension-induced cell death, known as anoikis, in kidney 
epithelial cells (Frisch, Vuori et al. 1996). This ability of FAK to protect cells 
from anoikis depended on both phosphorylation of the Y397 site and FAK kinase 
activity. Overexpression of FAK also protected the same epithelial cells from UV 
light induced cell death (Chan, Lai et al. 1999). Further work showed that 
increased FAK expression in a leukaemia cell line suppressed cell death, 
specifically apoptosis. Again, FAK phosphorylation and kinase activity were 
required for the observed effects on cell survival (Sonoda, Matsumoto et al. 
2000). Since then, induction of apoptosis has been demonstrated in a range of 
cell lines by attenuating FAK activity either by antibody injection (Hungerford, 
Compton et al. 1996; Liu, Yang et al. 2002), antisense oligonucleotides (Xu, 
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Owens et al. 1996) or expression of the isolated focal adhesion targeting domain 
(Ilic, Almeida et al. 1998; Jones, Machado et al. 2001; van de Water, Houtepen 
et al. 2001).  
FAK mediated pro-survival functions are thought to play an important role in 
cancer cell survival. Certainly, adhesion-dependent survival, which is often lost 
in tumour cells, is regulated by FAK (Frisch, Vuori et al. 1996) (Xu, Owens et al. 
1996). Hence, increased FAK expression may encourage matrix-independent 
survival of cancer cells, which then promotes or contributes to invasion and 
metastasis. Preliminary evidence in support of this in cancer cells stemmed from 
work in pancreatic and oral cancer cell lines in which FAK knockdown with siRNA 
resulted in anoikis (Duxbury, Ito et al. 2004; Zhang, Lu et al. 2004). Since then, 
modulation of FAK protein levels has been shown to influence the sensitivity of 
tumour cells to various chemotherapeutic agents (Smith, Golubovskaya et al.; 
Duxbury, Ito et al. 2003; Halder, Landen et al. 2005; Halder, Kamat et al. 2006; 
Wu, Yuan et al. 2006; Halder, Lin et al. 2007; Hochwald, Nyberg et al. 2009; Yu-
Ying, Zhan-Xiang et al. 2009). Is this simply linked to the ability of FAK to 
protect against anoikis? In support of this, signalling from integrins is involved in 
protection from drug induced apoptosis in lung cancer cells (Sethi, Rintoul et al. 
1999). However, in leukaemia cells, the increased sensitisation of cells to an 
anthracycline following reduced FAK expression is not dependent on the ECM 
(Recher, Ysebaert et al. 2004).  
One way in which FAK may contribute to survival (which may be ECM-dependent 
or independent) is by binding to receptor-interacting protein (RIP) (Kurenova, Xu 
et al. 2004), a major component of the death receptor complex. It seems that 
FAK may be able to sequester RIP from the death receptor complex, thereby 
suppressing apoptosis (Kurenova, Xu et al. 2004). Whether this is a common 
mechanism for promoting cancer cell survival has yet to be determined. In 
addition to suppressing apoptosis, there is growing evidence that FAK may 
contribute to other cytoprotective mechanisms such as autophagy (Sandilands, 
Serrels et al., submitted) and inhibiting senescence (Pylayeva, Gillen et al. 
2009). Even more intriguingly is the potential for FAK to influence cell survival 
by regulating p53. This will be discussed in more detail in Section 1.5.3.3.  
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1.5.3 FAK interacts with the tumour suppressor protein p53 
1.5.3.1 The role of p53 in cancer 
The discovery of p53 in 1979 marked the beginning of a dynamic era in cancer 
research. Since then, p53 has been established as a key tumour suppressor; with 
several lines of evidence demonstrating the importance of p53 in the prevention 
of tumour development. It is well recognised that the p53 gene is mutated in 
approximately 50% of all human cancers and that this is typically a late event. In 
the majority of the remaining cancers which retain the ability to express a 
normal p53 protein, there are defects in the ability to respond to p53. Moreover, 
germline mutations in p53 give rise to the Li-Fraumeni cancer susceptibility 
syndrome (Varley 2003). In the laboratory setting, mice deficient in p53 develop 
cancer, typically lymphoma, within the first six months of life (Donehower, 
Harvey et al. 1992; Jacks, Remington et al. 1994; Purdie, Harrison et al. 1994). 
Additionally, in a number of experimental animal models, loss of p53 has been 
shown to cooperate with a wide variety of other oncogenic events to promote 
and accelerate cancer development.  
p53 is particularly interesting, not only in terms of the frequency in which it is 
mutated in malignancy, but also in that it is quite distinct from other tumour 
suppressors whereby a mutation typically causes loss of a specific suppressor 
function. On the contrary, aberrations in p53 often lead to acquired oncogenic 
properties, so-called “gain of function” mutations. There is abundant in vitro 
and in vivo data in support of this, indicating that mutant p53 proteins can 
mediate tumour growth, invasion, and metastasis (Dittmer, Pati et al. 1993; 
Lang, Iwakuma et al. 2004; Olive, Tuveson et al. 2004; Hingorani, Wang et al. 
2005; Caulin, Nguyen et al. 2007). In spite of the convincing laboratory evidence 
linking mutant p53 proteins with more advanced malignancy, coupled with the 
prominence of p53 mutations in human cancers, it has proved difficult to 
definitively pinpoint p53 as a prognostic factor. However, this may be explained 
by poorly designed studies and/or inefficient means of p53 detection, 
particularly in the older reports. 
On balance it appears that while functional normally regulated p53 is not 
essential for normal growth and development, as evinced by knockout mouse 
Chapter 1  47 
models (which is perhaps surprising in view of its role as a key transcriptional 
regulator of cell cycle and apoptosis), it does appear to be crucial in preventing 
malignancy. Even more intriguingly, some mutant forms of p53 seem to actively 
promote a more aggressive cancer phenotype. Unsurprisingly, the prospect of 
targeting p53 in human cancer is an ever increasing field of research. 
1.5.3.2 Targeting p53 in cancer 
Therapeutic manipulation of p53 in cancer falls largely into two categories; (1) 
restoring p53 activation and function in tumours containing wt p53 and (2) 
elimination of mutant p53 or conversion of mutant p53 to wt p53. The latter can 
be achieved in a number of ways including viral mediated gene therapy 
(Bischoff, Kirn et al. 1996; Heise, Sampson-Johannes et al. 1997; Rogulski, 
Freytag et al. 2000) or the application of small molecules such as PRIMA-1 (and 
its analogues) which can restore wt p53 conformation and promote sequence-
specific DNA binding, leading to transactivation of target genes (Bykov, Issaeva 
et al. 2002; Bykov, Issaeva et al. 2005; Bykov, Zache et al. 2005; Magrini, Russo 
et al. 2008; Lambert, Gorzov et al. 2009). These approaches do appear to be 
effective in vitro and in vivo and are now under investigation in the clinical 
setting.  
Re-enabling the full functional capacity of p53 in cancers with deregulated wt 
p53 is far more challenging, not least because regulation of the p53 protein is 
highly complex (reviewed by (Boehme and Blattner 2009)). This occurs 
predominantly at post-translational level and involves a number of mechanisms, 
including phosphorylation, acetylation, and ubiquitination. Interestingly, p53 can 
influence its own regulation by transcriptional activation of the target gene 
MDM2, which ubiquitinates p53 and targets it for proteasome-mediated 
degradation (Momand, Zambetti et al. 1992). In this way, p53 and MDM2 form a 
negative regulatory loop that downregulates p53 expression. Of note, this 
feedback loop was shown to involve FAK (Lim, Chen et al. 2008), following 
speculation that FAK and p53 somehow interacted on a functional level. The 
evidence to date outlining the fascinating relationship between FAK and p53 will 
shortly be presented.  
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MDM2 is overexpressed in 5-10% of human cancers (Momand, Jung et al. 1998). 
Both in vitro and in vivo studies have indicated that the oncogenic activity of 
MDM2 is mainly attributable to its binding and degrading p53 (Montes de Oca 
Luna, Wagner et al. 1995; de Rozieres, Maya et al. 2000). Thus, it has been 
proposed that inhibiting MDM2 in a subset of human cancers should reactivate wt 
p53. To this end, two classes of small molecules have been identified which 
either disrupt MDM2-p53 binding (the most notable being the Nutlins) or inhibit 
MDM2 ubiquitin ligase activity. While encouraging results are being reported at 
the pre-clinical level (reviewed by (Wang and Sun 2010)), there are several 
concerns that must be borne in mind in the clinical development of MDM2 
inhibitors for anti-cancer therapy. Firstly, these compounds are likely to induce 
p53 in normal cells and this may cause adverse effects.  Secondly, MDM2 itself is 
likely to accumulate as a result of p53 activation and this may have deleterious 
effects (Gu, Zhu et al. 2009).  
The first concern is not specific to MDM2 and the activation of wt p53 in normal 
cells must be a consideration when developing any drug that is designed to 
restore p53 levels in cancer cells. Indeed, it is quite well recognised that normal 
tissue toxicity secondary to chemotherapy and/or radiotherapy is at least in part 
due to p53 activation and induction of apoptosis (Komarova, Chernov et al. 1997; 
Jiang and Dong 2008). This knowledge has in turn prompted the development of 
chemical inhibitors of p53 that can be used temporarily to protect against the 
side effects of cancer treatments (Komarov, Komarova et al. 1999). 
In order to target p53 in cancer effectively, it will be crucial to select the 
correct approach for each individual patient based on their tumour 
characteristics. This is likely to involve molecular profiling, a technique which is 
not routinely performed in current clinical practice. While some subsets of 
patients could be relatively easily identified, such as those with mutant p53 or 
overexpression of MDM2, some molecular profiles may be more difficult to 
interpret. In particular, it may not always to be appropriate to elevate tumour 
levels of wt p53.  There is evidence that in some situations possessing wt p53 
may be detrimental. This is illustrated not only by its connection with genotoxic 
induced normal tissue toxicity as outlined above; wt p53 can sometimes 
promote, rather than inhibit, tumour growth (reviewed by (Kim, Giese et al. 
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2009)). The exact reasons for this are unclear but merit intensive study. The 
paradoxical roles of p53 in cancer will be discussed further in Chapters 5 and 6.  
While there is no doubt that p53 plays a critical role in protecting against 
malignant development, understanding exactly how p53 functions will be key to 
the development of therapies based on activating or mimicking p53 functions.  
1.5.3.3 Understanding the FAK – p53 axis and its significance in cancer  
The FAK –/- MEFs described by Ilic et al. (Ilic, Furuta et al. 1995) suggested an 
important functional interaction between FAK and p53, as these cells could only 
proliferate in vitro in the absence of p53. Following this, several studies in 
normal and/or cancer cells reported an indirect link between FAK and p53, that 
seemed to be important in mediating cell survival (Ilic, Almeida et al. 1998; 
Lewis, Truong et al. 2002; Zhang, Lu et al. 2004). Meanwhile, there were a 
number of reports documenting the presence of a p53 binding site on FAK 
suggesting a direct interaction (Golubovskaya, Kaur et al. 2004; Golubovskaya, 
Finch et al. 2005; Golubovskaya and Cance 2007). In keeping with this, definitive 
evidence of a direct FAK–p53 functional interaction emerged in 2008. The work 
by Lim et al. demonstrated a scaffolding role for FAK in facilitating cell survival 
through enhanced p53 degradation under conditions of stress (Lim, Chen et al. 
2008). Intriguingly, this process requires translocation of FAK to the nucleus and 
is dependent on the FERM domain. In fact, it is the FERM domain that binds to 
p53 and stabilises the p53-MDM2 complex.  
Although the authors were able to show that the FAK-p53 axis exists in human 
fibroblasts and A549 lung cancer cells as well as murine derived tissue, the 
precise relevance of this axis in terms of human malignancy is unclear. Notably, 
an additional stress in the form of cisplatin was required in combination with 
FAK knockdown in order to induce significant levels of apoptosis in fibroblasts. 
However, cell death was not specifically examined in any cancer cell line.  
Further work has also illustrated the presence of a FAK-p53 relationship in 
cancer cells. Essentially, wt p53 was able to bind to and inhibit FAK promoter 
activity in a colorectal cancer cell line (Golubovskaya, Finch et al. 2008). Again, 
the functional significance of this is unclear. Interestingly, this study showed 
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that FAK expression was increased in human colorectal cancer tumour specimens 
containing p53 mutations compared to tumours with wt p53. Also, insertion of 
various p53 mutations into p53 -/- cancer cells failed to inhibit FAK promoter 
activity unlike wt p53 (Golubovskaya, Finch et al. 2008). However, a similar 
correlation was not seen in tissue samples from head and neck cancer (Rodrigo, 
Cabanillas et al. 2007). 
Taken together, current evidence suggests that FAK and p53 can exert important 
regulatory influences over the other, but this may be tissue specific. Exactly how 
this relationship is related to carcinogenesis or how it affects the response to 
anti-cancer therapies has yet to be fully elucidated. Interestingly, it hints that 
lowering FAK levels may be useful in both tumours with wt 53 and mutant p53. 
In the case of wt p53 tumours, a reduction in FAK may promote p53 mediated 
apoptosis, although it is likely that another stressor is required. On the other 
hand, if mutant p53 allows uncontrolled transcription of FAK which then 
contributes to tumour cell survival, inhibiting FAK under these circumstances 
may also be advantageous.  
However, we believe that the FAK-p53 axis is likely to be cell line and context 
dependent and in this thesis we will present data that challenges the view that 
FAK knockdown increases susceptibility to cell death in a wt p53 cancer cell line. 
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1.5.4 FAK as a potential target in human cancer 
1.5.4.1 FAK and carcinogenesis 
FAK has been implicated in a wide range of cellular processes that are 
deregulated in malignancy as just outlined in Section 1.5.2. In addition, elevated 
levels of FAK have been reported in a variety of human cancers. Confirmation of 
a causative role for FAK in tumour formation and progression was initially 
lacking, until work performed in this laboratory demonstrated that FAK was 
required for the initiation and development of skin cancer in a mouse model 
(McLean, Komiyama et al. 2004). It had already been shown using fak 
heterozygous (+/-) mice that FAK was involved in the formation of benign 
papillomas in response to DMBA/TPA induced topical carcinogenesis, but no 
effects were observed on malignant conversion, probably due to the fact that 
FAK protein levels were expressed in papillomas of both fak +/+ and fak+/- mice 
to equal levels (McLean, Brown et al. 2001).  By conditionally deleting fak in 
murine keratinocytes, however, and subjecting the animals to the same topical 
carcinogenesis protocol, it was clear that FAK was important for both papilloma 
formation and conversion to squamous cell carcinoma (McLean, Komiyama et al. 
2004).  
 
Parallel in vitro studies of keratinocytes from this model revealed that loss of 
FAK expression led to aberrant cell cycle profiles and cell death (McLean, 
Komiyama et al. 2004). Furthermore, FAK was essential for promoting cell 
survival via the MAPK signalling pathway. Taken together, this data was 
consistent with FAK-dependent survival signalling being required for cancer 
development and progression, at least in this model. More recently, FAK has also 
been directly implicated in mouse mammary tumour  development (Provenzano, 
Inman et al. 2008; Luo, Fan et al. 2009).  
 
1.5.4.2 FAK and human cancer 
Increased expression of FAK was first noticed in high grade and metastatic 
sarcomas (Weiner, Liu et al. 1994). Since then elevated FAK expression and/or 
activity has been reported in a variety of epithelial malignancies, including  
cancers of the thyroid, pancreas, prostate, cervix, rectum, head and neck, and 
Chapter 1  52 
ovary (Owens, Xu et al. 1996; Tremblay, Hauck et al. 1996; McCormack, 
Brazinski et al. 1997; Lori 1998; Patricia, Xiaping et al. 1999; Cance, Harris et al. 
2000; Lark, Livasy et al. 2003; Furuyama, Doi et al. 2006). Most of these studies 
are based on immunohistochemical or immunoblotting analysis. Hence, the 
precise mechanism of upregulation is not always clear. Amplification of the fak 
gene has been reported in a few cancer cell lines, and increased gene copy 
number are found in cells derived from head and neck cancer (Agochiya, Brunton 
et al. 1999).  It is noteworthy that mutations in FAK have not been reported in 
human cancer. Elevated FAK protein expression and activity need not be 
regulated at the genetic level, however, as FAK is regulated by a complex range 
of mechanisms. These include tyrosine phosphorylation, serine/threonine 
phosphorylation and many protein binding interactions (reviewed by (Li, Hua et 
al. 2008)). In light of recent observations, the possibility of p53 mediated FAK 
regulation must also be considered. 
 
Typically, the lowest levels of FAK expression are found in normal tissues with 
higher levels present in pre-neoplastic tissue and malignant tissue. In some 
situations, elevated FAK expression and/or activity has correlated with a poorer 
outcome (Recher, Ysebaert et al. 2004; Sood, Coffin et al. 2004; Cai, Han et al. 
2009). This suggests that FAK may be a useful prognostic indicator. However, a 
negative correlation between FAK expression levels and overall survival is not 
always seen, although several studies have failed to reach statistical significance 
due to insufficient patient numbers. Although FAK appears to be required at 
slightly different stages in carcinogenesis in the conditional mouse models, it is 
interesting that the highest levels of FAK recorded in human tumours are often 
detected in metastatic disease (Cance, Harris et al. 2000; Lark, Livasy et al. 
2003; Sood, Coffin et al. 2004). Based on the in vitro work outlined in Section 
1.5.2.3  and in vivo orthotopic studies (van Nimwegen, Verkoeijen et al. 2005; 
Mitra, Lim et al. 2006), FAK can contribute towards metastasis by promoting a 
pro-survival invasive phenotype that would permit passage through the ECM and 
entry to the lymphatic supply or vasculature. Does this mean that FAK is 
necessary for the maintenance and growth of metastatic deposits? Most of the 
evidence to date would suggest that this is the case but it is worth noting that in 
certain cases FAK levels appear to be lower in metastatic tumours compared 
with the primary (Ayaki, Komatsu et al. 2001). 
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Further clarification is still required regarding the precise functions of FAK in 
human cancer. However, in view of increasing circumstantial evidence linking 
elevated FAK protein levels with a range of human tumour types, coupled with 
the incriminating role for FAK in promoting carcinogenesis in conditional mouse 
models, FAK has been selected as a potential target at which to direct novel 
anti-cancer therapies. The next section will focus on the available anti-FAK 
agents and their progress in the clinical setting.  
 
1.5.4.3 Anti-FAK targeted agents 
Although FAK appears to have important scaffolding functions that are distinct 
from its catalytic activity, much of the work to date has focussed on inhibiting 
the latter. This is probably because kinases are more readily druggable targets. 
Two FAK kinase inhibitors have dominated the recent preclinical literature: PF-
562,271 (Pfizer) and TAE226 (Novartis).  
PF-562,271 is an ATP-competitive and reversible inhibitor, with selective activity 
against FAK and the related family member Pyk2. While this drug does not 
significantly inhibit proliferation or apoptosis in vitro, it does significantly inhibit 
migration in vitro and growth in vivo (Slack-Davis, Martin et al. 2007; Bagi, 
Roberts et al. 2008; Roberts, Ung et al. 2008; Bagi, Christensen et al. 2009) 
Interestingly, some of the effects in vivo are thought to be due to anti-
angiogenic effects. It has been suggested that compensatory signalling through 
Pyk2 may circumvent the anti-angiogenic features of selective FAK inhibition 
(Weis, Lim et al. 2008). As a dual inhibitor of both FAK and Pyk2, this particular 
function should not be compromised and may explain the promising actions of 
this drug. In the clinical setting, Phase I testing has now been undertaken in 
advanced solid malignancies. The drug was well tolerated with mild fatigue and 
gastrointestinal toxicity as the most common side effects. Although no partial 
responses were noted, disease stability was reported in several patients 
(Schwock, Dhani et al. 2010). This is encouraging in a heavily pre-treated 
population.  
TAE226 is a dual-specificity inhibitor targeting both growth promoting and 
adhesion pathways through its activity against the insulin-like growth factor 
receptor (IGF-1R) and FAK, respectively. While some very promising results have 
Chapter 1  54 
been observed in the laboratory setting (Halder, Lin et al. 2007; Liu, LaFortune 
et al. 2007; Shi, Hjelmeland et al. 2007; Beierle, Trujillo et al. 2008; 
Golubovskaya, Virnig et al. 2008; Roberts, Ung et al. 2008; Wang, Fukazawa et 
al. 2008; Watanabe, Takaoka et al. 2008; Sakurama, Noma et al. 2009), the 
overlapping activities of this agent make it difficult to decipher the precise 
mechanisms underlying any therapeutic efficacy. This drug has profound effects 
on glucose metabolism, most likely due to inhibition of IGF-1R, and for that 
reason did not enter clinical development. A number of second generation 
compounds with enhanced selectivity for FAK have been developed and are due 
to undergo Phase I trials. 
Although siRNA and anti-sense oligonucleotides can be useful tools with which to 
inhibit FAK in the laboratory, this type of approach is unlikely to prove useful in 
the clinic. Instead, it may be appropriate to develop protein-protein interaction 
inhibitors designed to interrupt FAK regulatory connections. These agents are 
typically much more complicated to develop than kinase inhibitors. Based on 
evidence to date, possibilities include FAK-RIP and FAK-p53 specific inhibitors. 
While there is more evidence in support of the latter, we will present data that 
suggests an indirect, but kinase-dependent relationship between FAK and p53. It 
may be that the catalytic versus adaptor functions of FAK vary in a cell line 
dependent or tissue dependent manner. More information is necessary regarding 
the specific kinase or scaffolding roles of FAK and how their respective 
attenuation will contribute to the effectiveness of anti-FAK therapies. 
Regardless of the exact underlying mechanism, be it reduced FAK levels, 
reduced FAK activity, or FAK-p53 deregulation, there is no convincing evidence 
to date that FAK inhibition alone in cancer cells will be sufficiently efficacious. 
For that reason, it is likely that modulation of FAK levels and/or activity will 
need to be combined with traditional anti-cancer modalities, or possibly other 
targeted agents. There is in vitro and in vivo evidence demonstrating that FAK 
knockdown can sensitise cells to cytotoxic chemotherapy (Smith, Golubovskaya 
et al.; Duxbury, Ito et al. 2003; Halder, Landen et al. 2005; Halder, Kamat et al. 
2006; Wu, Yuan et al. 2006; Halder, Lin et al. 2007; Hochwald, Nyberg et al. 
2009; Yu-Ying, Zhan-Xiang et al. 2009).  
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However, several interesting theories exist which may support the use of FAK 
inhibitors as a means of single agent therapy. Firstly, inhibiting FAK may prevent 
the progression of pre-invasive conditions to frank malignancy. Secondly, anti-
FAK targeted agents may be useful in the adjuvant setting as an anti-metastatic 
tool. Testing both of these hypotheses would require carefully designed clinical 
trials with extended periods of follow up. 
1.6 Exploring the role of cell adhesion signalling 
molecules in radiation survival 
1.6.1 FAK and radiation 
At the time of initiating this study, there was no published data available on FAK 
and cellular radiation survival. It had been documented that phosphorylation of 
FAK was induced following exposure to ionising radiation in vitro (Beinke, Van. 
Beuningen et al. 2003), although this report featured only a single cell line and 
it was unclear whether this phenomenon was simply a transient stress response 
as no clonogenicity studies were performed. We suspected that FAK may play a 
role in radiosensitivity in view of its multiple properties within the cell, 
particularly the accumulating evidence linking FAK to cell survival. In addition, a 
small body of work was emerging, predominantly from a laboratory in Germany, 
on the concept of ECM mediated radioresistance, whereby radiation can promote 
cell survival through cell adhesion signalling pathways. Initially this work did not 
focus specifically on FAK, but as FAK is an important central point in cell 
adhesion signalling, it was only a matter of time before FAK was investigated in 
this context.  In fact, data has now been published which demonstrates that FAK 
knockdown increases radiosensitivity in human pancreatic cancer cell lines 
(Cordes, Frick et al. 2007). While this was the first time FAK had been 
definitively linked with radiation survival, the authors were unable to provide a 
clear explanation of the underlying mechanism(s), prompting a number of 
questions about how exactly FAK exerted this effect. However, Src, which 
interacts closely with FAK as previously outlined, has been subject to more 
rigorous investigation as a potential radiomodulator (discussed below).  
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1.6.2 Src and radiation 
Increased Src activity has also been reported in response to ionising radiation 
(Li, Hosoi et al. 2006; Park, Park et al. 2006; Dittmann, Mayer et al. 2008; Kim, 
Byun et al. 2008). The first documented investigation of the role of Src in 
radiosensitivity was performed in endothelial cells using the Src inhibitor SU6656 
(Cuneo, Geng et al. 2006). A significant reduction in radiation survival was 
observed on clonogenicity assays but the dose employed was far in excess of that 
required to inhibit Src and the authors acknowledged that this effect was 
probably due to the off target anti-angiogenic effects of this drug. However, a 
number of recent studies have consistently shown inhibition of Src activity 
increases radiosensitivity (Contessa, Abell et al. 2006; Dittmann, Mayer et al. 
2008; Dittmann, Mayer et al. 2009; Purnell, Mack et al. 2009). What is more, one 
of these studies incorporated Src siRNA, indicating that the effects seen with a 
Src kinase inhibitor are indeed due to inhibition of Src, and not mediated by 
inhibition of kinases other than Src (Dittmann, Mayer et al. 2009). In terms of 
mechanism, it was recently shown that Src activation in response to ionising 
radiation promotes internalisation of EGFR, leading to nuclear translocation of 
EGFR and stimulation of DNA repair processes (Dittmann, Mayer et al. 2008; 
Dittmann, Mayer et al. 2009) 
1.6.3 ECM mediated radioresistance  
It has been recognised for some time that irradiating cells on tissue culture 
plastic coated with ECM components such as fibronectin can increase 
radioresistance (reviewed by (Sandfort, Koch et al. 2007)). This phenomenon 
occurs in both fibroblasts and tumour cells and can often be inhibited by PI3K 
inhibitors, suggesting reliance on adhesion mediated Akt signalling. Although 
interesting, the precise relevance of these findings are unclear, other than 
perhaps hinting at the employment of PI3K inhibitors in combination with 
radiotherapy. However, it has already been pointed out that these agents have 
proved troublesome to adapt in the clinical setting. More recently, work has 
focussed on integrin-linked kinase (ILK), a widely expressed serine/threonine 
protein kinase bound to the cytoplasmic tail of β-integrins (Hannigan, Leung-
Hagesteijn et al. 1996). Intriguingly, although ILK typically promotes cell survival 
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in various biological contexts, ILK -/- fibroblasts are more radioresistant than 
their ILK +/+ counterparts on 2D (Cordes 2004; Eke, Sandfort et al. 2007; Hess, 
Estrugo et al. 2007). However, this effect is lost when the fibroblasts are grown 
in a 3D matrix (Hehlgans, Eke et al. 2008). This indicates that ECM mediated 
signalling may be crucial to radiation survival in fibroblasts and suggests that 
adhesion linked kinases may have different roles in different cellular 
environments. While there is some evidence that ILK can also affect 
radiosensitivity in cancer cells (Eke, Sandfort et al. 2007), and that this might be 
related to EGFR signalling, whether this will translate into an effect in vivo has 
yet to be examined. 
1.7 Summary and Thesis Aims 
Radiotherapy is an essential component of cancer therapy but treatment is not 
always curative. Much effort is currently directed at improving the delivery of 
radiotherapy by increasingly sophisticated spatial and dosimetric methods in 
order to improve patient outcome. However, treatment failure may not 
necessarily result from inadequate dose or coverage of the tumour bed. Ionising 
radiation can promote activation of receptor and non-receptor tyrosine kinases 
leading to profound cytoprotective responses such as increased DNA repair, 
proliferation and reduced apoptosis (Cuneo, Geng et al. 2006; Li, Hosoi et al. 
2006; Park, Park et al. 2006; Cosaceanu, Budiu et al. 2007; Dittmann, Mayer et 
al. 2008; Dittmann, Mayer et al. 2009; Meyn, Munshi et al. 2009). Since these 
responses contribute to cellular radioresistance, which can limit the 
effectiveness of radiotherapy in cancer treatment, understanding these 
phenomena may provide new molecular targets for radiosensitisation and 
ultimately improve cancer outcomes. The epidermal growth factor receptor is 
the most extensively studied tyrosine kinase in this field. Strong preclinical 
evidence relating to the capacity of EGFR inhibition to enhance the antitumour 
activity of ionizing radiation has translated into the clinical setting based on the 
results of a pivotal Phase III trial in head and neck cancer (Bonner, Harari et al. 
2006; Bonner, Harari et al. 2009).  
The role of other tyrosine kinases, especially non-receptor tyrosine kinases, 
however, is less clear. FAK is a highly complex signalling molecule that has been 
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implicated in a wide range of crucial cellular processes that are perturbed in 
malignancy including proliferation, cell cycle, adhesion and invasion (reviewed 
by (Brunton and Frame 2008; Zhao and Guan 2009)). While FAK has been linked 
with resistance to certain cytotoxic chemotherapeutics (Smith, Golubovskaya et 
al.; Duxbury, Ito et al. 2003; Halder, Landen et al. 2005; Halder, Kamat et al. 
2006; Wu, Yuan et al. 2006; Halder, Lin et al. 2007; Hochwald, Nyberg et al. 
2009; Yu-Ying, Zhan-Xiang et al. 2009) a link between FAK and radiation is more 
tenuous. Upregulation of FAK activity following exposure to radiation has been 
reported (Beinke, Van. Beuningen et al. 2003), but whether this observation 
represented a transient stress response or signified that FAK may be critical in 
mediating radiation survival was largely unexplored. During the course of this 
work, other groups did attempt to answer this question. Recently, for example, 
it was shown that transient FAK knockdown with siRNA sensitised pancreatic 
cancer cells to radiation (Cordes, Frick et al. 2007). However, there was no clear 
explanation of a possible underlying mechanism. Hence there was much scope at 
the start of (and indeed during) this project to investigate whether FAK is 
important in radiosensitivity and, if so, to elicit the underlying mechanism. 
FAK regulates an array of important cellular functions that are often deregulated 
in cancer. In view of the roles for FAK in mediating adhesion signalling, cell 
cycle, cell survival, and angiogenesis, we wished to address whether FAK was 
involved in radiosensitivity. A schematic diagram outlining the potential ways in 
which FAK may influence radiosensitivity is shown in Figure 10.  
In this thesis, we set out to: 
1. Generate novel squamous cell carcinoma cells with inducible fak deletion 
in order to study the role of FAK in cellular radiation response. 
2. Evaluate whether the presence or absence of FAK influences 
radiosensitivity in vitro and in vivo. 
3. Dissect out the underlying mechanisms linking FAK to cellular radiation 
response.  
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Figure 10 - FAK may be an important mediator of radiation survival 
At the time of initiating this study, it was known that EGFR could influence radiation survival by 
activation of the Ras/PI3K pathways. Also, there was data that indicated involvement of integrin 
signalling pathways in the cellular response to radiation. ILK, for example, was shown to inhibit 
signalling through the PI3K pathway and promote radiation induced cell death. Following on from 
work demonstrating a role for Src in mediating radiosensitivity in cancer cells, we hypothesised that 
FAK, an important mediator of both growth factor receptor signalling and integrin signalling, could 
also influence radiosensitivity. 
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2 Materials and Methods 
2.1 Materials  
2.1.1 Animal experiments 
Supplier: Sigma Chemical Co, Poole, UK                                                                
Dimethylbenzanthracene (DMBA)                                                                           
4-hydroxy-tamoxifen (4-OHT)  
Sunflower oil                                                                                                            
12-o-tetradecanoyl-13-phorbol acetate (TPA) 
 
2.1.2  Cell culture reagents 
Supplier: Amaxa, Lonza, Cologne, Germany                                                         
Nucleofector solution V 
Supplier: Autogen Bioclear, Wiltshire, UK                                                   
Foetal bovine serum 
Supplier: BD Biosciences, Oxford, UK                                                   
Fibronectin 
Supplier:  Beatson Institute Central Services                                                        
Sterile PBS                                                                                                
Sterile PBS/1mM EDTA 
Supplier: Clonetics, Slough, UK                                                          
Keratinocyte basal medium                                                                    
Keratinocyte growth medium singlequotes 
Supplier: Dharmacon, Abgene Ltd., Epsom, UK                                           
Dharmafect transfection reagent                                                               
Smartpool siRNA pools (p53, p21, scrambled) 
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Supplier:  Invitrogen, Paisley, UK                                                         
Dulbecco’s modified Eagle’s medium (DMEM)                                              
Eagle’s Minimal Essential Medium with Earles salts (MEM)                                      
HBSS                                                                                                           
200mM L-glutamine                                                                                      
MEM vitamins (100x)                                                                                     
MEM non-essential amino acids (NEAA) (100x)                                                        
2.5% trypsin solution                                                                                        
Dispase II 
Supplier: Merck Biosciences, Sussex, UK                                                       
Hygromycin B 
Supplier: R&D systems, Abingdon, UK                                                    
Methylcellulose 
Supplier: Sigma Chemical Co, Poole, UK                                                                
Dimethyl sulphoxide (DMSO)                                                                                            
Sodium pyruvate 
2.1.3 Cell culture plasticware 
Supplier: BD Biosciences, Oxford, UK                                                                 
Cell strainers (40 and 70 µm)                                                                           
Collagen I coated 60mm dishes                                                                          
FACS polypropylene tubes                                                                                  
Falcon tissue culture dishes (60mm, 90mm and 120mm)                                         
Falcon tissue culture plates (6, 12, 24 and 96 well)   
                                                                                                                            
Supplier: Corning, Amsterdam, The Netherlands                                         
Transwell inserts  
Supplier: TCS biologicals, Botolph Clayton, UK                                                         
Nunc tissue culture flasks                                                                                        
Nunc cryotubes 
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2.1.4 Cell based assays and inhibitors 
2.1.4.1 Cell cycle analysis 
Supplier:  Qiagen, Crawley, UK                                                                         
RNase A 
Supplier:  Sigma Chemical Co, Poole, UK                                                       
Propidium iodide (PI) 
2.1.4.2 Cell proliferation assay 
Supplier:  Sigma Chemical Co, Poole, UK                                                                       
Dimethyl sulphoxide (DMSO)                                                                                            
Thiazolyl blue tetrazolium bromide (MTT) 
2.1.4.3 Clonogenic assay 
Supplier:  Sigma Chemical Co, Poole, UK                                                    
Crystal violet solution 
2.1.4.4 Inhibitors  
Supplier:  Bristol Myers Squibb, Middlesex, UK                                                             
Dasatinib 
Supplier: Pfizer, Groton, CT, USA                                                                        
PF-562,271 
Supplier:  Sigma Chemical Co, Poole, UK                                                       
Actinomycin-D                                                                                                
Cisplatin                                                                                                       
Doxorubicin                                                                                                     
4-hydroxy-tamoxifen                                                                                     
Staurosporine                                                                                                          
Taxol                                                                                                               
Topotecan 
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2.1.5 Protein detection 
2.1.5.1 Immunofluorescence  
Supplier: Invitrogen, Paisley, UK                                                                            
Anti-mouse/rabbit AlexaFluor conjugated secondary antibodies 
Supplier: Sigma Chemical Co, Poole, UK                                                                   
TRITC phalloidin                                                                                      
Paraformaldehyde 
Supplier: Vector Laboratories Ltd, Peterborough, UK                                                  
Vectashield mounting medium                                                                     
Vectashield mounting medium with DAPI 
Supplier: Olympus UK Ltd, Hertfordshire, UK                                                            
Olympus FV1000 Confocal microscope  
Primary antibodies 
Supplier:  New England Biolabs, Hertfordshire, UK                                                
Anti-FAK rabbit Ab                                                                                                          
Anti-LC3 rabbit Ab                                                                                                          
Anti-paxillin mouse Ab                                                                                                    
Anti- p53 (IC12) mouse Ab                                                                                               
Anti-phospho-Src-Y416 rabbit Ab 
Supplier:  Upstate (Millipore), Hampshire, UK                                                              
Anti-phospho-γH2AX mouse Ab  
2.1.5.2 Immunohistochemistry 
Supplier: Dako UK Ltd, Ely, UK                                                                                      
DAKO Envision kit ™ (mouse and rabbit)  
Supplier: Olympus UK Ltd, Hertfordshire, UK                                                            
Olympus BX51 microscope  
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Supplier: Sigma Chemical Co, Poole, UK                                                                        
Sodium citrate  
Primary antibodies 
Supplier: Abcam, Cambridge, UK                                                                             
Anti-K14 mouse Ab  
Supplier: Autogen Bioclear, Wiltshire, UK                                                           
Anti-p21 (M-19) mouse Ab 
Supplier:  New England Biolabs, Hertfordshire, UK                                                
Anti-FAK rabbit Ab            
Supplier: R&D systems, Abingdon, UK                                                                 
Anti-activated-Caspase 3 rabbit Ab   
Supplier: Thermo Fisher Scientific, Loughborough, UK                                           
Anti-Ki67 rabbit Ab 
Supplier: Vector Laboratories Ltd, Peterborough, UK                                          
Anti-p53 (CM-5) mouse Ab 
2.1.5.3 Western Blot and Immunoprecipitation 
Supplier: Beckman Coulter UK Ltd, Buckinghamshire, UK                              
Beckman DU® 650 spectrophotometer 
Supplier: Bertin Technologies, Provence, France                                             
Precellys 24 homogeniser                                                                                         
Precellys CK14 homogeniser tubes 
Supplier: Chemicon International, Harrow, UK                                                             
Re-blot Plus Strong antibody stripping solution 
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Supplier: GE Healthcare, Little Chalfont, UK                                                           
ECL reagent                                                                                                         
Full range molecular weight rainbow ™ marker                                                                 
Supplier: Genetic Research Instrumentation, Dunmow, UK                                           
Atto protein electrophoresis apparatus 
Supplier: Invitrogen, Paisley, UK                                                                         
NuPAGE® Bis-Tris gels                                                                                           
NuPAGE® Electrophoresis Apparatus                                                                       
NUPAGE® LDS Sample Buffer (4x)                                                                               
NuPAGE® MOPS Buffer 
Supplier: Jencons, Leighton Buzzard, UK                                                                
Wet blotting apparatus 
Supplier: New England Biolabs, Hertfordshire, UK                                                      
Anti-mouse/horseradish peroxidase conjugate                                                           
Anti-rabbit/horseradish peroxidase conjugate  
Supplier: PERBIO, Glasgow, UK                                                                            
Micro BCA ™ protein assay kit 
Supplier: Schleicher and Schuell, London, UK                                                      
Nitrocellulose membrane 
Supplier: Sigma Chemical Co, Poole, UK                                                             
Ammonium persulphate (APS)                                                                                     
0.1% (v/v) aprotinin                                                                                                        
Bovine serum albumin (BSA)                                                                                     
NP-40                                                                                                                        
2 mM phenylmethylsulponyl fluoride                                                                         
Protein G sepharose beads                                                                                     
Sodium deoxycholate                                                                                          
Sodium fluoride                                                                                                      
Sodium orthovanadate                                                                                              
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TEMED                                                                                                                
T-PER reagent                                                                                                     
Triton X-100                                                                                                                 
Tween 20 
Supplier: Whatman, Maidstone, UK                                                                              
3MM filter paper 
Primary antibodies 
Supplier: Abcam, Cambridge, UK                                                                             
Anti-K14 mouse Ab  
Supplier: Autogen bioclear, Wiltshire, UK                                                              
Anti-p21 (SC-421) rabbit Ab 
Supplier: Chemicon International, Harrow, UK                                                             
Anti-FAK (clone 4.47) agarose conjugated mouse Ab                                                        
Anti-MDM2 rabbit Ab 
Supplier: Invitrogen, Paisley, UK                                                                               
Anti-phospho-FAK-Y861 rabbit Ab 
Supplier: New England Biolabs, Hertfordshire, UK                                                        
Anti- Akt rabbit Ab                                                                                                          
Anti-ERK rabbit Ab                                                                                                          
Anti-FAK rabbit Ab                                                                                                          
Anti-LC3 rabbit Ab                                                                                                          
Anti-myc tag 9B11 mouse Ab                                                                                          
Anti-Src rabbit Ab                                                                                                           
Anti-paxillin rabbit Ab                                                                                                    
Anti-PARP(cleaved) mouse Ab                                                                                          
Anti-p53 (IC12) mouse Ab                                                                                               
Anti-phospho-Akt-S473 rabbit Ab                                                                                     
Anti-phospho-ERK-S42/S44 rabbit Ab                                                                               
Anti-phospho-FAK-Y576 rabbit Ab                                                                                    
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Anti-phospho-FAK-Y925 rabbit Ab                                                                                    
Anti-phospho-Src-Y416 rabbit Ab                                                                                     
Anti-phospho-Pyk2-Y402 rabbit Ab                                                                                   
Anti-PUMA(α/β) rabbit Ab                                                                                               
Anti-Pyk2 rabbit Ab 
Supplier: Sigma Chemical Co, Poole, UK                                                                        
Anti-β-actin mouse Ab                                                                                                   
Anti-γ-tubulin mouse Ab  
Supplier: Transduction Laboratories, BD Biosciences, Oxford, UK                             
Anti-phospho-FAK-Y397 mouse Ab   
2.1.6 Molecular biology techniques 
Supplier: Appleton Woods, Birmingham, UK                                                                  
96 well plates 
Supplier: Bio-Rad, Hertfordshire, UK                                                                  
DNA Engine ® thermal cycler                                                                                           
DNA Engine ® thermal gradient cycler 
Supplier: New England Biolabs, Hertfordshire, UK                                                        
DyNAmo SybrGreen qRT-PCR kit                                                             
Hyperladder IV molecular weight ladder 
Supplier: PERBIO, Glasgow, UK                                                                                      
Mastermix PCR mix (22.5µl aliquots)                                                                                
Supplier: Sigma Chemical Co, Poole, UK                                                                        
Agarose                                                                                                             
Ethidium bromide                                                                                         
Magnesium chloride                                                                                          
NP-40                                                                                                        
Potassium chloride                                                                                       
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Proteinase K                                                                                                  
Tween 20 
Supplier: Qiagen, Crawley, UK                                                                                      
miRNeasy mini RNA extraction                                                                        
Superscript First-Strand cDNA synthesis kit                                                           
QIAquick Gel purification Kit                                                                                           
QIAquick PCR purification Kit                                                                                        
Quantitect qRT-PCR validated primer pair assays  
Supplier: VH Bio, Gateshead, UK                                                                                   
PCR / Sequencing primers 
2.1.7 Stock solutions and buffers  
2.1.7.1 Cell culture solutions 
Cell culture medium – SCC 1.1 and SCC 7.1 cells                                                    
1x MEM supplemented with:                                                                                      
10% FBS                                                                                                                       
2mM L-glutamine                                                                                                      
1% Non Essential Amino Acids                                                                                          
1% MEM vitamins                                                                                                            
1% Sodium Pyruvate 
Cell culture medium – 83320 cells, FAK +/+ and FAK -/- MEFs                                
1x DMEM supplemented with:                                                                          
2mM L-glutamine                                                                                                 
10% FBS                                                                                                                          
 
Trypsin solution 
0.25% trypsin in sterile PBS/1mM EDTA 
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2.1.7.2 DNA and protein extraction / elution buffers 
DNA extraction buffer                                                                                         
50mM KCl                                                                                                           
10mM Tris (pH 7.4)                                                                                             
2.5mM MgCl2                                                                                                      
0.45% NP-40                                                                                                        
0.45% Tween 20                                                                                               
1mg/ml Proteinase K 
RIPA buffer                                                                                                                
50mM Tris/HCl, pH 7.4                                                                                              
150mM NaCl                                                                                                         
Triton X-100                                                                                                          
1% Sodium deoxycholate                                                                                            
1% NP40                                                                                                                      
5mM EGTA                                                                                                                   
100μM sodium orthovanadate                                                                               
1mM PMSF                                                                                                             
10μg/ml aprotinin                                                                                                     
100mM Sodium fluoride                                                                                       
10μg/ml leupeptin 
T-PER protein extraction buffer 
T-PER supplemented with: 
100μM sodium orthovanadate                                                                               
1mM PMSF                                                                                                             
10μg/ml aprotinin                                                                                                     
100mM Sodium fluoride                                                                                       
10μg/ml leupeptin 
 
2.1.7.3 Western blotting – gels and electrophoresis buffers 
Acrylamide gel – 7% 
10ml 30% acrylamide 
15ml Tris pH 8.8 
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15ml H2O 
400μl 10% SDS  
375μl 10% APS 
20μl TEMED 
 
Stacker gel 
3.2ml 30% acrylamide 
2.5ml Tris pH 6.8 
14ml H2O 
200μl 10% SDS  
200μl 10% APS 
20μl TEMED 
 
Sample buffer – 2x 
800μl 2-mercaptoethanol 
1.3ml Tris pH 6.8 
2ml glycerol 
5ml 10% SDS 
1.3ml H2O 
bromophenol blue to colour 
 
Tank buffer - 10x 
0.05M Tris 
0.05M glycine 
0.1% SDS 
 
Transfer Buffer 
50mM Tris 
40mM glycine 
0.04% SDS 
20% methanol 
 
Wash buffer  
0.2% Tween 20 in Tris Base Solution  
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2.2 Methods 
2.2.1 General animal husbandry 
Immune compromised CD-1 mice (Charles River, Edinburgh, UK) were housed in 
the animal unit at the Beatson Institute for Cancer Research. They were 
maintained in filter cages and all procedures performed according to the Home 
Office project licence conditions, rules and regulations. For drug experiments, 
all agents were prepared in a sterile environment and autoclaved where 
appropriate. For radiation experiments, the animals were irradiated in a 
specialised mouse holding chamber which allowed a large degree of 
immobilisation whilst keeping the animals safe with minimal distress. 5Gy γ-
irradiation was applied from a cobalt (60Co) source (Alcyon II teletherapy unit, 
General Electric, France) at a distance of 80cm. The typical dose rate was 1 – 
1.20 Gy/minute. Breeding and maintenance of K14CreER FAKflox/flox transgenic 
FVB mice is described by McLean et al. (McLean, Komiyama et al. 2004). 
2.2.2 Routine cell culture and generation of cell lines 
2.2.2.1 Routine cell culture 
The cell lines were grown in appropriate growth media and maintained in a dry 
5% CO2 incubator at 37oC. To subculture adherent cells the medium was removed 
by aspiration, the monolayer rinsed with PBS, followed with 10% trypsin/PE 
solution. Upon detachment the cells were resuspended in media, counted, and 
transferred into tissue culture flasks or flasks.  Cells were typically treated one 
day after plating unless stated otherwise. 
2.2.2.2 Generation of primary murine keratinocyte cultures 
Primary murine keratinocytes were isolated from the tail skin of adult mice.  
The skin from the tail was removed and placed in dispase (8mg/ml in PBS) 
overnight at 4°C.  The dermis and epidermis were separated and the dermis 
incubated with trypsin at 37°C for one hour.  Tryspin was inactivated using 
DMEM + 20% FBS and the resulting cell suspension filtered through a 75µM cell 
strainer (Becton Dickinson, Oxford, UK).  Cells were pelleted by centrifugation 
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at 1000 rpm for five minutes, washed in PBS, pelleted again, and resuspended in 
keratinocyte growth media (KGM, Clonetics).  Cells were plated onto collagen-I 
coated 60mm tissue culture dishes (Becton Dickinson, Oxford, UK), and cultured 
in a humidified incubator at 37°C / 3% CO2. 
2.2.2.3 Isolation of squamous carcinoma cells from mouse tumours 
Squamous carcinoma cells (SCC) were isolated from chemically induced skin 
tumours removed from K14CreER FAKflox/flox transgenic FVB mice. Skin 
carcinomas were induced using a two-stage chemical carcinogenesis protocol as 
previously described (McLean, Komiyama et al. 2004). Briefly, six week old mice 
were subjected to one topical application of 7,12-dimethylbenz(a)anthracene 
(DMBA, Sigma Chemical Co., Poole, UK), followed by twice weekly topical 
applications of 12-o-tetradecanoyl-phorbol-13-acetate (TPA, Sigma Chemical 
Co., Poole, UK) for a period of 20 weeks. This treatment schedule gave rise to 
benign papillomas approximately 6-8 weeks after the first treatment, with 
subsequent progression of a small proportion of papillomas to invasive squamous 
cell carcinomas from 15 weeks onwards. Following surgical excision of 
carcinomas, small tissue pieces were adhered to plastic tissue culture plates and 
cells allowed to grow out onto the plastic surface.  Tumour pieces and cells were 
maintained in Minimum Essential Medium (MEM) with Earle's Salts and without L-
Glutamine, supplemented with 2 mM L-glutamine, MEM vitamins, MEM 
aminoacids (Invitrogen, Paisley, UK), 1 mM Sodium Pyruvate (Sigma Chemical Co, 
Poole, UK) and 100 ml/L Foetal Bovine Serum (FBS, Autogen Bioclear, Wiltshire, 
UK). Outgrowth of cells was observed within one week under normal culture 
conditions at 37˚C / 5% CO2. 
2.2.2.4 Re-expression of FAK constructs 
FAK-/- SCC 7.1 cells expressing the various FAK constructs were generated by 
Amaxa nucleofection kit V (Amaxa, Lonza, Cologne, Germany), program P20, 
using pWZL FAK wt, FAK KD, FAK-Y397F, or FAK–Y4F-Y9F constructs previously 
generated in this laboratory. Cells were selected in hygromycin B (Merck 
Biosciences, Sussex, UK) and pooled populations maintained in 1mg ml-1. 
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2.2.2.5 Subcutaneous tumour growth 
Cells were trypsinised, washed in HBSS (Invitrogen, Paisley, UK), and re-
suspended in sterile HBSS at a concentration of 2.5x105 to 1x106 cells / 100µl.  
100 µl of cell suspension was injected subcutaneously into the flank of immune-
compromised nude mice and tumour growth measured every two to three days 
using callipers.  Measurements were taken from at least 8 mice for each cell 
line. Tumour volume was calculated in Excel by the formula l x s 2 / 2 where “l” 
represents the maximal diameter and “s” represents the diameter perpendicular 
to “l”.   
2.2.2.6 Transient transfection with siRNA 
The Dharmacon Smartpool method (Dharmacon, Abgene Ltd., Epsom, UK) of 
mammalian cell transfection was used for the transfection of SCC 7.1 FAK -/- 
and FAK wt cells. Flasks of confluent cells were passaged the day prior to 
transfection and seeded at an appropriate concentration in 6 well plates to 
ensure 50% confluence on the day of transfection.  These plates were incubated 
overnight at 37oC in an atmosphere of 95% air and 5% CO2.  The siRNA for 
transfection was diluted in sterile PBS and added to serum free MEM containing 
5μl of Dharmafect Transfection Reagent 1 (Dharmacon, Abgene Ltd., Epsom, UK) 
to give a total volume of 400μl.   The complexes were incubated at room 
temperature for 20 minutes then added directly to the appropriate well of the 
transfection plate containing 1600μl of complete medium (final concentration of 
siRNA, 100nM).  The plates were incubated for approximately 24 hours at 37oC in 
an atmosphere of 95% air and 5% CO2 prior to any cell treatments and harvesting. 
In each experiment, a scrambled pool of siRNA was utilised as a control.  
2.2.3 Cell based assays and addition of inhibitors 
2.2.3.1 Cell cycle analysis 
Cells were treated as indicated, trypsinised, and washed twice in ice cold PBS 
prior to fixation in 70% ethanol/PBS overnight at 4oC. For DNA content analysis 
(including sub-2n DNA), cells were pelleted and resuspended in PBS containing 
1µg/ml RNase A (Qiagen, Crawley, UK) and 10µg/ml propidium iodode (PI) 
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(Sigma Chemical Co, Poole, UK), incubated at room temperature for 30 minutes, 
then passed through a FACSCalibur flow cytometer with CELLQuest software 
(Becton Dickinson, Oxford, UK).  The data was analysed on FloJo (Treestar, 
Stanford, CA, USA) and a graphical representation obtained. Experiments were 
performed at least 3 times and the data presented represents the combined 
mean ± SEM, unless stated otherwise. 
2.2.3.2 Cell proliferation assay 
Cell proliferation was assayed indirectly by a modified MTT assay which provides 
a measure of cell viability. This assay is based on the enzymatic reduction of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Sigma 
Chemical Co, Poole, UK) to formazan crystal by mitochondria and cellular 
dehydrogenase enzymes (Mosmann 1983). Briefly, 100µl of cell suspension 
containing 250 - 2500 cells from each cell line of interest was dispensed in 
quadruplicate into 96-well flat bottomed microplates. Plates were then 
incubated in a 5% CO2 humidified incubator at 37oC. At the time points 
indicated, 50µl of MTT solution (5mg/ml in sterile PBS) was added and the 
plate(s) incubated for a further 4 hours. The formazan crystals were than 
dissolved in 100µl DMSO (Sigma Chemical Co, Poole, UK) and the optical density 
determined at 590nm using a plate reader (SpectraMax Plus 384, Molecular 
Devices, Wokingham, UK). Experiments were performed at least 3 times. The 
data presented (mean ± SD) is representative of a single experiment. 
2.2.3.3 Clonogenic assay 
Cells were irradiated in tissue culture flasks with increasing doses of radiation at 
70% confluence and immediately trypsinised, counted, and diluted in complete 
growth medium to a concentration that would yield approximately 50 – 150 
colonies after the required period of incubation. The cell suspension was directly 
added to 60mm tissue culture dishes and the plates were incubated for sufficient 
time to allow 6 doubling times. This was previously determined by performing a 
proliferation assay in each individual cell line under investigation. At the 
appropriate time point, the plates were washed in PBS, fixed in methanol for 15 
minutes and stained with crystal violet (Sigma Chemical Co, Poole, UK). The 
numbers of colonies present per plate were counted on low power bright field 
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microscopy. Plating efficiency was determined by dividing the number of 
colonies present by the number of cells seeded. Surviving fraction was then 
calculated by dividing the plating efficiency at each radiation dose by the 
plating efficiency of unirradiated cells. Each experiment was performed in 
triplicate and on at least 3 separate occasions. The data was combined and 
displayed graphically as mean ± SEM. 
2.2.3.4 Clonogenic assay (limiting dilution method) 
Cells were passaged at 70% confluence, counted, and diluted in complete growth 
medium to yield a final concentration that would permit single colony growth 
after the required period of incubation. 100µl of this cell suspension was added 
to each well of a flat bottomed 96 well microplate.  The plates were incubated 
for 6 hours to allow cell adhesion then irradiated at increasing doses of 
irradiation. After 5 – 8 days (to allow 6 cell doubling times), the plates were 
washed in PBS, fixed in methanol, and stained with crystal violet (Sigma 
Chemical Co, Poole, UK). The numbers of colonies present per plate were 
counted on low power bright field microscopy. Plating efficiency was determined 
by dividing the number of colonies present by the total number of cells seeded 
per plate. Surviving fraction was then calculated by dividing the plating 
efficiency at each radiation dose by the plating efficiency of unirradiated cells. 
Each experiment was performed in triplicate and on at least 3 separate 
occasions. The data was combined and displayed graphically as mean ± SEM. 
2.2.3.5 Irradiation of cells 
Cells were grown to 70% confluence in plates or tissue culture flasks then 
exposed to γ-irradiation from a cobalt (60Co) source (Alcyon II teletherapy unit, 
General Electric, France). The receptacles were set at a distance of 80cm from 
the source and a Perspex layer added to the surface of the receptacles in order 
to achieve build-up. The average dose rate was 1 – 1.20 Gy/minute and doses of 
1 – 30Gy were applied. 
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2.2.3.6 Methylcellulose growth assay 
In order to study cell growth and proliferation in a 3-D environment, 2.5 x 105 
cells were suspended in a solution of 1.4% methylcellulose in growth media, 
plated over a layer of 0.9% agarose, and grown at 37oC in 5% CO2. Cells were 
photographed after 10 days (x10 magnification). When appropriate, the numbers 
of colonies were counted from 10 random fields; colony area was calculated 
using Image J. 
2.2.3.7 Soft agar assay 
2-4x104 cells were suspended in a solution of 0.45% low melting point agarose in 
growth media and plated over a layer of 0.9% agarose in growth media in each 
well of a 6-well dish. Cells were grown under normal conditions at 37oC / 5% CO2 
and colonies were photographed after the appropriate time periods.  
2.2.3.8 Treatment with inhibitors 
The various inhibitors were reconstituted in tissue culture grade DMSO (Sigma 
Chemical Co, Poole, UK) to provide a stock solution of 20mM. This was aliquoted 
to prevent loss of activity from repeat freeze / thaw and stored at -20oC. At the 
appropriate time, the inhibitors were diluted to the required concentration in 
growth medium and added to the cells for the indicated time period. 
2.2.4 Protein detection 
2.2.4.1 Immunofluoresence 
Cells were grown on sterile coverslips for 24 hours then washed in cold PBS and 
fixed in 4% paraformaldehyde for fifteen minutes. Permeabilisation was then 
achieved with exposure to 0.2% Triton X-100 in PBS for 5 minutes. This was 
repeated 3 times and excess Triton solution removed by blotting. The cells were 
blocked in PBS containing 10% FBS and 1% BSA for one hour then incubated 
overnight at 4oC with the primary antibody of interest. The appropriate dilution 
for each primary antibody is outlined below in Table 2. The coverslips were 
washed 3 times with blocking solution and incubated with secondary antibody 
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conjugated to Alexa® 488 or 594 fluorescent dyes (Invitrogen, Paisley, UK) at a 
1/200 dilution for one hour. Finally, the coverslips were mounted using 
Vectashield (Vector Laboratories Ltd, Peterborough, UK) and cells visualised on 
an Olympus FV1000 confocal microscope (Olympus UK Ltd, Hertfordshire, UK)            
under an oil immersion lens. The experiments were performed 3 times and the 
images shown representative of the localisation observed in the majority of 
cells. In the case of phosphorylated-γH2AX, 100 cells under each condition and 
for each separate experiment were counted. Data shown is a mean ± SD of 3 
independent experiments. 
Table 2 - Antibody dilutions for immunofluorescence 
 
Antibody Dilution 
FAK 1/100 
LC3 1/200 
Paxillin 1/200 
p53 1/200 
phospho-γH2AX 1/250 
phospho-Src-Y416 1/200 
 
2.2.4.2 Immunohistochemistry 
Fixed paraffin embedded (FFPE) tissue sections mounted on slides were dewaxed 
in xylene solution followed by stepped rehydration via a series of graded alcohols 
to water. Antigen retrieval was then performed by boiling the slides in sodium 
citrate solution (pH 6) for 20 minutes. The slides were incubated with peroxidase 
block for 5 minutes to quench endogenous peroxidase activity and blocked in 
10% FBS in 0.01M Tris buffered saline (pH 7.5) for one hour at room 
temperature. The primary antibody of choice was diluted in blocking solution 
and added to the slides which were then incubated overnight at 4oC. A negative 
control was compared in parallel to the investigated sections by omitting the 
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primary antibody step. Visualisation was carried out with a DAKO EnVision kit ™ 
(Dako UK Ltd, Ely, UK) as per manufacturers' instructions. The resulting sections 
were analysed and images captured digitally using an Olympus BX51 microscope 
and cell^D software (Olympus UK Ltd, Hertfordshire, UK). Primary antibody 
dilutions are outlined below. 
Table 3 - Antibody dilutions for immunohistochemistry  
 
Antibody Dilution 
Activated-Caspase 3 1/400 
FAK 1/250 
K14 1/500 
Ki67 1/250 
p21 (M-19) 1/800 
p53 (CM-5) 1/150 
 
2.2.4.3 Western blotting and immunoprecipitation 
Preparation of whole cell lysates / tissue extracts 
Confluent cells were harvested at temperatures less than 4oC using buffers that 
had been previously chilled to minimise protein degradation in the whole cell 
extract.  The cell culture media was aspirated and the cells were washed twice 
with ice cold sterile PBS.  The cell plates were drained thoroughly and the 
appropriate volume of RIPA lysis buffer added.  For a 6 well plate, 50 - 100μl of 
cell lysis buffer was added whereas a 90mm plate received 200 - 250μl of cell 
lysis buffer. The cells were incubated for 5 minutes with buffer on ice and then 
scraped into a 1.5ml Eppendorf® tube.  The cell lysates were centrifuged in a 
bench-top, refrigerated centrifuge at 13000rpm at 4oC and the supernatant 
retained.  The cell lysates were then snap frozen on dry ice and stored at –80oC.  
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Animal tissue was removed post mortem and immediately frozen in liquid 
nitrogen for storage at –80oC. At the required time the frozen tissue was added 
to a Precellys tube (Bertin Technologies, Provence, France) with 100μl of ice 
cold T-PER buffer.  The samples were homogenised (Precellys 24 device – Bertin 
Technologies, Provence, France), transferred to a 1.5ml Eppendorf® tube and 
centrifuged as outlined above. 
Determination of protein concentration 
Protein content was determined using the MicroBCATM Protein Assay Kit (PERBIO, 
Glasgow, UK) as per manufacturers' instructions and quantified by measuring 
light absorbance with a DU® 650 spectrophotometer at a wavelength of 562nm 
(Beckman Coulter UK Ltd, Buckinghamshire, UK).  
Immunoprecipitation 
500µg of whole cell lysate was pre-cleared by adding 20µl protein-G sepharose 
slurry (Sigma Chemical Co, Poole, UK) and rotating at 4oC for one hour. 
Following this, the lysate was transferred to a clean tube and incubated with 
10µl anti-FAK agarose conjugated primary antibody (Chemicon International, 
Harrow, UK) overnight at 4oC. As a negative control, lysate was 
immunoprecipitated with an anti-histidine agarose conjugated antibody (Sigma 
Chemical Co, Poole, UK). The antibody-protein complexes were then washed in 
RIPA buffer and resuspended in sample buffer prior to western blot analysis. 
SDS-PAGE 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is a 
method that is routinely employed to separate proteins by virtue of their 
molecular weight.  Protein samples of 5 - 40μg were denatured and reduced by 
addition of NuPAGE® 4x LDS sample buffer (Invitrogen, Paisley, UK). The 
samples were boiled for 5min and then loaded directly to an appropriate well of 
a NuPAGE® Bis-Tris polyacrylamide gel immersed in Invitrogen™ NuPAGE® MOPS 
SDS running buffer.  10%, 12% or 4-12% gradient gels were used depending on the 
molecular weight of the protein of interest. 5μl of pre-stained molecular weight 
rainbow ™ protein marker (GE Healthcare, Little Chalfont, UK)  was also loaded 
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to the first well of the gel to allow the molecular weight of the proteins within 
the sample to be determined.  The gels were run at 200V for 1h.   
Western blotting 
Proteins separated by SDS-PAGE can be visualised by a variety of methods.  
Western blotting allows the detection of individual proteins with specific anti-
sera.  Hence, the proteins separated by SDS-PAGE were transferred to a 
nitrocellulose membrane using wet blotting apparatus (Jencons, Leighton 
Buzzard, UK) with an applied voltage of 30V for 90 minutes. Following transfer 
of the sample proteins, as indicated by successful transfer of the pre-stained 
molecular weight markers, the nitrocellulose membrane was blocked in 5% 
bovine serum albumin (BSA), re-constituted in 20mM Tris-Cl; pH 7.6, 150mM NaCl 
and 0.1% Tween20 (TBST), for one hour at room temperature with gentle 
agitation.  The primary antibody was added at the appropriate dilution to a 5% 
BSA - TBST solution.  Details of the primary antibodies used in experiments 
described in this thesis are shown in Table 4.  The blocked nitrocellulose 
membrane was then sealed in an airtight plastic carrier containing the primary 
antibody solution and this was incubated overnight at 4oC, with vigorous 
agitation.  The membrane was then washed several times with TBST before the 
application of the appropriate horseradish peroxidase (HRP) conjugated anti-
immunoglobulin G (IgG) secondary antibody diluted 1:5000 in 5% BSA - TBST 
solution. This was incubated for 45 minutes at room temperature with vigorous 
agitation.  The membrane was again washed several times with TBST before 
employing the Amersham Biosciences (Little Chalfont, UK) enhanced 
chemiluminescence (ECL) Western immuno-blotting kit as the visualisation 
protocol.  Briefly, the bound antibodies were detected by exposure of the 
membrane, following washing in ECL solution, to blue-light sensitive 
autoradiography film and developed using the Kodak® X-Omat Model 2000 
processor. When necessary, blots were stripped using the Re-Blot Plus Strong 
antibody stripping solution (Chemicon International, Harrow, UK) according to 
the manufacturer’s instructions. The blots shown are representative of 
experiments repeated at least twice. Densitometry analysis was carried out 
using Image J. The relative number of arbitary units was measured and 
normalised to β-actin. 
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Table 4 - Antibody dilutions for western blotting 
  
Antibody Dilution Antibody Dilution 
Akt 1/500 p53 (IC12) 1/1000 
β-actin 1/5000 phospho-Akt-S473 1/1000 
ERK 1/1000 phospho-ERK-S42/S44 1/1000 
FAK 1/1000 phospho-FAK-Y397 1/1000 
K14 1/2000 phospho-FAK-Y576 1/1000 
LC3 1/1000 phospho-FAK-Y861 1/1000 
MDM2 1/500 phospho-FAK-Y925 1/1000 
myc 1/2000 phospho-Src-Y416 1/1000 
Src 1/1000 phospho-Pyk2-Y402 1/1000 
paxillin 1/1000 PUMA(α/β)  1/1000 
PARP(cleaved) 1/500 Pyk2 1/1000 
p21 1/1000 α-tubulin 1/2000 
 
2.2.5 Molecular biology techniques 
2.2.5.1 Extraction of genomic DNA and genotyping 
Genomic DNA was isolated from cells in culture by lysing in extraction buffer 
(50mM KCl, 10mM Tris (pH 7.4), 2.5mM MgCl2, 0.45% NP-40, 0.45% Tween 20, 
1mg/ml proteinase K) for 10 minutes on ice, followed by heating at 95°C for 5 
minutes.  The DNA was quantified using a GeneQuant RNA/DNA calculator with a 
spectrophotometer cell and stored at -20°C. Cells containing the K14CreER 
transgene were identified by PCR analysis on a DNA thermal cycler (Bio-Rad, 
Hertfordshire, UK) using the following primers: 5'-ATT TGC CTG CAT TAC CGG 
TC-3' and 5'-ATC AAC GTT TTC TTT TCG G-3 '.  A Cre specific PCR product was 
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amplified using 25ng of DNA and the following protocol: 94°C for 1 minute; 55°C 
for 30 seconds; 72°C for 30 seconds (39 cycles).  Following amplification PCR 
products were analysed by agarose gel electrophoresis using a 1.5% agarose gel.  
Cells positive for the K14CreER transgene exhibited a single PCR product of 350 
bp. 
To determine floxed fak gene status, the same genomic DNA was subjected to 
PCR analysis using the following primers: LP2s; 5'-ATT GTG CTA TAC TCA CAT 
TTG GA-3', LP2as; 5'-TTA ATA AGA CCA GAG GAC TCA GC-3', and LP2h; 5'-GGA 
AGA AGC TTG TAT ACT GTA TG-3'. A FAK-specific PCR product was amplified 
using 25ng of DNA and the following protocol: 95°C for 5 minutes (1 cycle); 95°C 
for 45 seconds + 62°C for 45 seconds + 72°C for 1 minute (35 cycles); 72°C for 7 
min (1 cycle). Following amplification, PCR products were analysed by agarose 
gel electrophoresis. Cells homozygous for the floxed fak mutation (FAKflox/flox) 
exhibited a single major band of 580 bp, cells heterozygous for the floxed FAK 
(FAKwt/flox) contained three major bands at 650 bp, 580 bp, and 400 bp, and wild 
type (wt) cells (FAKwt/wt) contained a double band at 650 bp and 400 bp.  
2.2.5.2 Extraction of RNA and qRT-PCR analysis 
RNA was isolated from 1x106 cells using miRNeasy mini RNA extraction kit 
(Qiagen, Crawley, UK) as per the manufacturer’s instructions. 1µg of RNA was 
then converted to cDNA using Superscript First-Strand cDNA synthesis kit 
(Qiagen, Crawley, UK). The cDNA was diluted 1 in 5 then prepared for qRT-PCR 
analysis by adding 5µl to 45µl SybrGreen master mix (Invitrogen, Paisley, UK) 
containing 1µM of paired validated primers directed against the target gene of 
choice (Qiagen, Crawley, UK).   All primer pairs were assessed for linearity prior 
to use and produced a PCR single product of the correct size as outlined by the 
manufacturer. Real time PCR was performed on a gradient cycler (Bio-Rad, 
Hertfordshire, UK) with the following programme: 95°C for 15 minutes (1 cycle); 
95°C for 15 seconds + 55°C for 30 seconds + 72°C for 30 seconds (39 cycles); 
72°C for 5 minutes (1 cycle); melting curve 70 – 95°C, hold every 0.1 seconds; 
72°C for 10 minutes (1 cycle); 15°C for 10 minutes (1 cycle). Data was analysed 
using Opticon software V3.1 (Bio-Rad, Hertfordshire, UK). β-actin controls were 
included with each reaction to act as a housekeeping gene and fold change in 
mRNA levels calculated by the ddC(t) method (Livak and Schmittgen 2001). The 
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samples were loaded in triplicate and the mean ± SEM from three combined 
experiments displayed graphically.  
2.2.5.3 Routine PCR analysis and sequencing 
RNA was isolated from cells and converted to cDNA as outlined above. 2µl of 
cDNA was added to 22.5µl pre-aliquoted Mastermix PCR mix (PERBIO, Glasgow, 
UK) containing 1µM of forward and reverse primers. All primers were obtained 
from VH Bio (Gateshead, UK) and details are listed in Table 5. PCR amplification 
was performed on a DNA thermal cycler (Bio-Rad, Hertfordshire, UK) using the 
programme: 95°C for 10 minutes (1 cycle); 95°C for 30 seconds; 60°C for 30 
seconds; 72°C for 45 seconds (35 cycles); 72°C for 5 minutes (1 cycle). Following 
amplification, PCR products were separated by agarose gel electrophoresis using 
a 1.5% agarose gel with an applied voltage of 30V and imaged using SYNGENE UV 
gel visualisation system. 
Table 5 - Primer sequences for RT-PCR  
 
Gene Sense primer  
5'-3' 
Anti-sense primer  
5'-3' 
Fragment size 
(bp) 
 
H-Ras CAG CCG CTG TAG  
AAG CTA TGA 
 
TCA GTT TCC GCA  
ATT TAT GCT 
531 
GAPDH GTG GAT ATT GTG 
CCC AAT GAC ATC 
 
GGA CTC CAC GAC 
GTA CTC AGC GCC 
AGC 
214 
K14 CCT GGA GAT GCA  
GAT TGA GAG 
 
ATT CTC CAG GGA  
TGC TTT CAT 
370 
p21 AGC CTG ACA GAT  
TTC CAC 
 
CTT TAA GTT TGG 
AGA CTG GGA 
222 
p53 CCT GTC ATC TTT  
TGT CCC TTC 
 
TGC GGA AAT TTT  
CTT CTT CTG 
494 
 
For sequencing analysis, ten RT-PCR amplification reactions were carried out 
simultaneously for each line of interest using the method outlined above. The 
primer pair for H-Ras was as described in Table 5. p53 primer pairs were as 
follows: 5'- AGA TAT CCT GCC ATC ACC TCA -3' and 5'- CCA GAC TCC TCT GTA 
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GCA TGG -3' which yielded a single product size of 975 bp. The PCR products 
were then pooled, purified with QIAquick PCR purification Kit (Qiagen, Crawley, 
UK) as per the manufacturer’s instructions, and the concentration of DNA 
quantified using a GeneQuant RNA/DNA calculator with a spectrophotometer cell 
as previously mentioned. The DNA was diluted to 50 – 100ng/µl and direct 
sequencing analysis performed using the Big-Dye method. 20ng/µl of primer was 
included in the final reaction mix. The primers were designed to sequence codon 
61 of H-Ras and the DNA binding domain of p53 (further information is provided 
in Chapter 4) and are listed below in Table 6. 
Table 6 - Sequencing primers  
 
Gene Sense primer  
5'-3' 
Anti-sense primer  
5'-3' 
 
H-Ras GCA GCC GCT GTA  
GAA GCT AT 
TCA GTT TCC GCA  
ATT TAT GCT 
 
p53 CCT GTC ATC TTT  
TGT CCC TTC 
CGG GTG GAA GGA  
AAT TTG TAT 
TGC GGA AAT TTT 
CTT CTT CTG 
CCA GAC TCC TCT  
GTA GCA TGG 
 
 
2.2.6 Statistical analysis 
Graphs and bar charts were created in Excel and represent the mean value ± SD 
or mean value ± SEM from three separate experiments. Statistical tests were 
performed in Minitab 15, p<0.05 was considered significant and is denoted by *. 
An unpaired t-test was used to compare the means of two populations with 
approximately equal variance and normal distribution, where n = number of data 
sets that contributed towards the mean. For the purposes of 
immunohistochemistry data analysis, the mean percentage of positively stained 
cells per xenograft was calculated based on examination of twenty high powered 
fields. The mean values of two test groups were then analysed by either the 
Kruskal-Wallis test or the Mann Whitney U test (typically three to five xenografts 
from separate mice were included in each defined experimental group).            
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3 Development of a FAK -/- murine squamous cell 
carcinoma cell line 
3.1 Aims 
We set out to evaluate the role of FAK in cellular radiation survival in vitro and 
in vivo and opted to use a genetic deletion model to achieve FAK knockout as we 
believed that this would be a clean and precise biological method. It is widely 
accepted that gene deletion studies in cells constitute a useful scientific tool for 
investigating the roles of specific gene products / proteins in particular 
biological contexts. FAK deficient mouse embryo fibroblasts (FAK -/- MEFs), for 
instance, have provided invaluable information about the role of FAK in cell 
adhesion and motility. As opposed to working solely with FAK +/+ and FAK -/- 
MEFs, which are readily available, we wanted to utilise a tumour cell line as this 
would be more relevant to human cancer. Also, the use of a cell line of 
malignant origin would enable us to investigate the role of FAK in vivo as well as 
in vitro. There were no such cell lines available when we decided to embark on 
this project. Therefore, our first aim was to develop a novel murine squamous 
cell carcinoma with inducible fak deletion, based on a conditional mouse model 
that was already established in this laboratory.  
3.2 Results 
3.2.1 Skin specific FAK deletion. 
Previous work in this laboratory has demonstrated that FAK is important in 
mouse skin carcinogenesis. Initially, it was shown using fak heterozygous (+/-) 
mice, that reduced FAK expression had a negative impact on chemically induced 
papilloma formation (McLean, Brown et al. 2001). However, the benign tumours 
from fak +/- mice had elevated expression of FAK to a level that was 
indistinguishable from papillomas from wild-type fak +/+ mice. The key question 
of whether FAK expression is causally involved in malignant progression 
therefore remained unanswered. However, this question was addressed by 
adopting a conditional gene targeting system. Briefly, Cre/loxP technology was 
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used to generate mice that are homozygous for a floxed fak allele and that also 
express a 4-hydroxy-tamoxifen (4-OHT) regulated Cre recombinase (Cre-ERT2) 
expressed under the control of the keratin 14 promoter (K14CreERT2/FAKflox/flox), 
a highly active promoter in dividing cells of the epidermis from day E14.5 
(Vasioukhin, Degenstein et al. 1999).  A schematic representation of this model 
is described in Figure 11A.  It was then possible to study the role of FAK in 
cancer development by subjecting these mice to the well established chemical 
carcinogenesis protocol (DMBA-TPA) which is outlined in Figure 12. Rendering 
keratinocytes FAK -/- by 4-OHT treatment (Figures 11B and 11C depict 
successful skin specific FAK protein loss by western blotting and 
immunohistochemistry respectively) resulted in a lower frequency of papilloma 
development and inhibited progression to malignant carcinoma. This work  
demonstrated that FAK is crucial in carcinogenesis and tumour progression, at 
least in this system (McLean, Komiyama et al. 2004).   
An advantage of this model is that fak deletion is under temporal as well as 
spatial control. It was shown that FAK could be deleted from the epidermis in an 
established papilloma (Figure 13A). In addition, FAK knockout was also achieved 
ex vivo in cultured keratinocytes with low dose 4-OHT (Figure 13B). Thus, we 
hypothesised that it should be possible to delete FAK in an established tumour 
cell line by inducing malignancy, isolating a cell line and exposing this cell line 
to 4-OHT in vitro.  
3.2.2 Generation of murine squamous cell carcinoma cell lines. 
Two squamous cell carcinoma (SCC) cell lines were propagated from 
K14CreERT2/FAKflox/flox mice which underwent treatment with DMBA/TPA; these 
were called SCC 1.1 and SCC 7.1. SCC 1.1 was derived from a newly formed 
carcinoma that developed at 18 weeks following induction, while SCC 7.1 was 
derived from an advanced ulcerative tumour at 24 weeks post induction. 
Interestingly, the cell lines proved to be morphologically distinct with the 
former exhibiting an epithelial morphology, remarkably similar to cultured 
normal keratinocytes, while the latter was mesenchymal in appearance, 
suggestive of spindle cell carcinoma, a variant of squamous cell carcinoma that 
is associated with a more aggressive phenotype.  
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Figure 11 - Deletion of FAK from the epidermis of mouse skin 
 (A) Schematic diagram representing the K14CreERT2FAKflox/flox system. Cre/LP2 homozygous mice 
were generated to express a CreER fusion protein under the Keratin 14 (K14) promoter which is 
present in developing keratinocytes. After exposure to tamoxifen, Cre translocates to the nucleus 
and excises the loxP sites which flank the FAK kinase domain. A frameshift mutation incorporated 
into this system ensures that no functional protein is synthesised. (B) Protein extracts were 
obtained from spleen, kidney and skin of K14CreERT2FAKflox/flox mice treated with either vehicle or 
tamoxifen (4-OHT), separated by SDS-PAGE, transferred to nitrocellulose and blotted with either 
anti-FAK (upper panel) or anti-tubulin (lower panel). (C) K14CreERT2FAKflox/flox mice were treated 
with either vehicle (left) or 4-OHT (right). Paraffin embedded dorsal skin sections were stained with 
an anti-FAK antibody and visualised under bright field microscopy (x20 magnification), E-epidermis, 
D-dermis, HF-hair follicle.  Experiment courtesy of GW McLean. 
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Figure 12 - Topical carcinogenesis 
Schematic diagram demonstrating the well described mouse skin carcinogenesis protocol. Briefly, 
initiation with a single application of DMBA results in an activating missense mutation in codon 61 
of the H-Ras gene in which an adenosine is converted to a thymidine. Subsequent twice weekly 
TPA treatment selects for clonal expansion of initiated cells, giving rise to papillomas after 5-7 
weeks and conversion to carcinomas from 16 weeks onwards. 
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Figure 13 - FAK deletion is temorally and spatially controlled 
(A) Immunohistochemistry detailing FAK staining of papilloma sections of K14CreERT2FAKflox/flox 
mice treated with either vehicle (left) or 4-OHT (right), E-epidermis. (B) Keratinocytes derived from 
the skin of 2 day old K14CreERT2FAKflox/flox pups were plated on glass coverslips, treated with either 
vehicle (left) or 10nM 4-OHT (right) for 48 hours, fixed, and stained with an anti-FAK antibody prior 
to visualisation by confocal microscopy. Experiment courtesy of BR Serrels. 
vehicle                                                         + 4-OHT(A)
(B)
vehicle                                                         + 4-OHT
FAK FAK
E E
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Representative phase contrast images of the SCC cell lines are shown in Figure 
14A. PCR analysis of genomic DNA extracts from both cell lines demonstrated 
homozygous expression of Cre and the loxP sites, confirming the correct 
genotype (Figure 14B). However, prior to 4-OHT treatment we wanted to be 
certain that the cell lines were in fact malignant, particularly the mesenchymal 
line, as fibroblast contamination is a common problem in primary cell culture. 
This was approached in several ways.  
Firstly, sequencing analysis of H-Ras was undertaken in DNA prepared from SCC 
1.1 and SCC 7.1 cell lines. The reasoning for this is that the DMBA/TPA 
carcinogenesis protocol promotes an activating missense mutation in codon 61 of 
H-ras (CAA – CTA), which is typically homozygous in carcinomas (Balmain, 
Ramsden et al. 1984; Quintanilla, Brown et al. 1986). Examination of codon 61 
revealed a single T at the centre base in both cell lines signifying homozygous 
mutation (Figure 15).  By contrast, parallel analysis of DNA prepared from 
K14CreERT2/FAKflox/flox keratinocytes demonstrated a base sequence of CAA at 
codon 61, in keeping with wild type (wt) H-Ras. This data indicates that SCC 1.1 
and SCC 7.1 cells are tumour cell derived and not fibroblasts.  
Secondly, the ability of cell lines to establish xenografts following subcutaneous 
injection into nude mice is an indicator of malignant origin. Accordingly, both 
SCC 1.1 and SCC 7.1 cells formed tumours after injection into female nude mice.  
Unsurprisingly, the histological appearance was markedly different. SCC 1.1 
xenografts demonstrated features of a highly keratinising moderately to well 
differentiated squamous cell carcinoma with cell nests and keratin pearls. On 
the other hand, SCC 7.1 xenografts were composed of a homogeneous mass of 
fusiform cells arranged in fascicles, and to a lesser extent, whorls. 
Representative H & E images of paraffin embedded sections are shown in Figure 
16A.  Of interest, the SCC 7.1 xenografts grew much more rapidly (data not 
shown), and examination of the H & E sections under high powered microscopy 
revealed an abundance of mitotic figures (Figure 16B). A high mitotic index is 
known to be a feature of spindle cell tumours. 
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Figure 14 - Isolation of squamous cell carcinoma cell lines 
(A) K14CreERT2FAKflox/flox female mice were subjected to the DMBA/TPA carcinogenesis protocol 
and monitored regularly for papilloma and carcinoma formation. Tumours were then disaggregated 
and cell lines established in vitro as outlined in Methods section. Phase contrast images of the 
derived cell lines SCC 1.1 (left) and SCC 7.1 (right) are shown (scale bar, 30µm). (B) Genomic 
DNA was extracted from cell lines SCC 1.1 and SCC 7.1, subjected to RT-PCR for Cre (upper 
panel) and loxP (lower panel) as outlined in Methods section, and separated on 1.5% and 3% 
agarose gels respectively. 
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Figure 15 - SCC 1.1 and SCC 7.1 cells possess a mutation in codon 61 of H-Ras 
RNA was extracted from SCC 1.1 and SCC 7.1 cell lines, and K14CreERT2FAKflox/flox keratinocytes, 
converted to cDNA using Superscript II, amplified by PCR, and purified as outlined in Methods 
section. The cDNA was then diluted and subjected to direct sequencing analysis. Chromatograms 
for codons 60-62 of H-Ras are demonstrated for SCC 1.1 cells, SCC 7.1 cells, and 
K14CreERT2FAKflox/flox keratinocytes. 
 
K14CreERT2FAKflox/flox
keratinocytes
SCC 1.1 SCC 7.1
60                 61                  62
G  G  T       C  T A        G  A  A
60                 61                   62
G  G  T       C  T A        G  A  A
60                 61                  62
G  G  T       C  A  A        G  A  A
Chapter 3  95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 - SCC 1.1 and SCC 7.1 cells produce tumours in nude mice 
(A) 1x106 cells were injected subcutaneously into the right flank of 6 week old female CD-1 nude 
mice. Growth was monitored regularly and the animals sacrificed when the xenograft reached 
10mm in maximal diameter. H&E staining of paraffin embedded sections was then performed and 
representative images of SCC 1.1 (left) and SCC 7.1 (right) are shown (scale bar, 200µm). (B) High 
powered image of SCC 7.1 xenograft, arrows indicating mitotic figures (M) (scale bar, 100µm). 
SCC 1.1                                                         SCC 7.1
100 µm
M M
M
(A)
(B) SCC 7.1
H&E
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Taken together, we reasoned that both cell lines were indeed of tumour origin 
with SCC 1.1 representing a moderately / well differentiated carcinoma and SCC 
7.1 a more advanced spindle cell carcinoma. 
3.2.3 FAK expression is increased in SCC 1.1 and SCC 7.1 cells. 
FAK protein levels have been shown to increase during the process of tumour 
development in the mouse skin carcinogenesis model, with low levels detected 
in normal keratinocytes, intermediate levels detected in papillomas, and high 
levels detected in squamous cell carcinomas, implying that FAK signalling is a 
prerequisite, at least in certain types of epithelial malignancies (McLean, Brown 
et al. 2001; McLean, Avizienyte et al. 2003; McLean, Komiyama et al. 2004; 
McLean, Carragher et al. 2005). In keeping with these findings, FAK protein 
levels were clearly upregulated in the cancer cell lines we derived compared 
with cultured K14CreERT2/FAKflox/flox keratinocytes, as shown in Figures 17A and 
17B. Interestingly, FAK (and the related kinase Pyk2) protein levels were 
equivalent in SCC 1.1 and SCC 7.1 cells (Figure 18), despite reports that spindle 
cell carcinomas may contain more FAK than differentiated squamous cell 
carcinomas (McLean, Carragher et al. 2005).  
FAK phosphorylation levels were also similar in SCC 1.1 and SCC 7.1 cells (Figure 
18). However, downstream signalling effectors which have been linked to FAK, 
for example phospho-ERK and phospho-Akt, were present at different levels 
(Figure 18). Obviously, these effectors are subject to control by multiple 
upstream pathways, and the situation is further complicated by extensive cross-
talk and feedback loops between signalling molecules. However, the variance in 
phospho-protein levels between these cell lines hints that FAK may be involved 
in different signalling pathways and hence may have different functions in SCC 
1.1 cells compared with SCC 7.1 cells. 
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Figure 17 - FAK is upregulated in SCC 1.1 and SCC 7.1 cells 
(A) Protein extracts from K14CreERT2FAKflox/flox keratinocytes, SCC 1.1 cells, and SCC 7.1 cells 
were separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-FAK antibody 
(upper) and anti-β-actin antibody (lower). (B) FAK protein levels in SCC 1.1 and SCC 7.1 cells were 
compared to keratinocytes by densitometry analysis and normalised to β-actin. The difference is 
demonstrated by an increase in arbitary units and is representative of one of three separate 
experiments.  
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Figure 18 - FAK levels are similar in SCC 1.1 and SCC 7.1 cells 
Protein extracts from SCC 1.1 and SCC 7.1 cells were immunoblotted with the various antibodies 
demonstrated. β-actin loading is also shown. 
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3.2.4 Tamoxifen treatment does not result in stable FAK 
knockdown in pooled cell populations. 
Increasing doses of 4-OHT were added to pooled populations of SCC 1.1 and SCC 
7.1 cells in culture and FAK expression was assessed by western blotting at 
various time points following drug exposure for a period of 4 weeks. We noted 
that very high concentrations of drug (10-15µM) were required to induce 
substantial FAK knockout. Greater knockout was consistently achieved in the SCC 
7.1 pools compared with SCC 1.1 pools as judged by both immunoblotting and 
immunofluorescence. An example of FAK protein levels following 72 hours 
exposure to either vehicle or 10µM 4-OHT is demonstrated in Figure 19A. Within 
3 - 4 weeks, however, the FAK expression in 4-OHT treated populations returned 
to pre-treatment levels as depicted in Figure 19B. This observation led us to 
question whether induced FAK -/- cells have a proliferation, or even survival, 
disadvantage. We did not address the issue of proliferation at this time due to 
the lack of a stable knockout cell population, but we did attempt to address the 
question of survival by evaluating the subG1 fraction on FACS analysis in 4-OHT 
treated SCC 1.1 and SCC 7.1 cells versus vehicle treated controls (data not 
shown). However, interpreting this data proved to be problematic as 4-OHT 
itself is known to cause G1/S phase arrest and the doses of drug used here 
resulted in a significant degree of cytotoxicity. It was, therefore, very difficult 
to attribute any differences in subG1 fraction to a FAK -/- mediated survival 
disadvantage as opposed to the effects of 4-OHT on cell cycle and cell survival 
alone. 
In fact, the concentration of 4-OHT that was required to effect significant FAK 
knockout in the SCC cell lines surprised us. As the Cre-LoxP system is designed 
for in vivo work, and the regimen of 4-OHT which induces optimal recombination 
in vivo well described (Indra, Warot et al. 1999; McLean, Komiyama et al. 2004), 
we wondered whether the outcome would be different in vivo compared with in 
vitro. We therefore treated nude mice bearing SCC 1.1 or SCC 7.1 xenografts 
with the recommended schedule of intraperitoneal 4-OHT. Interestingly, this did 
not result in any FAK knockout at all in either cell line (Figure 20). This data, 
coupled with the fact that FAK knockout can be achieved in vitro in 
keratinocytes with only 10nM 4-OHT (Indra, Warot et al. 1999; McLean, 
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Komiyama et al. 2004) suggests that the high dose of 4-OHT required to produce 
the desired effect in the SCC cells was probably not related to in vitro versus in 
vivo drug activity. Instead, we suspected that underlying cell line factors were 
more likely to determine the outcome of these experiments. 
It is well recognised, for example, that the expression of Cre recombinase in 
conditional mouse models is not 100%. Based on these reports, it seemed 
reasonable to consider the possibility that the expression of Cre was suboptimal 
in the derived SCC cell lines. Attempts were made to directly quantify the level 
of Cre expression in SCC 1.1 and SCC 7.1 cells by immunofluorescence but the 
commercially available antibodies were not sufficiently robust and produced 
non-specific results (data not shown).  
As Cre recombinase expression is driven by the K14 transgene in this system, we 
decided to examine the K14 status in more detail. Intriguingly, although both 
SCC cell lines were positive for mRNA, the mRNA levels were visibly lower in SCC 
7.1 cells compared with SCC 1.1 cells; the latter, on the other hand displayed 
similar mRNA levels to normal keratinocytes (Figure 21A). Furthermore, K14 
protein could only be detected in SCC 1.1 cells, but not SCC 7.1 cells, as 
evidenced by immunoblotting of cellular protein extracts (Figure 21B) and 
immunohistochemistry staining of xenografts (Figure 21C). For the latter, skin 
from a K14CreERT2/FAKflox/flox mouse which had not been treated with either 
DMBA/TPA or 4-OHT was included as a positive control (Figure 21D); this image 
demonstrates K14 expression in the basal layer of the epidermis. The 
appearance of two bands in the SCC 7.1 lane on immunoblotting (Figure 21B) is 
likely to represent the presence of different keratin proteins which are not 
expressed at detectable levels in either normal keratinocytes or SCC 1.1 cells. 
We did consider the possibility that these may have simply represented non-
specific bands, but they were not present in the other lanes. Review of 
pathological case series of squamous cell carcinomas reveals that keratin 
expression is often lost or aberrant in spindle cell carcinomas (Zarbo, Crissman 
et al. 1986). Hence, the lack of K14 expression in SCC 7.1 cells was not entirely 
unusual, but we did initially find it a little surprising that we were able to 
achieve more substantial FAK knockout in this cell line. 
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Figure 19 - 4-OHT treatment does not induce stable FAK knockout in pooled cells 
(A) Subconfluent populations of SCC 1.1 and SCC 7.1 were treated with either vehicle (DMSO) or 
10µM 4-OHT for 72 hours, protein extracts prepared and separated by SDS-PAGE, transferred to 
nitrocellulose, and probed with anti-FAK antibody (upper) and anti-β-actin antibody (lower). (B) 
SCC 1.1 cells were treated with 10µM 4-OHT for 72 hours after which time the drug was washed 
out and lysates were prepared on the indicated days. Immunoblotting was then performed with an 
anti-FAK antibody (upper) and an anti β-actin antibody (lower). 
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Figure 20 - 4-OHT treatment does not induce FAK knockout in vivo 
6 week old female nude mice were injected with 5x105 SCC 1.1 or SCC 7.1 cells and monitored 
regularly. When tumours reached approximately 100mm3, the animals then received either vehicle 
(100µl sunflower oil) or 4-OHT (0.1mg in 100µl sunflower oil) by intraperitoneal injection once daily 
for 5 days, n=3 per group. Protein extracts were prepared 48 hours after the last injection as 
detailed in methods, separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-
FAK antibody (upper) and anti-β-actin antibody (lower), a – l represent the individual mice 
examined.  
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Figure 21 - K14 protein is readily expressed in SCC 1.1 but not SCC 7.1 cells 
(A) RNA was extracted from K14CreERT2FAKflox/flox keratinocytes, SCC 1.1 and SCC 7.1 cell lines, 
converted to cDNA using Superscript II as described in Methods section, and RT-PCR performed 
using K14 primers (upper panel). β-actin RT-PCR is shown as a loading control (lower panel). (B) 
Protein extracts from cultured normal keratinocytes, SCC 1.1, and SCC 7.1 cell lines were 
separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-K14 antibody (upper) 
and anti-β-actin antibody (lower). (C) Paraffin embedded sections from SCC 1.1 and SCC 7.1 
xenografts were stained with the same anti-K14 antibody used for immunoblotting following 
appropriate antigen retrieval as outlined in Methods section. Representative images taken on bright 
field microscopy are demonstrated (SCC 1.1 – left panel and SCC 7.1 – right panel) (scale bar, 
200µm). (D) K14 immunohistochemistry was repeated using skin from a K14CreERT2FAKflox/flox 
mouse and a representative image is demonstrated, arrows indicate epidermis (E) and basal layer 
of the epidermis (B) (scale bar, 200µm). 
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3.2.5 Isolation of a FAK -/- single cell clone. 
In order to overcome the potential problem of  suboptimal Cre-mediated gene 
deletion, we adopted a single cell cloning approach and screened up to 40 
colonies by  western blotting following 72 hours treatment with 10µM 4-OHT. It 
was not possible to produce a FAK null cell clone from the SCC 1.1 cell line 
under these conditions (Figure 22), and further attempts varying the 4-OHT 
dose, exposure time and cell density did not yield a knockout cell line.  
A FAK-/- cell line was, however, successfully generated from the SCC 7.1 cell 
line, as demonstrated by the absence of FAK protein in clone 11 on 
immunoblotting (Figure 23). Of note, further immunoblotting analysis of clones 
10 and 31, which appeared to display lower levels of FAK, illustrated that this 
was a protein loading issue rather that a true reduction.  There were no obvious 
morphological differences noted between the parental SCC 7.1 FAK +/+ cells and 
the derived FAK -/- cell line, both of which were mesenchymal in appearance 
(Figure 24A). The absence of FAK in clone 11 was illustrated by both western 
blotting (Figure 24B) and immunofluorescence (Figure 24C), and the cell line 
remained stable over several months in culture. RT-PCR analysis of genomic DNA 
was performed to validate these findings. Both the parental cells and clone 11 
demonstrated the presence of Cre, as expected, but the loxP sites were excised 
in clone 11, confirming fak deletion (Figure 24D).  
Interestingly, unlike FAK -/- MEFs which have upregulation of Pyk2 compared 
with their FAK +/+ counterparts, the levels of Pyk2 recorded here were 
equivalent regardless of FAK status (Figure 24B). This result is significant as it 
suggests that Pyk2 does not compensate for the loss of FAK in this particular cell 
line. Also, despite our initial impressions from the 4-OHT FAK knockout 
experiments that FAK may be important for cell survival in the SCC 1.1 and SCC 
7.1 cell lines as it is in keratinocytes (McLean, Komiyama et al. 2004); this was 
not the case, at least in SCC 7.1 cells. Similar subG1 fractions on propidium 
iodide based FACS analysis were demonstrated for both parental SCC 7.1 FAK +/+ 
cells and the derived FAK -/- clone (Figure 24E), indicating that FAK was not 
critical for survival in vitro in these cancer cells.  
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Figure 22 - 4-OHT treatment does not yield a FAK -/- single cell clone in SCC 1.1 cells 
A subconfluent population of SCC 1.1 cells was treated with 10µM 4-OHT for 72 hours, trypsinised 
and replated at low density (100 cells per 90mm dish). After 14 days, 40 colonies were selected 
with a cloning disc and transferred into 12 well plates. Protein lysates were prepared from surviving 
clones, separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-FAK antibody 
(upper) and anti-γ-tubulin antibody (lower). 
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Figure 23 - 4-OHT treatment yields a FAK -/- single cell clone in SCC 7.1 cells 
A subconfluent population of SCC 7.1 cells was treated with 10µM 4-OHT for 72 hours, trypsinised 
and replated in a 96 well plate at a dilution of 1 cell per well. After 10 days, 40 colonies were 
selected and transferred into 12 well plates. Protein lysates were prepared from surviving clones, 
separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-FAK antibody. 
Experiment courtesy of A Serrels. 
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Figure 24 - Isolation of an SCC 7.1 FAK -/- single cell clone 
(A) Phase contrast images of SCC 7.1 FAK +/+ parental cells and the derived FAK -/- cell line 
clone 11 (scale bar, 25µm). (B) SCC 7.1 FAK +/+ and FAK -/- clone 11 cellular protein extracts 
were separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-FAK antibody 
(upper), anti-Pyk2 antibody (middle), and anti-γ-tubulin antibody (lower). (C) Cells were plated on 
glass coverslips at low density, fixed, and stained with antibodies directed at FAK and actin, prior to 
visualisation by fluorescent confocal microscopy. Representative images of SCC 7.1 FAK +/+ (left) 
and FAK -/- clone 11 (right) cells are shown, red – actin, green – FAK, blue – DAPI (scale bar, 
20µm). (D) Genomic DNA was extracted from SCC 7.1 FAK +/+ and FAK -/- clone 11 cells, 
subjected to RT-PCR for Cre (left) and loxP (right) as outlined in Methods section, and separated 
on 1.5% and 3% agarose gels respectively. (E) Subconfluent populations of SCC 7.1 FAK +/+ and 
FAK -/- clone 11 cells were suspended in ice cold PBS and fixed in 70% ethanol overnight prior to 
staining with propidium iodide and analysis by FACS as outlined in methods. Representative FACS 
profiles are demonstrated from one of three separate experiments. 
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3.2.6 Do underlying biological factors influence cell survival in 
the absence of FAK? 
Thus, we have established that it is possible to derive a FAK -/- cancer cell line. 
Yet, it is unclear whether this is a cell line specific phenomenon and a number 
of important questions remain unanswered. For instance, was the lack of 
production of a FAK -/- single cell clone in the SCC 1.1 cell line a result of 
technical or biological problems within this system, such as the level of Cre 
recombinase expression? Alternatively, was the deletion of FAK effectively 
inducing proliferation arrest or cell death in this cell line and, if so, why? If we 
consider the skin carcinogenesis model outlined earlier in Figure 12 (page38), 
this protocol typically induces a missense mutation in codon 61 of H-Ras which 
we were able to demonstrate in both cell lines. However, a number of key 
genetic mutations and biological alterations are thought to contribute to 
malignant progression, in addition to the previously described activating 
mutation in H-Ras, notably loss of important tumour suppressors such as p53, 
PTEN, and  p16INK4a (Frame, Crombie et al. 1998; Suzuki, Itami et al. 2003; 
Zoumpourlis, Solakidi et al. 2003; Mao, To et al. 2004). With this information in 
mind, we aimed to identify whether any major genetic differences existed 
between the two SCC cell lines.     
Currently, there is little in the literature to link FAK with these genes, with the 
exception of p53. A considerable body of evidence is emerging that connects FAK 
and p53 in cell survival. We, therefore, decided to focus on p53. First we 
determined that the gene was present in both SCC cell lines by RT-PCR, using 
3T3 mouse fibroblasts as a positive control and p53 -/- MEFs as a negative 
control (Figure 25A). Next, we assessed p53 protein levels by immunoblotting. 
While protein was detected in both cell lines, a discrepancy was noted in the 
levels of p53 protein (Figure 25B). Intriguingly, low basal levels of p53 were 
present in SCC 1.1 cells. This indicated the presence of an un-mutated gene 
since wt p53 is normally expressed at very low levels in unstressed cells.  On the 
other hand, greater levels of p53 were detected in SCC 7.1 cells, suggestive of a 
stabilising mutation. Consequently, the p53 levels in SCC 7.1 cells were found to 
be comparable with those in a mouse cell line, 83320, with a confirmed 
accumulating mutation of p53 (R175H +/-) (Figure 25B).  
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Figure 25 - p53 is overexpressed in SCC 7.1 cells compared with SCC 1.1 cells 
 (A) RT-PCR for p53 was performed with cDNA from 3T3, p53-/- MEFs, SCC 1.1 and SCC 7.1 
cells, and separated on a 1.5% agarose gel. (B) Cellular protein extracts from 83320 cells, p53-/- 
MEFs, SCC 1.1 and SCC 7.1 cells were separated by SDS-PAGE, transferred to nitrocellulose, 
and probed with antibodies to p53. For further information on the 83320 cell line see Appendix 1 
(page 234). 
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A full description of the 83320 cell line is provided in Appendix 1 (page 236). In 
view of the data linking FAK and p53, these findings may well be biologically 
relevant and merit investigation in future chapters. 
3.3 Discussion 
We aimed to evaluate the role of FAK in radiation survival in vitro and in vivo by 
performing proof of principle experiments using a genetic deletion model. 
Rather than restricting our work to FAK +/+ and FAK -/- MEFs, we opted to 
develop a cancer cell line with inducible fak deletion as we believed this would 
be more relevant to human disease. There is evidence that, compared with 
tumour cells, fibroblasts respond differently to DNA damaging agents, including 
ionising radiation. Also, we intended to progress to in vivo studies which would 
not be possible with MEFs. In order to generate such a cell line, we utilised a 
conditional knock out mouse model that had already been used in this laboratory 
to investigate the role of FAK in skin carcinogenesis. 
The advent of Cre/loxP technology has provided researchers with the means to 
conditionally delete a gene of interest in the mouse (Brault, Besson et al. 2007). 
This approach is obviously useful in situations where gene deletion in the embryo 
is lethal, for example in the case of FAK, where profound mesodermal and 
vascular abnormalities result in death at E8.5 (Ilic, Furuta et al. 1995). However, 
another major advantage of this system is that it allows temporal regulation in 
addition to spatial regulation. For the purposes of carcinogenesis, this degree of 
control is important as the function of the gene of interest can be evaluated at 
different stages of tumour initiation and progression. Indeed, we have already 
outlined that this system provided useful insights into the role of FAK in mouse 
skin carcinogenesis (McLean, Komiyama et al. 2004).  
As we wished to develop a FAK -/- cancer cell line with which to investigate 
radiosensitivity, this model seemed ideal for several reasons, in addition to the 
obvious advantage of the 4-OHT-inducible system. Firstly, skin carcinogenesis 
with DMBA/TPA permits the development of squamous cell carcinomas as 
opposed to adenocarcinomas (or other histological tumour types). The former 
are more readily treated by radiation and therefore more biologically relevant. 
Chapter 3  111 
Admittedly H-Ras mutations are not particularly common in human tumours (Bos 
1989), at less than 5% (www.sanger.ac.uk/genetics/CGP/cosmic/), but this 
model has some similarities to human disease (Balmain and Harris 2000). 
Secondly, tumours form on the skin and the progression to frank carcinoma is 
often apparent by gross pathological appearance. As these tumours are readily 
visible and accessible, the likelihood of successfully developing a cancer cell line 
is high.  
Accordingly, the generation of novel cell lines from established tumours was 
relatively straightforward. Deleting fak, however, proved to be more 
challenging. While 10nM tamoxifen promoted highly efficient fak excision in 
K14CreERT2/FAKflox/flox keratinocytes (McLean, Komiyama et al. 2004), this dose 
had no effect on the cancer cell lines we generated. In fact, a 1000-fold dose 
increase was necessary to induce reasonable knockout. Full knockout was never 
achievable and we suspected this was due to a combination of suboptimal Cre 
recombinase expression and the dose limiting toxicity of 4-OHT (doses in excess 
of 15µM resulted in profound cytotoxicity). Despite testing several commercially 
available Cre antibodies in a variety of applications, namely western blotting, 
immunofluorescence, and immunohistochemistry, we were unable to find a good 
enough antibody to determine whether Cre expression was a problem. For these 
reasons, we would in the future incorporate a reporter gene such as lacZ into 
the system, to allow visualisation of Cre recombinase expression by β–
galactosidase staining.  
Although we were unable to confirm our hypothesis regarding Cre expression in 
the SCC lines we generated, another group has since developed a Chk1 knockout 
cancer cell line using a similar model and have been able to demonstrate 
approximately 70-80% Cre recombinase activity using β–galactosidase staining as 
a surrogate marker (personal communication – Lye Mun Tho). The discrepancy in 
Cre activity between normal keratinocytes and cancer cells (and the 
considerable difference in drug dose required to induce this activity) has led us 
to question whether a significant change occurs in the Cre-ER fusion protein 
during the process of carcinogenesis. An alteration in the conformation and/or 
cellular localisation of this fusion protein could perhaps explain why lower doses 
of 4-OHT were ineffective at inducing FAK loss. This may also explain why 4-OHT  
was ineffective in the SCC 1.1 and SCC 7.1 xenografts despite using a well 
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documented regimen. While we accept that this view is largely speculative at 
present, there is some evidence to suggest that Cre undergoes silencing in the 
form of methylation (Long and Rossi 2009). 
One final point on the application of the Cre/loxP system is that our results 
unexpectedly, but consistently, showed lower levels of FAK knockout in the SCC 
1.1 cell line. We were able to demonstrate that this was not due to lack of the 
K14 promoter as this cell line had high levels of both K14 mRNA and protein. 
Conversely, SCC 7.1 cells, which had very low levels of K14 transcript and did 
not express K14 at the protein level, displayed more efficient FAK loss. The 
reasons for this are not entirely clear but our findings would suggest that when 
K14 is turned on in the embryo it drives the expression of Cre which is stably 
maintained in cells even in the event of aberrant or lost cytokeratins during the 
process of malignancy. Alternatively, low levels of K14 mRNA may be sufficient 
to drive Cre expression. Either way, this does not necessarily explain why FAK 
knockout was less efficient in the high K14 expressing cell line, and implies that 
Cre function may be critically important, as we suggested above, and may vary 
from cell line to cell line. 
FAK is elevated genetically, by amplification, and/or at the protein level in a 
number of epithelial cancers, including breast, colon, thyroid, and ovary 
(Owens, Xu et al. 1995; Owens, Xu et al. 1996; Agochiya, Brunton et al. 1999; 
McLean, Avizienyte et al. 2003; Golubovskaya, Kweh et al. 2009).  Further, we 
know from previous work, that FAK protein levels are increased in squamous cell 
carcinomas of mouse skin compared with normal keratinocytes and papillomas 
(McLean, Avizienyte et al. 2003; McLean, Komiyama et al. 2004; McLean, 
Carragher et al. 2005). Similarly, the two isolated cell lines here displayed 
higher levels of FAK and Pyk2 compared with normal counterpart keratinocytes. 
This hints that FAK signalling is somehow crucial in the process of 
carcinogenesis, but does not answer the question of whether FAK is necessary 
for survival in established cancer cells. Clearly it is not the case in SCC 7.1 cells 
where a stable  FAK -/- clone was isolated and did not demonstrate any increase 
in subG1 population on FACS analysis, when compared with its FAK +/+ 
counterpart. However, a number of studies have shown the induction of cell 
death, primarily by apoptosis, in a variety of cancer cell lines exposed to either 
FAK siRNA, FAK antisense oligonucleotides, or small molecule tyrosine kinase 
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inhibitors (Smith, Golubovskaya et al. 2005; Halder, Kamat et al. 2006; Wu, Yuan 
et al. 2006; Halder, Lin et al. 2007; Liu, LaFortune et al. 2007; Shi, Hjelmeland 
et al. 2007; Beierle, Trujillo et al. 2008; Golubovskaya, Virnig et al. 2008; 
Roberts, Ung et al. 2008; Watanabe, Takaoka et al. 2008; Sakurama, Noma et al. 
2009). While we struggled to develop an SCC 1.1 FAK -/- single cell clone and 
strongly suspected that the difficulties were due to Cre expression and / or 
function; in the absence of any definitive data, we had to consider the 
possibility that SCC 1.1 cells simply could not survive in the absence of FAK, 
thereby precluding the development of a FAK -/- clone.  
We demonstrated that the SCC 1.1 and SCC 7.1 cell lines were morphologically 
distinct and it seemed likely that they would each possess a different pattern of 
genetic mutations and biological characteristics. One particular gene product 
that certainly appeared to differ was p53. The large discrepancy in basal protein 
level suggested the presence of wt p53 in the SCC 1.1 cell line and mutant p53 in 
the SCC 7.1 cell line. Interestingly, it has been proposed that the spindle cell 
carcinoma phenotype arising from the topical carcinogenesis model is dependent 
on the presence of mutant p53 (Ruggeri, Caamano et al. 1991; Han and Kulesz-
Martin 1992), although this is controversial (Buchmann, Ruggeri et al. 1991).  
More importantly, a link between p53 and FAK and cell survival has already been 
established (Ilic, Furuta et al. 1995; Lim, Chen et al. 2008). In the pivotal work 
performed by Ilic et al  FAK -/- MEFs could only proliferate in the absence of 
p53, although it is pertinent to note that the loss of p53 did not rescue 
embryonic lethality (Ilic, Furuta et al. 1995). In addition, inducing fak deletion 
in K14CreERT2/FAKflox/flox keratinocytes (which we assume have wt p53) led to 
increased cell death (McLean, Komiyama et al. 2004).  
During the course of this work, further information has come to light indicating a 
close relationship between FAK and p53. In fact, it was recently documented 
that FAK and p53 directly interact, and more importantly the FAK – p53 axis is 
responsible for cell fate decisions (Lim, Chen et al. 2008). It is becoming clear 
that FAK and p53 maintain a delicate balance of pro-growth/survival and anti-
growth/survival signals, at least in normal cells with wt p53. While there is 
growing indirect and direct evidence demonstrating that this balance also exists 
in cancer cells (Ilic, Almeida et al. 1998; Zhang, Lu et al. 2004; Lim, Chen et al. 
2008), induction of cell death in FAK knockdown cancer cells may require an 
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additional stress, such as the addition of a cytotoxic drug. A crucial difference 
between these reported studies and our system is their reliance on FAK siRNA, as 
opposed to our much cleaner genetic deletion model. It may be the case that 
even in cancer cells, with their potential for multiple factors to control cell 
survival, that complete absence of FAK protein is critical in terms of survival. We 
therefore postulated that p53 status may be a key factor in the survival of 
cancer cells, as it is in fibroblasts, in the context of a FAK null background (see 
Figure 26). 
3.4 Summary 
We have generated a FAK -/- squamous cell carcinoma cell line which will now 
be a useful tool in evaluating the role of FAK in radiation sensitivity. We 
hypothesised at this point that p53 status may be an important determinant of 
cancer cell survival in the absence of FAK. 
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Figure 26 - FAK/p53 hypothesis 
We hypothesised that the SCC 1.1 cell line has wt p53 and undergoes cell death or proliferation 
block following 4-OHT inducible fak deletion as opposed to the SCC 7.1 cell line which we suspect 
has mutant p53 and can propagate in the absence of FAK. 
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4 Evaluating the p53 status of the SCC 1.1 and 
SCC 7.1 cell lines. 
4.1 Aim 
In the previous chapter we described the development of two novel squamous 
cell carcinoma cell lines; SCC 1.1 and SCC 7.1. However, we were only able to 
successfully excise fak from one of these cell lines (SCC 7.1). We suspected that 
the ability of these cancer cell lines to survive in the absence of FAK was linked 
to p53. Here, we set out to determine the p53 status of each cell line (and the 
derived SCC 7.1 FAK -/- single cell clone). 
4.2 Results 
4.2.1 SCC 1.1 cells have wt functional p53. 
The majority of p53 mutations are missense mutations which are readily 
detectable by direct sequencing. Since more than 90% of these lie within the 
central DNA binding domain, primers were designed to cover this region (Figure 
27) and cDNA was analysed following PCR amplification and purification. As 
expected, no mutations were detected in SCC 1.1 cells.  
While a cell can possess wt p53 protein, the p53 pathway may not be fully 
operational due to dysfunction and / or mutation in either upstream or 
downstream effectors. Therefore, we attempted to learn more about the 
function of p53 by studying the effect of ionising radiation on p21 induction. 
Under normal conditions, p53 is maintained at a low level, largely due to its 
extremely short half-life. However, in response to stresses such as DNA damage 
(including ionising radiation), p53 levels rapidly increase. This is predominantly 
due to stabilisation of the protein, which is in turn triggered by a series of 
phosphorylation, de-phosphorylation, and acetylation events on the polypeptide. 
p53 then has an increased ability to bind DNA and mediate transcription by 
inducing specific target genes. It binds to short genomic sequences, called p53-
responsive  elements  (PREs),  and  hundreds of potential target  genes with PREs 
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Figure 27 - p53 sequencing region 
Primers were designed to amplify the central DNA binding domain of mouse p53 (exons 5 – 8), red 
arrows denote the specific area under investigation. 
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have now been identified. One well recognised p53 target gene is CDKN1A, 
which encodes the protein p21Waf1/Cip1 (Kastan, Onyekwere et al. 1991), hereafter 
referred to simply as p21. This protein belongs to the Cip and Kip family of 
cyclin-dependent kinase (CDK) inhibitors that includes p21, p27 and p57. p21 
inhibits the kinase activity of CDKs and CDK-cyclin complexes. Further, micro-
array based studies suggest that p21 expression positively correlates with the 
suppression of genes that are important for cell cycle progression (Chang, 
Watanabe et al. 2000). Hence, it is no surprise that p53 mediated induction of 
p21 in response to DNA damage is often associated with cell cycle arrest. This 
protein has a number of additional functions that can influence the outcome of 
DNA damage. For example, it can interfere with PCNA–dependent DNA 
polymerase activity, thereby inhibiting DNA replication and modulating various 
PCNA – dependent DNA repair processes. The precise role of p21 in each 
individual cancer cell line exposed to DNA damaging agents, such as ionising 
radiation, is likely to be different. For that reason, we opted to investigate 
whether p21 protein was upregulated in response to stress and use this test as a 
surrogate for p53 activity. Trying to examine functional downstream effects of 
p21 upregulation, such as cell cycle arrest, is more problematic in cancer cell 
lines compared with normal cells like fibroblasts, due to the potential 
complexity of the DNA damage response.  
To assess the effect of ionising radiation on p21 induction and gain insight into 
the function of p53 in this cell line, subconfluent cell populations were 
irradiated with 5Gy and lysates prepared for immunoblotting at various time 
points. Following exposure to radiation, SCC 1.1 cells exhibited an increase in 
p53 protein levels within 2 hours, quickly followed by induction of p21 at 4 hours 
(Figure 28A). The increase in p21 was maintained until the final 24 hour time 
point. 
A parallel experiment was set up in vivo whereby 5x105 cells were injected 
subcutaneously into nude mice and xenografts grown to 400 – 500 mm3. The 
animals were then sacrificed before or 6 hours after 5Gy whole body irradiation. 
Paraffin embedded sections were then stained for both p53 and p21. Nuclear 
accumulation of p53 was visible after radiation, but basal levels of the protein 
were difficult to detect in control animals (Figure 28B – upper panels). p21, on  
the other hand, was readily detected in both groups, allowing an objective 
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statistical comparison. The proportion of p21 positive cells per field was scored   
(20 fields per mouse) and the mean values of non-irradiated versus irradiated 
mice were then analysed. A robust p21 response was visualised (Figure 28B – 
lower panels) suggesting the presence of functional, normally regulated, p53 
protein in this cell line although this did not quite reach statistical significance 
(Mann Whitney, p=0.0809, n=3).  
4.2.2 The SCC 7.1 cell line is a mixed population of wt and mutant 
p53 cells. 
Initial sequencing analysis of the SCC 7.1 cell line did not reveal any mutations, 
but it quickly became apparent that some of the features of this cell line 
appeared to change over time. We noticed that the basal levels of p53 at early 
passage were actually very low, and in fact similar to SCC 1.1 cells (Figure 29A). 
However, the levels of p53 increased with passage number, and by passage 25 
the levels were comparable with that of the 83320 (R172H +/-) cell line 
described in the previous chapter (Figure 29A). The converse was true for p21; 
substantial protein levels were detected in early passage cells, but were 
markedly lower by passage 25 (data not shown). The pattern of p53 
immunofluorescence also differed with most of the cells in early cultures 
illustrating weak diffuse staining of both the cytoplasm and nucleus (although a 
number of cells did demonstrate stronger predominantly nuclear staining). In 
contrast, the vast majority of cells in later cultures exhibited robust nuclear 
staining and minimal cytoplasmic staining (Figure 29B).  
Further investigation revealed that, in addition to variances in p53 and p21 
levels and p53 localisation, the morphology of the cell population seemed to 
change from predominantly spindle at early passage to a more refractile 
morphology at later passage (Figure 30). Based on these findings, we suspected 
that the original SCC 7.1 cell line was composed of a mixture of cell populations, 
some with wt p53 and some with mutant p53. In order to address this, we 
repeated the sequencing analysis at passage 5 and passage 25. No mutations 
were detected in low passage cells. Remarkably, examination of the high 
passage population did reveal a mutation: a T to G substitution was detected at  
codon 254 (Figure 31). 
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Figure 28 - SCC 1.1 cells have functional wt p53 
(A) SCC 1.1 cells were irradiated with 5Gy at 70 – 80% confluence and lysates prepared at various 
time points. Immunoblotting was then performed for p53, p21, and β-actin.  (B)  5x105 SCC 1.1 
cells were injected subcutaneously into the right flank of 6 week old female nude mice. Xenograft 
growth was monitored until tumours reached 400 – 500 mm3. The animals were then sacrificed 
either before or 6 hours after 5Gy whole body irradiation. Representative bright field images of 
paraffin embedded sections stained with p53 (upper) and p21 (lower) are shown (scale bar, 
0.1mm).  
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Figure 29 - p53 levels and p53 localisation vary in SCC 7.1 cells depending on passage 
(A) Protein extracts were obtained from 83320, p53-/- MEFs, SCC 1.1 cells and either SCC 7.1 
passage 5 (left) or passage 25 (right) cells, separated by SDS-PAGE, transferred to nitrocellulose, 
and blotted with anti-p53 (upper panels), anti-p21 (middle panels) and anti-β-actin (lower panels). 
(B) SCC 7.1 cells were plated at low density on glass coverslips, fixed, and stained with anti-p53 
antibody. Representative images taken on fluorescent confocal microscopy are shown for a 
passage 5 population (left) and passage 25 population (right), green – p53, arrows indicate cells 
with predominantly nuclear staining (N) and cells with both cytoplasmic and nuclear staining (C+N) 
(scale bar, 50µm).  
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Figure 30 - SCC 7.1 cellular morphology alters with passage number 
Phase contrast images of subconfluent populations of SCC 7.1 passage 5 (left) and passage 25 
(right), arrows indicate spindle morphology (S) and refractile morphology (R) (scale bar, 25µm). 
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R
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Figure 31 - The SCC 7.1 cell line is a mixed population of cells with different p53 status 
RNA was extracted from SCC 7.1 cells at passage 5 and passage 25 and converted to cDNA as 
previously described. The cDNA was then amplified by PCR, purified, and subjected to direct 
sequencing analysis. Details of the primers are provided in the Methods section. Chromatograms 
for codons 253 – 255 of p53 are demonstrated for SCC 7.1 passage 5 (left) and passage 25 (right). 
 
SCC 7.1 passage 5                                               SCC 7.1 passage 25
253              254               255
A   C  A       C  G G        G  A  A
253              254               255
A   C  A       C  T G        G  A  A
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The missense mutation found, L254R, is located in a highly conserved region of 
the DNA binding domain. The resultant amino acid change (leucine to arginine) is 
likely to significantly alter the structure and/or function of the p53 protein as 
leucine is positively charged as opposed to the negatively charged arginine. In 
addition, leucine is hydrophobic whereas arginine is hydrophilic. However, this is 
not a well documented mutation, with just a single report in UVA induced mouse 
squamous cell carcinoma (van Kranen and de Gruijl 1999). The corresponding 
mutation in humans (L257R) has been documented several times in basal cell 
carcinoma of the skin (Agar, Halliday et al. 2004) and ovarian adenocarcinoma 
(Ramus, Bobrow et al. 1999; Rose, Robertson et al. 2003; Wang, Kringen et al. 
2004) but, again, has not been studied in much detail.  
At this point, we were unsure whether this mutation was present within the 
original tumour, meaning that the derived SCC 7.1 cell line was a mixed 
population at the outset, or if the mutation arose in culture. Either possibility 
was a reasonable conjecture as advanced cancers are likely to consist of 
populations of cells that have acquired different genetic mutations, plus p53 
mutations commonly occur do novo in the cell culture environment. We 
consistently found that different batches of SCC 7.1 cells expressed low levels of 
p53 protein on immunoblotting at passage 5. The presence of wt 53 was 
confirmed by sequencing in each case. In contrast, high levels of p53 were    
always observed in older cells at passage 25.  Critically, the same mutation 
(L254R) was detected in each batch of late passage SCC 7.1 cells. So, we 
surmised that this mutation had arisen in the original mouse tumour, and that 
over time the mutant p53 cells overpopulated the culture due to a proliferation 
advantage. This theory is explored in more detail in the next chapter.  
In light of our findings demonstrating a mixed cell population, it seemed 
appropriate to perform p53 functionality experiments in the SCC 7.1 cell line in 
early passage versus late passage populations. As shown in Figure 32A, p53 
levels increased in early passage SCC 7.1 cells in response to radiation, although 
this was not as marked compared with SCC 1.1 cells. Correspondingly, p21 was 
induced, albeit transiently (Figure 32A). Unlike SCC 1.1 cells, the increase in 
p21 was not sustained. Low passage SCC 7.1 xenografts also illustrated minimal 
basal p53 but this was still difficult to detect after radiation (Figure 32B – upper            
left panels). There was a small increase in p21 levels at 6 hours post irradiation 
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(Figure 32B – lower left panels) but this did not reach statistical significance 
(Mann Whitney, p=0.1914, n=3). However, based on immunoblotting, the 
transient increase in p21 occurred at 4 hours in vitro. Hence, it is possible that 
the maximal increase in vivo was missed, assuming that the cellular response to 
radiation in these cell lines was similar in vitro and in vivo.  
High passage populations of SCC 7.1 cells, on the other hand, had high basal 
levels of p53 (in keeping with mutant protein) and no detectable difference 
could be detected after radiation exposure at all, although there was a late 
increase in p21 at 24 hours (Figure 33A). As expected, SCC 7.1 high passage 
xenografts displayed abundant levels of p53 in the majority of cells, and this 
pattern did not change after 5Gy irradiation (Figure 33B – upper right panels). 
p21 levels were generally lower in these specimens and did not alter in response 
to radiation (Figure 33B – lower right panels, Mann Whitney, p=1.0, n=3).  
Taken together, this work pointed towards the presence of both wt p53 and 
mutant 53 cells within the original SCC 7.1 cell line. As a result, compared with 
the more straightforward data from the SCC 1.1 cell line, the functionality 
experiments in this section were more difficult to interpret. Nonetheless, early 
passage SCC 7.1 cells, which demonstrated wt p53 on sequencing analysis, did 
behave in a manner suggestive of functional p53.  
One major unexplained phenomenon was the late increase in p21 protein levels 
in response to radiation in high passage SCC 7.1 cells (which we believed 
consisted of predominantly mutant p53 cells). It is likely that there were still wt 
p53 cells present in the population at passage 25 – 30 which would be capable of 
transactivating p21 (and indeed a double peak on the chromatogram was highly 
suggestive of the presence of both wt and mutant p53 containing cells – Figure 
31). However, this would probably not justify such a substantial delay in p21 
induction. For a long time, it was assumed that mutant p53 proteins were 
incapable of transactivation, but studies have now shown that this is not 
necessarily the case (Aurelio, Kong et al. 2000; Weisz, Oren et al. 2007). As 
already outlined, there is minimal information available on the L254R mutant 
p53 protein. Hence, the specific properties of this protein in murine cancer cells     
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Figure 32 - Investigating p53 function in SCC 7.1 low passage cells 
 (A) SCC 7.1 cells (passage 5) were irradiated with 5Gy at 70 – 80% confluence and lysates 
prepared at various time points. Immunoblotting was then performed for p53, p21, and β-actin. (B)  
5x105 SCC 7.1 cells (passage 5) were injected subcutaneously into the right flank of 6 week old 
female nude mice. Xenograft growth was monitored regularly until tumours reached 400 – 500 
mm3. The animals were then sacrificed either before or 6 hours after 5Gy whole body irradiation. 
Representative bright field images of paraffin embedded sections stained with p53 (upper) and p21 
(lower) are shown (scale bar, 0.1mm).  
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Figure 33 - Investigating p53 function in SCC 7.1 high passage cells 
(A) As above, SCC 7.1 cells (passage 25) were irradiated and immunoblotting was performed for 
p53, p21, and β-actin at the determined time points. (B)  5x105 SCC 7.1 cells (passage 25) were 
injected subcutaneously into the right flank of 6 week old female nude mice. Xenograft growth was 
monitored regularly until tumours reached 400 – 500 mm3. The animals were then sacrificed either 
before or 6 hours after 5Gy whole body irradiation. Representative bright field images of paraffin 
embedded sections stained with p53 (upper) and p21 (lower) are shown (scale bar, 0.1mm).  
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have yet to be elucidated. However, the human equivalent, L257R, has been 
assessed in a yeast-based functional assay. Kato et al. performed a screen of 
over 2000 p53 mutations and determined that this particular mutant protein did 
not lead to transactivation of p53 target genes such as p21 and Bax (Kato, Han et 
al. 2003). Although these findings have yet to be validated in another cell line, 
they suggest that the p21 induction seen here is probably not explained by 
mutant p53 transactivation either. Of course, it must be pointed out that the 
human and mouse mutant proteins may not have identical properties. On 
balance, we conclude that the probable mechanism for the pattern of p21 
induction in this case is independent of p53. Although p21 is a well known p53 
target gene, the regulation of this protein is highly complex and it is subject to 
control by an array of transcription factors and cellular proteins (reviewed by 
(Abbas and Dutta 2009)).  
4.2.3 The SCC 7.1 FAK -/- single cell clone has wt functional p53. 
An important question was posed following the observation that the original SCC 
7.1 cell line was a mixed population of wt p53 and mutant p53 cells - did the 
derived SCC 7.1 FAK -/- single cell clone possess wt or mutant p53? Examination 
of codon 254 by sequencing analysis did not reveal a T to G substitution and no 
mutations were detected in the remainder of the DNA binding domain. As it is 
difficult to ensure that a clonal population is definitely derived from a single 
cell, we were concerned about possible contamination with a mutant p53 cell. 
Repeat sequencing analysis was therefore performed at passage 25 – 30. This did 
not demonstrate any evidence of a mutation (Figure 34A). Furthermore, 
western blotting for p53 showed low basal levels which did not change over 
time, as did immunofluorescence studies, which also demonstrated weak diffuse 
p53 staining similar to that of the majority of cells in early passage SCC 7.1 
populations (Figures 34B and 34C respectively). The spindle morphology of the 
clone 11 cell line was also in keeping with the majority of the cells in early 
passage SCC 7.1 populations and did not vary with increased passage (data not 
shown). Collectively, this data implied that the FAK -/- single cell clone 
consisted only of wt p53 cells. 
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Figure 34 - SCC FAK -/- clone 11 is derived from a wt p53 cell 
(A) RNA was extracted from SCC 7.1 FAK -/- cells at passage 5 and passage 25 and converted to 
cDNA which was then amplified by PCR, purified, and subjected to direct sequencing analysis as 
previously described. Chromatograms for codons 253 – 255 of p53 are demonstrated for SCC 7.1 
FAK -/- clone 11 cells, passage 5 (left) and passage 25 (right). (B) Protein extracts were obtained 
from SCC 7.1 FAK +/+ passage 25 and SCC 7.1 FAK -/- clone 11 cells at passage 5 and passage 
25, separated by SDS-PAGE, transferred to nitrocellulose, and blotted with anti-p53 (upper panels) 
and anti-β-actin (lower panels). (C) SCC 7.1 FAK -/- clone 11 cells were plated at low density on 
glass coverslips, fixed, and stained with anti-p53 antibody. Representative images taken on 
confocal microscopy are shown for a passage 5 population (left) and passage 25 population (right), 
green – p53 (scale bar, 50µm).  
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Figure 35 - SCC FAK -/- clone 11 has functional wt p53  
SCC 7.1 FAK -/- clone 11 cells (passage 5) were irradiated with 5Gy at 70 – 80% confluence and 
lysates prepared at various time points. Immunoblotting was then performed for p53, p21, and       
β-actin.   
 
75
50
35
50
35
p53
30
15
0       1       2       4       6      10     24    hrs
p21
β-actin
Chapter 4  132 
As previously discussed, the presence of wt p53 protein does not necessarily 
equate with functional p53 activity. Immunoblotting for p53 and p21 following 
irradiation demonstrated stabilisation of p53 and a corresponding increase in p21 
protein levels, indicating that p53 was functional in this cell line (Figure 35). 
Interestingly, the induction of p53 in this cell line demonstrated a cyclical 
pattern, with increases in protein levels visible at 2 hours, 6 hours, and 24 hours 
following irradiation. This finding is not atypical as ionising radiation often 
produces a biphasic, or even oscillatory, effect on protein induction (Zhang, Liu 
et al. 2009).  
In keeping with our proposal in the previous chapter that the SCC 1.1 cell 
possessed wt p53 and the SCC 7.1 cell line possessed mutant p53, we have 
demonstrated the presence of wt functional p53 in the SCC 1.1 cell line. 
However, we unexpectedly discovered that the SCC 7.1 cell line was composed 
of (at least) two different cell types, one with wt p53 and one with a p53 
mutation, L254R. Even more intriguingly, the derived SCC 7.1 FAK -/- single cell 
clone was clearly not dependent on mutant p53 for survival. This clone had, in 
fact, been developed from a cell with wt p53.  
4.3 Discussion 
The presence of wt p53 was confirmed in the SCC 1.1 cell line and in a subset of 
SCC 7.1 cells by sequencing the central DNA binding domain. Screening the 
entire gene was deemed unnecessary given that in excess of 90% of the 
mutations detected in human cancers occur in this region. What is more, the p53 
pathway appeared to be functional based on p21 induction assays, indicating an 
un-mutated gene. We did consider the fact that there are some crucial 
differences between human p53 and mouse p53. In general, p53 mutations are 
not detected as readily in murine solid tumours (Hollstein, Hergenhahn et al. 
1999; Zielinski, Liu et al. 2002), possibly due to lower exposure to carcinogens. 
However, review of the literature regarding p53 mutations in chemically induced 
mouse skin cancers reveals that the majority of mutations are also missense 
mutations located in the DNA binding domain (Ruggeri, Caamano et al. 1991; 
Ruggeri, DiRado et al. 1993; Zhang, Bauer et al. 1995; Wang, Greenhalgh et al. 
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1998), although gene deletions are probably more common compared with 
human tumours.  
A missense mutation, L254R, was detected in another subset of SCC 7.1 cells. 
Although this is not a well documented mutation, it has previously been reported 
in squamous cell carcinoma and basal cell carcinoma of the skin in mice and 
humans, respectively (van Kranen and de Gruijl 1999; Agar, Halliday et al. 2004), 
suggesting that it is a physiologically significant mutation in skin cancer. As 
anticipated, high passage SCC 7.1 populations containing a significant proportion 
of mutant L254R cells behaved very differently from low passage populations 
containing mainly wt 53 cells. While the abundant levels of p53 protein present 
in these late passage populations indicated that L254R was an accumulating 
mutation, it was difficult to precisely attribute any specific properties to this 
mutant protein, especially in view of the mixed cell nature of the original SCC 
7.1 cell line. Based on our results, we speculated that the mutant p53 cells were 
not capable of transactivating p53 target genes, such as p21, suggestive of a 
dominant negative effect. In contrast, we noted that the mutant p53 containing 
cells appeared to outgrow the wt p53 containing cells, suggestive of a gain of 
function effect on proliferation. It is important to note, however, that dominant 
negative and gain of function effects are not mutually exclusive; even if a 
particular p53 mutant protein does not result in transactivation of target genes, 
it may exert a gain of function effect on the cell by non-transcriptional means. 
Hence, these observations regarding p21 induction and proliferation may be 
significant but we did not attempt to validate our findings at this point; we will 
return to this point of discussion in the next chapter.  
Contrary to our initial impressions, the SCC 7.1 FAK -/- single cell clone 
originated from a wt p53 cell. This was a fascinating result for two crucial 
reasons. Firstly, we strongly suspected that mutant p53 offered a proliferative 
advantage and we were, therefore, extremely surprised that 4-OHT treatment 
had selected out a wt p53 cell. Secondly, we have obtained conclusive evidence 
that cancer cells can in fact survive and propagate in the absence of FAK on a wt 
p53 background (more importantly on a functional wt p53 background). This 
evidence obviously refutes our earlier hypothesis but does this mean that we can 
extrapolate these findings to the SCC 1.1 cell line? We have already shown that   
these cell lines are morphologically and biologically distinct so it cannot be 
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assumed that FAK is dispensable for survival in both. In fact, if we return to the 
FAK -/- embryos described by Ilic, the mesoderm was more susceptible to fak 
loss than the ectoderm (Ilic, Furuta et al. 1995). Further studies using 
conditional fak deletion have shown that increased cell death occurs in 
endothelial cells (Shen, Park et al. 2005), but not necessarily in neuronal cells 
(Beggs, Schahin-Reed et al. 2003). It is also interesting to note that in the mouse 
skin model induction of apoptosis following fak deletion is seen only within the 
stem cell bulge region (McLean, Komiyama et al. 2004). Crucially, it has now 
been demonstrated that p53 is upregulated only in the mesoderm of FAK -/- 
embryos (Lim, Chen et al. 2008). This indicates that survival in the absence of 
FAK is not only tissue specific or cell type specific, but suggests that it is likely 
to hinge on the cross talk and functional interaction between FAK and p53 so it 
would be of interest to assess whether cell death in the conditional models is 
p53 dependent. Further work is required to pinpoint the underlying biological 
reason why a FAK -/- clone was not achievable in the SCC 1.1 population, but we 
suspect that the ability of cancer cells to survive genetic deletion of FAK will 
vary from cell line to cell line and depend perhaps not only on the FAK-p53 axis, 
but also on other as yet undefined mutations arising during cancer progression in 
each individual tumour.  
4.4 Summary 
We determined that the SCC 1.1 cell line did, in fact, possess wt p53. Although 
the SCC 7.1 cell line contained a mixed population of cells with wt p53 and 
mutant p53, the SCC 7.1 FAK -/- single cell clone was derived from a cell with 
wt p53. This indicates that some cancer cells can survive in the absence of FAK 
on a wt p53 background, although this may be a cell line dependent 
phenomenon.  
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FAK in the cellular characteristics of 
the original SCC 7.1 cell line. 
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5 Dissecting out the roles of p53 and FAK in the 
cellular characteristics of the original SCC 7.1 
cell line. 
5.1  Aim 
Following the realisation that the original SCC 7.1 FAK +/+ cell line was a mixed 
population of at least two different cell types, one with wt p53 and one with 
mutant p53, we were concerned that a direct comparison with the derived SCC 
7.1 FAK  -/- single cell clone would be unjustifed for a number of reasons. 
Firstly, the proliferation characteristics of a particular cell line must be 
established before proceeding to clonogenicity experiments. This is because the 
doubling time of a cell population determines the length of incubation period for 
the clonogenic assay. Preliminary observations suggested that there were crucial 
differences in proliferation rate between SCC 7.1 FAK +/+ cells at various 
passages, and possibly between SCC 7.1 FAK +/+ and SCC 7.1 FAK -/- cells. 
However, at this point, it was difficult to pinpoint whether these potential 
differences were due to p53 (or FAK) and exactly how these differences would 
influence the outcome of clonogenicity experiments. Secondly, p53 status is 
thought to be an important determinant of radiosensitivity. The complicated 
literature on this subject will be discussed in detail later. Suffice to say, the 
presence of both wt p53 and mutant p53 cells in a cell population could 
potentially render data interpretation problematic. 
Therefore, we set out to determine whether p53 status did affect proliferation 
rate in the original SCC 7.1 cell line by separating out wt p53 and mutant p53 
cells by single cell cloning. In addition, we aimed to establish whether the 
presence of wt p53 or mutant p53 influenced radiation survival by performing 
clonogenic assays in these derived single cell clones.  
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5.2 Results 
5.2.1 Early passage and late passage SCC 7.1 populations have 
different growth characteristics in vitro and in vivo. 
It is important to establish certain cellular characteristics prior to performing 
clonogenicity assays, namely the doubling time of a cell population and the 
ability to form colonies at low density. We suspected from our previous findings 
that the SCC 7.1 FAK +/+ mutant p53 subpopulation had a growth advantage in 
vitro. Proliferation curves were therefore obtained for low passage cells (5 – 10) 
versus high passage cells (25 – 30). Accordingly, high passage populations had a 
higher proliferation rate as illustrated by MTT assay (Figure 36). Both 
populations yielded colonies when seeded at low density, but perhaps not 
surprisingly, colonies formed earlier in the late passage populations (at 5 days as 
opposed to 7 or 8 days in the early passage populations). It was also noteworthy 
that late passage colonies displayed a regular-shaped, compact appearance as 
opposed to the very diffuse scattered pattern of early passage colonies (Figure 
37A). In fact, the latter were so diffuse that the colonies appeared to merge and 
it was impossible to reliably count the number of colonies present per plate.  
Performing a clonogenic assay in soft agar as opposed to standard 2D tissue 
culture plastic is an acceptable means of assessing radiosensitivity. Therefore, 
low passage and high passage SCC 7.1 FAK +/+ cells were seeded in soft agar and 
colony formation was monitored over a period of 2 weeks. Both populations grew 
readily (Figure 37B) but, as the low passage populations contain mutant p53 
cells as well as wt p53 cells, we considered the possibility that the mutant p53 
containing cells may possess a growth advantage in this environment also and 
potentially bias the experiment. To answer this question, we plated out low 
passage cells into soft agar, extracted a number of colonies by fine needle 
aspiration, and performed p53 sequencing analysis. All of these colonies 
demonstrated wt p53 (Figure 38), indicating that the both the wt p53 containing 
cells and mutant p53 containing cell types formed viable colonies. It would 
therefore have been reasonable to assess clonogenicity by this method.  
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Figure 36 - SCC 7.1 high passage populations have a proliferation advantage in vitro 
1x103 SCC 7.1 cells (passage 5-10 and passage 25-30) were seeded into 96 well plates in 
quadruplicate. After 48 hours incubation, cell viability was evaluated on days 0 – 4 by colorimetric 
assay (MTT) as described in Methods section. Representative means ± SD from one of three 
separate experiments are shown. 
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Figure 37 - SCC 7.1 colony formation in 2D and 3D environments 
(A) SCC 7.1 cells were seeded into 90mm dishes at low density and observed for colony formation 
at 5 – 8 days. The colonies were fixed in methanol and stained with crystal violet. Representative 
phase contrast images are demonstrated for a low passage population (left) and a high passage 
population (right) (scale bar, 0.5mm). (B) 2x104 SCC 7.1 cells were seeded soft agar as outlined in 
Methods section and growth monitored over 14 days. Representative phase contrast images are 
demonstrated for a low passage population (left) and a high passage population (right) (scale bar, 
0.5mm). 
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Figure 38 - SCC 7.1 low passage cells containing wt p53 do not have a proliferation 
disadvantage in soft agar 
SCC 7.1 low passage cells were seeded into soft agar and monitored for 14 days. 6 colonies were 
removed from the agar by fine needle aspiration and RNA was immediately extracted. The RNA 
was then converted to cDNA which was amplified, purified and subjected to direct sequencing 
analysis for p53 as previously described. Chromatograms for codons 253 – 255 are demonstrated 
for each of these 6 colonies. 
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However, parallel experiments in SCC 7.1 FAK -/- cells demonstrated that these 
particular cells, which were deficient in FAK, could not survive in an anchorage 
independent environment. This will be discussed later in Section 5.2.7. In order 
to maintain uniformity across all cell types and cell populations, we decided to 
explore another alternative means of assessing clonogenicity.  A limiting dilution 
assay, where cells were seeded in a 96 well plate at a dilution that allowed 
single colony growth after 5 – 8 days incubation emerged as a viable option. This 
method proved to be reproducible across all cell populations. 
While late passage populations appeared to have a proliferative advantage in 
vitro, this did not translate into a proliferative advantage in vivo. In fact, low 
passage populations appeared to grow much more readily as xenografts as shown 
in Figure 39A and demonstrated a significantly higher proliferation level based 
on nuclear scoring of Ki67 (Figure 39B, Mann Whitney, p=0.0404, n=3). We also 
observed that while early passage xenografts reached a diameter of well over 
1cm before the mice had to be culled, animals bearing late passage xenografts 
had to be sacrificed by the time the tumours reached 7 or 8 mm due to signs of 
imminent central necrosis. One of the animals bearing a late passage xenograft 
developed abdominal swelling which we initially thought may have been due to a 
B-cell lymphoma, but post mortem examination demonstrated tumour extending 
from the xenograft into the abdominal cavity. These findings led us to question 
whether the mutant p53 containing cells have a higher propensity for invasion in 
vivo. 
Collectively, this data illustrated that there were indeed crucial differences in 
proliferative capacity within the cells of the original SCC 7.1 FAK +/+ population 
in various cellular environments, both in vitro and in vivo. We were keen to 
determine if radiosensitivity varied in the low passage and high passage 
populations but were concerned that the different growth rates would influence 
the results. Hence, we endeavoured to separate out wt p53 cells from mutant 
p53 cells before proceeding with clonogenicity assays. 
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Figure 39 - SCC 7.1 low passage populations have a proliferation advantage in vivo 
(A) 5x105 SCC 7.1 cells (passage 5 and passage 25) were injected subcutaneously into 6 week old 
female nude mice and growth monitored regularly. Mice were sacrificed when tumours reached 
1.7cm in maximal diameter or developed signs of imminent central necrosis. Tumour volume was 
calculated as described in Methods section. A graphical representation of mean tumour volume ± 
SEM is shown. (B) Similar to above, 5x105 SCC 7.1 cells (passage 5 and passage 25) were 
injected into nude mice. The animals were sacrificed when the tumour volume reached 
approximately 500mm3. Paraffin embedded sections were then stained for Ki67 and representative 
bright field images are shown (passage 5 – upper panel and passage 5 - lower panel) (scale bar, 
0.1mm).  
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5.2.2 Isolation of wt p53 versus mutant p53 single cell clones. 
SCC 7.1 passage 10 cells were trypsinised and diluted such that a single cell was 
seeded into each well of a 96 well plate. After 10 – 14 days, 10 colonies were 
selected, of which 7 survived repeated passage. A summary of their 
morphological appearance, p53 protein levels based on immunoblotting (IB), p53 
localisation as judged by immunofluorescence (IF), and sequencing analysis of 
codon 254 is outlined in Table 7. All of these experiments were performed in 
each cell line between passage 5 and passage 10.  
Table 7 - Isolation of wt and mutant p53 single cell clones  
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The actual results for 2 representative wt clones (D1 and H9) and 2 
representative mutant clones (A10 and H7) are illustrated in Figure 40. Both D1 
and H9 cells demonstrated spindle cell morphology, similar to that of early 
passage SCC 7.1 FAK +/+ cells, whereas A10 and H7 cells demonstrated a more 
refractile morphology in keeping with late passage SCC 7.1 FAK +/+ cells (Figure 
40A). As anticipated, low levels of p53 were present in D1 and H9 cells, although 
there appeared to be less nuclear staining compared with early passage SCC 7.1 
FAK +/+ cells and  the distribution of staining in the D1 cells was predominantly 
perinuclear (Figures 40B and 40D). A10 and H7 cells, on the other hand, 
displayed higher levels of p53, which were predominantly nuclear in distribution 
(Figures 40B and 40D). Sequencing analysis of p53 revealed wt p53 
conformation in D1 and H9 cells and mutant p53 conformation in A10 and H7 
cells at codon 254 (Figure 40C). Further sequencing of the entire DNA binding 
domain of p53 in each cell line did not reveal any additional mutations. To be 
certain that D1 and H9 were not contaminated by mutant cells, all of the above 
was repeated at passage 25 – 30. There was no evidence of contamination (data 
not shown). We were interested to learn whether FAK levels varied across these 
single cell clones, especially in view of recent work which suggests that FAK is 
upregulated in cells with mutant p53 (Golubovskaya, Finch et al. 2008). 
However, this did not appear to be the case, and FAK levels were similar in all 
clones, regardless of p53 status (Figure 40D).     
5.2.3 Characterisation of wt p53 versus mutant p53 single cell 
clones. 
MTT proliferation assay and xenograft growth curves confirmed that the mutant 
p53 containing cells had a proliferation advantage in vitro (Figure 41) but not in 
vivo (Figures 42A). Intriguingly, there appeared to be differences between the 
wt p53 containing clones, for example D1 cells had a much faster proliferation 
rate than H9 cells in vivo. Similarly, there were also differences between the 
mutant p53 containing clones; A10 cells proliferated more rapidly than H7 cells 
in vitro.  
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Figure 40 - Isolation of wt p53 and mutant p53 single cell clones 
(A) Phase contrast images of two representative wt p53 single cell clones (D1 and H9) and two 
representative mutant p53 single cell clones (A10 and H7) (scale bar, 25µm). (B) A10, D1, H7 and 
H9 cells were plated at low density on glass coverslips, fixed and stained with an anti-p53 antibody. 
Representative images taken on fluorescent confocal microscopy are demonstrated for each of the 
isolated single cell clones, green – p53 (scale bar, 20µm). (C) RNA was extracted from each of the 
isolated single cell clones at passage 5 and converted to cDNA which was then amplified by PCR, 
purified, and subjected to direct sequencing analysis. Chromatograms for codons 253 – 255 of p53 
are illustrated. (D) Protein extracts from each of the isolated clones were separated by SDS-PAGE, 
transferred to nitrocellulose and probed with anti-FAK, anti-p53 and anti-β-actin antibodies. 
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Figure 41 - Mutant p53 single cell clones have a proliferation advantage in vitro 
Each of the cell lines indicated were seeded at a density of 1x103 cells into wells of a 96 well plate 
in quadruplicate. After 48 hours incubation, cell viability was evaluated on days 0 – 4 by 
colorimetric MTT assay. Representative means ± SD from one of three separate experiments are 
shown. 
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Figure 42 - Mutant p53 single cell clones do not have a proliferation advantage in vivo 
(A) 5x105 cells from each of the cell lines indicated were injected subcutaneously into 6 week old 
female nude mice. Xenograft growth was monitored regularly and the animals were sacrificed when 
tumours reached 1.7cm in maximal diameter or developed signs of imminent central necrosis. 
Tumour volume was calculated as described in Methods and a graphical representation of mean 
volume ± SEM is shown (n=8). (B) H&E stained paraffin embedded sections from xenografts 
generated by the cell lines indicated (scale bar 0.1mm). 
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In keeping with their distinct cellular morphology patterns, both wt p53 clones 
formed xenografts consisting of sheets of pleomorphic spindle cells as opposed 
to the rounder aggregates of cells produced by mutant p53 clones (Figure 42B). 
While D1 xenografts were firm and well circumscribed, generally reaching >1cm 
in diameter prior to termination, all of the other cell lines, including H9, formed 
tumours with a more spongy consistency that were difficult to dissect out post 
mortem (partly due to consistency and partly due to infiltration into host tissue),  
and which developed signs of necrosis at < 1cm. A number of these infiltrative 
xenografts extended into the abdominal cavity. Table 8 outlines the number of 
invading tumours per total number of xenografts. Only A10 and H7 cells 
displayed this particular phenotype of frank invasion, and although this data is 
by no means definitive, again it suggests that the mutant p53 containing cells 
may have a propensity for invasion in vivo. An example of an H7 xenograft 
invading into underlying tissues is outlined in Figure 43. 
Table 8 - Number of xenografts invading into the abdominal cavity  
 
Clone p53 status Invading xenografts Total number of 
xenografts 
D1 wt 0 8 
H9 wt 0 8 
A10 mutant 2 8 
H7 mutant 3 8 
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Figure 43 - Mutant p53 single cell clones have a higher propensity for invasion in vivo 
Photograph of a female nude mouse bearing a xenograft generated by the H7 cell line with a close 
up image of the area of interest (inset). 
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5.2.4 Radiosensitivity is not conditional on the basis of p53 status 
alone in the isolated wt p53 and mutant p53 clones. 
Having successfully separated wt p53 from mutant p53 cells in the form of single 
cell clones, it was now possible to accurately examine radiosensitivity, and we 
did this by performing a limiting dilution assay at various doses of radiation (up 
to a maximum of 10Gy in 2Gy increments).  Clonogenicity in response to ionising 
radiation was not identical across these isolated clones (Figure 44A). We found 
that the presence of wt p53 or mutant p53 did not determine either 
radiosensitivity or radioresistance. In fact, the most radioresistant cell line was 
consistently H9, which possesses wt p53, and the least radioresistant was the 
mutant p53 containing H7.  
The extremely radioresistant phenotype of H9 may be partly explained by the 
findings from propidium iodide based FACS analysis (Figure 44B). While this 
revealed a normal cell cycle profile in D1 cells, the H9 cells demonstrated 
marked aneuploidy. In fact, it was virtually impossible to delineate the separate 
phases of the cell cycle in this cell line. This would suggest the presence of 
chromosomal abnormality and genetic instability, which can result in resistance 
to DNA damaging agents and interestingly, is often linked to mutant p53 as 
opposed to wt p53 (Mekeel, Tang et al. 1997; Akyuz, Boehden et al. 2002; 
Okorokov, Warnock et al. 2002; Linke, Sengupta et al. 2003; Okorokov 2003). 
A10 and H7 cells also demonstrated a degree of genomic instability in the form 
of both aneuploidy and polyploidy but the level of aneuploidy was not quite as 
striking compared with the H9 cells. We can only speculate as to why the H9 cell 
line possessed this particular phenotype, but overall this data highlights both the 
complexity of cellular radiation survival and hints at the likelihood of additional 
mutations and / or molecular alterations within these “isogenic” cell lines. 
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Figure 44 - Radiosensitivity of the isolated wt p53 and mutant p53 clones 
(A) The cell lines indicated were diluted and seeded into each well of a 96 well plate at appropriate 
density to allow single colony growth at 5 – 8 days. After 6 hours the plates were irradiated with 
various doses of radiation as indicated. Following incubation for 5 – 8 days, the colonies were 
counted and the surviving fraction calculated at each dose of radiation. Each experiment was 
performed in triplicate and the combined results (mean ± SEM) from at least three separate 
experiments are shown. (B)  Subconfluent populations of the cell lines indicated were suspended in 
ice cold PBS and fixed in 70% ethanol overnight prior to staining with propidium iodide and analysis 
by FACS. Representative profiles from one of three separate investigations are demonstrated. 
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5.2.5 Development of wt p53 versus mutant p53 FAK -/- cell lines. 
Our suspicions that the original SCC 7.1 FAK +/+ cell line contained a mixture of 
cells with different p53 status and different properties were confirmed. This 
precluded a direct comparison of radiosensitivity with the strictly wt p53 
containing SCC 7.1 FAK -/- cell line. In view of the variation between the D1 and 
H9 wt p53 single cell clones, which we suspected was due to inconsistencies in 
their genetic background, we had to acknowledge that the original SCC 7.1 FAK 
+/+ cell line may have consisted of a vast number of cancer cells containing wt 
p53 but different additional mutations, any one of which could have given rise to 
the FAK -/- single cell clone. As we had no evidence that the SCC 7.1 FAK -/- cell 
line was derived from a D1 type cell or an H9 type cell, it was also inappropriate 
to compare the SCC 7.1 FAK -/- cell line with either of these wt p53 clones. With 
both of these means of comparison, it would have proved very difficult to 
attribute any potential differences in radiation response to FAK alone.  
In order to reliably compare FAK -/- cells with their FAK +/+ counterpart, we 
decided to develop novel FAK -/- cell lines from the isolated clones (A10, D1, H7 
and H9), which would have the advantage of a paired parental cell line from an 
identical genetic background. This work is still ongoing and has not yet yielded a 
FAK knockout cell line from any of the isolated clones. 
5.2.6 Reconstituting wt FAK into FAK -/- cells overcomes the 
problem of a mixed FAK +/+ parental cell line. 
As paired FAK +/+ and FAK -/- cell lines from the isolated clones were not easily 
forthcoming, we opted to take the alternative approach of reconstituting wt FAK 
into the SCC 7.1 FAK -/- cell line using a myc-tagged CMV driven expression 
vector and subsequent selection in antibiotic containing media. Both FAK 
knockout and FAK reconstituted cells exhibited the same spindle cell morphology 
(Figure 45A). We ascertained that FAK was correctly localised at focal adhesions 
in these reconstituted cells (Figure 45B) and FAK protein levels were 
comparable to those of low passage original SCC 7.1 FAK +/+ cells (Figure 45C).  
 
Chapter 5  153 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45 - Reconstituted wt FAK is expressed in focal adhesions 
(A) Phase contrast images of SCC 7.1 FAK -/- cell line (left) and SCC 7.1 FAK wt cell line (right), 
following addition of myc-tagged wt FAK vector and selection in hygromycin (scale bar, 25µm). (B) 
SCC 7.1 FAK -/- and SCC 7.1 FAK wt cells were plated at low density on glass coverslips, fixed 
and stained with mouse anti-paxillin antibody and rabbit anti-FAK antibody. Representative images 
taken on confocal microscopy are shown, red – paxillin and green – FAK (scale bar, 20µm). (C) 
Lysates from SCC 7.1 FAK +/+ (passage 5), SCC 7.1 FAK -/-, and SCC 7.1 FAK wt cells were 
immunoblotted for FAK, myc and β-actin. 
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5.2.7 FAK is dispensable for growth in vitro but is essential for 
anchorage-independent growth. 
FAK has previously been noted to promote proliferation in certain cell lines in 
vitro. Comparison of the proliferation rate in SCC 7.1 FAK -/- versus SCC 7.1 FAK 
wt cells by MTT assay, however, did not reveal any difference indicating that 
FAK was dispensable for growth on 2D in this system (Figure 46A). Similar to the 
predominantly wt p53 containing cells of early passage SCC 7.1 populations, both 
SCC 7.1 FAK -/- and SCC 7.1 FAK wt cells formed dispersed colonies at low 
density (Figure 46B).  Colony formation was assessable by limiting dilution assay 
and there was no significant difference in plating efficiency (Figure 46C, 
student’s unpaired t-test, p=0.4290, n=9). 
We noted in previous experiments that SCC 7.1 FAK -/- cells failed to establish 
colonies in soft agar. We wanted to confirm that FAK was essential for 
anchorage-independent survival and therefore directly compared SCC 7.1 FAK -/- 
with SCC 7.1 FAK wt cells. At this point, however, we switched soft agar for 
methylcellulose as it proved easier to extract cells or colonies for further 
analysis from this medium. As shown in Figure 47A FAK was a prerequisite for 
growth in this medium. Quantification of the number of colonies present in ten 
random fields revealed an average of 15 - 20 colonies in the FAK wt population, 
but virtually no colonies in the FAK -/- population (Figure 47B).  
We speculated whether the kinase function of FAK was responsible for this 
phenomenon. This was based on previous evidence suggesting that FAK signalling 
is an important survival mechanism for cells in suspension (Frisch, Vuori et al. 
1996; Ilic, Almeida et al. 1998; Xu, Yang et al. 2000) coupled with our own 
observations. We found that phospho-FAK-Y397 levels were constitutively active 
in SCC 7.1 FAK wt cells even in suspension as opposed to keratinocytes which 
switched on phosphorylation following adhesion to fibronectin (Figure 47C). To 
ensure that these results were not related to the FAK plasmid, the experiment 
was repeated in an early passage parental SCC 7.1 FAK +/+ population. The same 
outcome was obtained (Figure 47C – far right panels).  
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Further evidence that this phenomenon is kinase dependent was provided by the 
incorporation of a small molecule FAK kinase inhibitor into the methylcellulose 
assays. The addition of PF-562,271 to FAK wt cells resulted in a dose-dependent 
inhibition of colony formation with concentrations of 0.25µM and above resulting 
in around a 45% reduction in the number of colonies (Figure 47D). Notably, 
substantial FAK inhibition could be demonstrated by western blotting at doses of 
0.25µM and above (Figure 47E), although complete inhibition of Y397 
phosphorylation was never achieved when cells were grown on tissue culture 
plastic. We did consider the possibility that the drug may have affected 
proliferation through off-target effects which could restrict colony growth. 
However, further work demonstrated that the IC50 for this particular drug in FAK 
wt cells was in excess of 3µM (data not shown). Thus, the effects of 0.25µM 
concentration of drug on colony formation were clearly not due to proliferation. 
As there are always some concerns over the specificity of kinase inhibitors, we 
have generated a FAK kinase dead (FAK KD) cell line using the same system 
which we used to develop the FAK wt cell line. These cells, which have lost the 
catalytic function of FAK, behave in a very similar manner to the FAK -/- cells in 
methylcellulose (personal communication – Kenneth McLeod), indicating that it 
is indeed the kinase activity of FAK that drives colony growth in a 3D 
environment. 
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Figure 46 - FAK is dispensable for proliferation in vitro 
(A) 1x103 SCC 7.1 FAK -/- and SCC 7.1 FAK wt cells were seeded into 96 well plates in 
quadruplicate. After 48 hours incubation, cell viability was evaluated on days 0 – 4 by colorimetric 
assay (MTT). Representative means ± SD from one of three separate experiments are shown. (B) 
SCC 7.1 FAK -/- and SCC 7.1 FAK wt cells were seeded at 100 cells per 90 mm dish and growth 
monitored over 7 days. The colonies were then fixed in methanol and stained with crystal violet. 
Representative phase contrast images of colony morphology are illustrated (scale bar, 0.5mm). (C) 
A single cell was seeded into each well of a 96 well plate and the percentage of wells with a viable 
colony (>50 cells) calculated at 7 days. The experiment was set up in triplicate and the bar chart 
demonstrates the combined mean ± SEM from three separate experiments based on SCC 7.1 FAK 
-/- cells (left) and SCC 7.1 FAK wt cells (right). Statistical significance was evaluated by student’s 
unpaired t-test, n=9. 
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Figure 47 - FAK kinase activity is required for anchorage-independent growth 
(A) 2.5x105 cells were resuspended in a solution of 1.4% in growth media and plated over a layer of 
0.9% agarose. Cells were photographed after 9 days. Representative phase contrast images at 10 
days are demonstrated for FAK -/- cells (left) and FAK wt cells (right) (scale bar, 0.5mm). (B) The 
numbers of colonies were counted in ten random fields (x10 magnification) and colony area was 
calculated in Image J. Results are shown from a representative experiment in a series of three, 
mean ± SEM. (C) 3x106 cells were suspended (S) in ice cold PBS and rotated at 4oC. After 1 hour, 
the cells were centrifuged and either collected for protein extraction or resuspended in growth 
media and seeded on to fibronectin (FN) coated plates. Further lysates were then prepared after 30 
minutes and 60 minutes. Protein extracts were separated by SDS-PAGE, transferred to 
nitrocellulose, probed with anti-phospho-FAK-Y397 antibody then stripped and re-probed with anti-
FAK antibody. (D) FAK wt cells were added to methylcellulose as described above in the presence 
of increasing doses of PF-562,271 and colonies counted at 9 days, results shown are 
representative mean ± SEM from one experiment in a series of three. (E) FAK wt cells were treated 
overnight with a range of doses of PF-562,271 prior to western blot analysis for phospho-FAK-
Y397 and total FAK. The relative density of the Y397 signal was quantitated by densitometry (lower 
panel). 
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5.2.8 FAK is not required for tumour cell growth in vivo. 
As we intended to proceed to evaluating the role of FAK in radiation survival in 
vivo as well as in vitro, it was essential to elucidate whether loss of FAK 
prevented or impaired the development of xenografts. In fact, SCC FAK -/- cells 
formed tumours readily with a success rate in excess of 90%. However, we noted 
that the FAK -/- xenografts took longer to establish compared with their FAK wt 
counterparts (Figure 48A). Of note, there was no substantial difference in the 
gross or microscopic appearance of xenografts from either cell line (H & E 
stained histological specimens from an SCC 7.1 FAK -/- and an SCC 7.1 FAK wt 
xenograft are shown in Figure 48B), although the vasculature did appear to be 
more tortuous and leaky in the FAK -/- tumours, but this has not yet been 
formally assessed.  
The presence or absence of FAK could be demonstrated by western blotting of 
tumour lysates (Figure 48D). The weak levels of FAK protein in the FAK -/- 
extracts most likely represents the presence of host infiltrate, such as tumour 
associated fibroblasts, from the host animal. Interestingly, proliferation was not 
markedly affected. Ki67 staining of paraffin embedded tissue from SCC 7.1 FAK  
-/- and SCC 7.1 FAK wt xenografts (Figure 48C) measuring approximately 
500mm3 demonstrated median nuclear positivity of 16.0% versus 17.05% 
respectively which was not statistically significant (Mann Whitney, p=0.5309, 
n=5). So, it would appear that loss of FAK impedes the initial phase of xenograft 
development, but does not dramatically impact on growth and development 
when tumours have managed to establish. 
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Figure 48 - Loss of FAK delays the establishment of xenografts but does not significantly 
impede proliferation in vivo 
(A) 2.5x105 SCC 7.1 FAK -/- and SCC 7.1 FAK wt cells were injected subcutaneously into the right 
flank of 6 week old nude mice. Xenograft growth was monitored regularly and animals were 
sacrificed when tumours reached 1.7cm in maximal diameter or developed signs of imminent 
central necrosis. Tumour volume was calculated as previously described and a graphical 
representation of mean volume ± SEM is shown (n=8). (B) H&E stained paraffin embedded 
sections from an SCC 7.1 FAK -/- xenograft (upper panel) and an SCC 7.1 FAK wt xenograft (lower 
panel) (scale bar, 0.1mm). (C) 2.5x105 SCC 7.1 FAK -/- and SCC 7.1 FAK wt cells were injected 
into nude mice and the animals were sacrificed when the tumour volume reached approximately 
500mm3. Paraffin embedded sections were then stained for Ki67 and representative bright field 
images are shown (FAK -/- in upper panel and FAK wt in lower panel) (scale bar, 0.1mm).           
(D) Protein extracts from FAK -/- xenografts and FAK wt xenografts were immunoblotted for FAK 
and γ-tubulin. 
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5.3 Discussion 
The realisation that the SCC 7.1 parental cell line was composed of a mixed 
population of cells with different properties highlighted the difficulties that can 
arise working with a novel cell line. Despite the fact that this precluded a direct 
comparison between the original SCC 7.1 FAK +/+ cell line and the derived FAK   
-/- single cell clone, it did present some interesting observations. For example, 
it was fascinating to note that while the mutant p53 containing cells had a 
proliferation advantage in vitro over the wt p53 containing cells, this was not 
reproduced in the in vivo setting, indicating the importance of the cellular 
environment, a topic that we will return to shortly. The lack of a proliferation 
advantage in vivo could be attributed to a number of factors, but we suspect 
that this may be at least partly explained by the propensity of these cells to 
invade locally. In fact, the potential relationship between p53 and invasion is an 
exciting area of research at the moment (Dong, Tada et al. 2007; Gadea, de 
Toledo et al. 2007; Dong, Xu et al. 2009; Muller, Caswell et al. 2009; Wang, 
Wang et al. 2009; Morton, Timpson et al. 2010).  
One particular topic of interest that may be relevant to our findings is the work 
by Gadea et al. which links p53 to proteins involved in actin cytoskeleton 
dynamics (Gadea, de Toledo et al. 2007). They showed that p53 deficiency in 
MEFs cultured in 3D matrices induced a switch from elongated spindle 
morphology to a markedly spherical and flexible one. This morphological 
transition required the RhoA-ROCK pathway and these rounded, motile cells 
exhibited amoeboid–like movement and had considerably increased invasive 
properties. These observations were also extended to cancer cells. The addition 
of a dominant negative p53 mutation (R273H) to wt p53 A375P melanoma cells 
induced similar morphological changes and invasive characteristics which were 
associated with upregulated levels of activated RhoA.  
Hence, the presence of the L254R mutation may dictate the more refractile 
morphology of the mutant p53 cells compared with the fibroblastoid appearance 
of the wt p53 cells in the SCC 7.1 population. It may also explain the apparent 
propensity for these mutant cells to invade in vivo. However, it is important to 
point out that it is very likely these cells possess other mutations and / or 
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molecular aberrations and it cannot be assumed that any of the disparities we 
see are due to p53 alone, especially as the L254R mutation has yet to be studied 
in much detail. For this reason, it would be prudent to clarify the effects of the 
L254R p53 mutant protein on cell morphology and invasion in this cell system by 
siRNA studies, or alternatively by inserting the mutation into wt p53 and / or p53 
-/- cells. 
While the role of p53 in cancer cell invasion constitutes a relatively recent field 
of investigation, the role of p53 in radiosensitivity has been explored for many 
years. Much of the work in this field is difficult to interpret as often only a small 
number of cell lines were analysed in each individual study, usually across 
different histological subtypes. While it is often assumed that the presence of wt 
p53 denotes a radiosensitive phenotype in vitro, the situation is not clear cut 
and wt p53 has been associated with equivalence or even increased resistance to 
radiation (Bristow, Benchimol et al. 1996; Servomaa, Kiuru et al. 1996; Chiarugi, 
Cinelli et al. 1998; Dahm-Daphi 2000; Matsui, Tsuchida et al. 2001; Weber and 
Wenz 2002; Williams, Zhang et al. 2008; Williams, Zhang et al. 2008). Indeed, 
some of the most radioresistant cell lines recorded, for example melanoma and 
glioblastoma, typically possess wt p53, although it is important to point out that 
p53 may not be functional in some of these cell lines due to defects elsewhere in 
the p53 pathway. A more rational and scientifically accurate overview of this 
topic is that wt p53 can increase radiosensitivity and mutant p53 can reduce 
radiosensitivity when inserted into certain p53 -/- cells (Bristow, Peacock et al. 
2003), although this does seem to depend on the specific mutation (Okaichi, Ide-
Kanematsu et al. 2008).  However, this statement is in itself not without 
criticism as the addition of wt p53 to p53 -/- cells can result in massive 
apoptosis (Diller, Kassel et al. 1990; Michalovitz, Halevy et al. 1990; Martinez, 
Georgoff et al. 1991; Kaeser, Pebernard et al. 2004; Mazzatti, Lee et al. 2005) 
and attempts to circumvent this using reversible short term systems such as 
temperature sensitive constructs may be skewed as the conformation of p53 can 
be altered at low temperature (Cuddihy, Jalali et al. 2008). Similarly, clinical 
data supporting a role for p53 genotype as in independent predictive factor for 
radiotherapy outcome in the treatment of various solid tumours continues to be 
controversial due to variable methodology in detecting p53 function and variable 
endpoints in clinical trial design. 
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Thus, it was not surprising that p53 status alone did not determine 
radiosensitivity here. What was more intriguing was the variation between the 
two wt p53 clones and the two mutant p53 clones. A small difference in clonal 
populations (clonal variation) is to be expected and can be explained by 
discrepancies in gene expression.  However, the contrast between the D1 and H9 
wt p53 clones was quite marked, not only in terms of radiation survival 
response, but also in terms of proliferative capacity and gross tumour 
morphology when cells were injected into nude mice. One of the most 
significant observations we made while studying these clones was the disparity 
in their FACS profiles, for two main reasons.  
Firstly, the apparent genomic instability which was inherent in the H9 clone 
probably explained the radioresistant phenotype and may also have explained 
the slower proliferation rate in vivo, as the degree of chromosomal abnormality 
could prevent effective chromosome segregation and mitosis. If so, why 
proliferation in vitro was not impaired is open to question. Secondly, we 
suspected that the differences in cellular characteristics between the isolated 
clones were not simply due to clonal variation alone. The striking difference in 
the level of aneuploidy between the D1 and H9 clones was a strong indicator of 
the presence of additional mutations in the H9 cell line. We did confirm that all 
of the isolated clones possessed the codon 61 mutation in H-Ras (data not 
shown), but we have not yet screened for the presence or absence of other 
significant mutations. At this point, it was clear that the SCC 7.1 FAK -/- cell line 
could not be reliably compared with either the D1 or H9 wt p53 single cell 
clones, or an early passage SCC 7.1 FAK +/+ population with predominantly wt 
p53 containing cells, due to significant concerns over the genetic background of 
these cells.  
We then endeavoured to develop FAK -/- cell lines from the isolated clones. This 
strategy would have the obvious advantage of a paired parental FAK +/+ cell line 
for comparison.  In addition, it would be possible to compare and contrast FAK 
knockdown as opposed to fak deletion. Furthermore, it would provide an 
opportunity to study fak deletion on both a wt p53 and a mutant p53 
background. This work is ongoing but has not been straightforward. A potential 
problem that we have considered is expression of the Cre recombinase,    
especially in view of the single cell lineage. Hence, it may be necessary to 
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generate new clones from an early passage SCC 7.1 FAK +/+ population and 
repeat the process. 
FAK has been shown to influence proliferation in several cell lines through an 
effect on cell cycle proteins, but this is not a universal finding, so it is 
unremarkable that FAK is dispensable for growth in culture in this cell system. 
FAK is, however, not dispensable for colony formation in an anchorage-
independent environment in these cells and we have definitive evidence that 
this property is mediated through the kinase function of FAK. In fact, we have 
demonstrated constitutive activation of FAK in this cancer cell line. This data 
provides an intriguing insight into the complex biological functions of FAK in 
different environments. The uncoupling of FAK activity from adhesion signalling 
appears to be critical for anchorage-independent growth, although the exact 
mechanism is unclear. We initially thought that FAK kinase activity was 
protecting cells from death signals induced by loss of adhesion.  This was not 
unreasonable, particularly as these cells contain wt p53 and the current 
literature depicts an important functional interaction between FAK and wt p53 
in cell survival as already discussed (although the evidence to date linking the 
two proteins is based on the scaffolding function of FAK rather than its kinase 
function). However, we did not find that either loss or inhibition of FAK activity 
had any significant effect on anoikis (data not shown).  In addition, although the 
FAK -/- cells and FAK kinase defective cells did not form large colonies in soft 
agar, they did form clusters consisting of several cells and would proliferate if 
they were removed from the agar and replated on tissue culture plastic. This 
would imply that loss of FAK kinase activity induces growth or proliferation 
arrest, but not necessarily cell death, in an anchorage-independent 
environment, which can be overcome by integrin adhesion.  
The results discussed above may explain why FAK -/- xenografts can establish, 
albeit with a delayed onset. Preliminary data suggests that the delayed onset of 
FAK -/- xenografts is also due to loss of kinase activity (personal communication 
– Alan Serrels). Similarly, there was no evidence of increased apoptosis in vivo, 
as measured by activated Caspase-3 staining, in the FAK -/- xenografts (data not 
shown) or FAK kinase defective xenografts (personal communication – Alan  
Serrels). It may actually be easier for cells deficient in FAK kinase activity to   
overcome growth / proliferation arrest in the in vivo setting compared with soft 
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agar/methylcellulose due to the infrastructure and integrin signalling provided 
by the host animal. 
A number of important questions stem from this section of work, such as; how 
exactly does FAK signalling differ in 2D versus 3D environments and what precise 
biological functions are mediated by FAK when it is uncoupled from adhesion 
signalling, are the anchorage–independent findings here dependent on 
expression or activity of p53 (and if so how does FAK kinase activity influence 
p53 function), and does the phenotype that we see in FAK kinase deficient cells 
grown in soft agar reflect tumour cell dormancy? The subject of tumour cell 
dormancy, a stage in cancer progression in which residual disease is present but 
undetectable, is poorly understood. There are several mechanisms that can 
explain tumour cell dormancy, including immunosurveillance and the inability of 
a tumour cell population to recruit blood vessels (Aguirre-Ghiso 2007). However, 
more directly relevant to our work, is that the disruption of crosstalk between 
growth factor and adhesion signalling can also lead to dormancy. Notably, it has 
previously been shown that interruption of FAK mitogenic signalling by 
expression of FRNK induced dormancy in human carcinoma cells in vivo (Aguirre 
Ghiso 2002). It could be argued that the FAK kinase deficient cells undergo 
senescence in an anchorage-independent environment, but as this is typically a 
response to replicative or oncogenic stress, and often permanent, we thought 
that a temporary cellular quiescence was a better mechanistic fit for our data. 
As quiescent cells are characterised by G0-G1 arrest, we are currently trying to 
establish the cell cycle status of the small clusters of FAK kinase deficient cells 
that we see in the soft agar growth medium.  
It is already clear from the earlier work in this laboratory that FAK is important 
in skin carcinogenesis (McLean, Komiyama et al. 2004). However, it was unclear 
whether the effects of FAK in this context were mediated through its scaffolding 
function or kinase function. The work presented here suggests that FAK kinase 
activity is important in contributing to tumour initiation and development.  
These findings are significant, and alongside the orthotopic data provided by 
Mitra et al., who showed that expression of FRNK inhibited breast cancer  
progression and lung metastases in a mammary fat pad tumour model (Mitra, Lim 
et al. 2006), would support the further investigation of FAK kinase inhibitors. But     
does this mean that FAK kinase inhibitors will necessarily have a profound effect 
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on established tumours? We have yet to examine the effect of a FAK kinase 
inhibitor on established SCC 7.1 FAK wt xenografts, but significantly there was 
no marked difference in proliferation rate between SCC 7.1 FAK -/- and SCC 7.1 
FAK wt xenografts. Other groups have shown some effects on proliferation using 
FAK kinase inhibitors in human xenograft models (Halder, Lin et al. 2007; 
Roberts, Ung et al. 2008; Watanabe, Takaoka et al. 2008; Hochwald, Nyberg et 
al. 2009), although it is important to note that these effects may be mediated by 
inhibition of kinases other than FAK.  
Interestingly, some of these studies have also illustrated an effect on tumour 
vascularity (Halder, Lin et al. 2007; Roberts, Ung et al. 2008). This is of 
particular significance as FAK is known to influence VEGF expression via 
signalling through its 925 phosphorylation site (Mitra, Mikolon et al. 2006). We 
did find that the FAK -/- xenografts displayed a more tortuous vascular pattern 
and the vasculature tended to be prone to haemorrhage. While conditional loss 
of FAK in endothelial cells is known to induce leaky vessels (Ilic, Kovacic et al. 
2003; Shen, Park et al. 2005), the vascular endothelial cells supporting a 
xenograft will be provided by the host animal which is not deficient in FAK, but 
we do wonder whether the absence of FAK in the surrounding tumour cells 
affects the signalling and architecture of the developing vasculature. It may well 
be the case that FAK kinase inhibitors have important anti-angiogenic effects in 
addition to or instead of anti-proliferative effects.  
If so, this may have important implications in terms of radiation. Although work 
in xenograft models has demonstrated that VEGF-R inhibition in combination 
with radiation is both beneficial and not usually dependent on scheduling, it may 
be the case that modulating the tumour vasculature in the more complex setting 
of human malignancy may either increase or decrease radiosensitivity depending 
on the timing and sequencing of each modality (Duda, Batchelor et al. 2007). 
Should FAK kinase inhibitors prove to be useful in combination with radiation, it 
would be important to assess whether the effects on radiosensitivity are 
mediated by modulation of the vasculature and, if so, to determine whether 
scheduling of both agents is critical. One final point on the use of FAK kinase 
inhibitors, which does not specifically apply to radiation, is a note of caution  
based on the apparent quiescent state of FAK kinase deficient cells in an   
anchorage–independent environment. The potential for FAK inhibitors to induce 
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dormancy in cancer cells has significant implications on the future of these 
agents as a viable means of anti-cancer therapy and requires further 
investigation. 
5.4 Summary 
The original SCC 7.1 cell line we derived was composed of a variety of cells with 
different clonal origins. Hence, these cells illustrated differential morphological 
and growth characteristics and radiosensitivity patterns. Some of the properties 
of each constituent cell were likely to have been influenced by the presence of 
either wt or mutant p53. However, we strongly suspected the presence of 
additional mutations within these cells. This mixed cell population precluded a 
direct comparison with the SCC 7.1 FAK -/- cell line which originated from a 
single wt p53 cell. Reconstituting wt FAK into the FAK -/- cell line, however, was 
an acceptable and better controlled means of comparison. We have established 
that it will be possible to evaluate the radiosensitivity of these FAK -/- and FAK 
wt cell lines in vitro and in vivo,  and in doing so have learned more about the 
role of FAK, particularly its kinase function, in various cellular environments. 
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6 FAK deletion is associated with increased 
radioresistance in vitro and in vivo. 
6.1 Aim 
In the previous chapters, we described the development of novel SCC 7.1 FAK 
+/+ and SCC 7.1 FAK -/- squamous cell carcinoma cell lines. However, 
characterisation of these cell lines revealed that the original SCC 7.1 FAK +/+ 
parental cell line was composed of a mixture of different cell types, which 
precluded direct comparison between FAK +/+ and FAK -/- cells. This obstacle 
was overcome by reconstituting wt FAK into the SCC 7.1 FAK -/- cell line, 
thereby allowing a more accurate assessment of the functions of FAK in this cell 
line. Hereafter, these cell lines will be referred to as simply FAK -/- and FAK wt 
cells. In this chapter, we set out to establish whether the presence or absence of 
FAK influenced radiosensitivity in these cell lines in both the in vitro and in vivo 
settings and, if so, to elicit the underlying mechanism(s).  
6.2 Results 
6.2.1 FAK deletion is associated with increased radioresistance in 
vitro and in vivo. 
In order to assess radiosensitivity, a limiting dilution clonogenic assay was 
performed comparing FAK -/- with FAK wt cells at increasing doses of radiation 
up to 10Gy. This assay revealed that the complete absence of FAK in these cells 
was associated with increased radioresistance in vitro (Figure 49). A statistically 
significant difference in surviving fraction was seen at doses of 4Gy, 6Gy, 8Gy 
and 10Gy (p values of 0.0136, 0.0097, 0.0045, and 0.0036 respectively, analysed 
by student’s unpaired t-test, n=9).  
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Figure 49 - FAK deletion is associated with increased radioresistance in vitro 
Subconfluent populations of FAK -/- and FAK wt cells were trypsinised and diluted in growth 
medium to a final concentration that would permit single colony growth. 100µl of this suspension 
was added to each well of a 96 well plate. Following incubation for 6 hours to allow cell attachment 
the plates were irradiated with 0, 2, 4, 6, 8 or 10Gy. The plates were set up in triplicate for each 
radiation dose. After 7 days the number of colonies per plate was counted and the surviving 
fraction calculated. The graphical representation shown represents the mean ± SEM from three 
separate experiments. Surviving fractions at each dose of radiation were compared with 
unirradiated cells by student’s unpaired t-test, n=9. 
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As one of our initial aims was also to evaluate whether FAK was an important 
mediator of radiosensitivity in vivo, we proceeded to investigate the effect of 
radiation on FAK -/- versus FAK wt xenografts. 2x105 cells were injected 
subcutaneously into the right flank of female nude mice and the animals were 
either irradiated with 5Gy whole body irradiation or mock irradiated when the 
xenografts reached approximately 150mm3. This size was selected as the FAK -/- 
tumours have become well established by this point and their growth rate does 
not significantly differ from their FAK wt counterparts. Previous studies 
demonstrated that this strain of mice could tolerate 5Gy total body dose for 10-
14 days. Nonetheless, the mice were carefully observed for haematological and 
gastrointestinal toxicity afterwards. After 7 days the xenografts were measured 
and the animals were sacrificed. The tumour volume was calculated before 
(Figure 50A) and after (Figure 50B) 5Gy irradiation or mock irradiation and 
analysed by student’s unpaired t-test. A statistically significant reduction in 
tumour volume was observed in the irradiated FAK wt xenografts compared with 
the mock irradiated controls (p=0.0030, n=10), but this was not replicated in the 
FAK -/- xenografts (p=0.3300, n=10). Protein extracts were prepared from five 
mice in each group and subjected to western blotting analysis to confirm 
appropriate FAK status (Figure 50C). 
We have shown that FAK is important in mediating radiosensitivity in vitro and, 
for the first time, we have shown that FAK also influences the response to 
radiation in vivo. However, our in vitro findings are in contrast to the published 
work to date (Cordes, Frick et al. 2007), suggesting that FAK may mediate 
different pro-survival or pro-death mechanisms in response to ionising radiation 
in different cell lines. 
 
 
 
 
 
Chapter 6  171 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50 - FAK -/- xenografts are more resistant to radiation 
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Figure 50 - FAK -/- xenografts are more resistant to radiation (cont) 
(A) 2x105 FAK -/- and FAK wt cells were injected subcutaneously into the right flank of female nude 
mice. Xenografts were allowed to reach approximately 150 mm3. The animals were then irradiated 
with 5Gy whole body irradiation or mock irradiated. After 7 days the xenografts were measured and 
the mice were sacrificed. The mean xenograft volumes ± SEM before radiation (upper panels) and 
after radiation (lower panels) are shown. Statistical analysis of mock irradiated versus irradiated 
volumes at 7 days was assessed by student’s unpaired t-test, * denotes p<0.05, n=10. (B) Protein 
extracts were prepared from the xenografts, separated by SDS-PAGE, transferred to nitrocellulose, 
and blotted with anti-FAK (upper) and anti-β-actin (lower) antibodies. A sample of five extracts from 
each group is shown. A positive control (FAK wt cell extract) was added to the final lane of the FAK 
-/- xenograft samples. 
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6.2.2 Ionising radiation results in p21 induction in vitro and in 
vivo in FAK -/- cells and xenografts respectively, but not FAK 
wt cells or xenografts. 
It has already been shown by sequencing analysis that the cells used here 
possessed wt p53 but when we attempted experiments to assess p53 
functionality, it became clear that there was a difference. Remarkably, exposing 
both cell lines to 5Gy irradiation and assessing p21 levels, as outlined earlier in 
Chapter  4, demonstrated p21 induction only in the FAK -/- cells, not FAK wt 
cells (Figure 51A). Interestingly, basal levels of p21 mRNA and protein in 
subconfluent populations of both cell lines were similar (Figures 51B and 51C 
respectively). p21 levels were upregulated in both cell lines with increased 
confluency as expected in view of the widely accepted  role of p21 in cell cycle 
arrest (Figure 51D), and this was the same in both cell lines, indicating some 
similarities in the control of p21 and its function between FAK -/- and FAK wt 
cells. To ensure that the discrepancy in p21 induction following exposure to 
ionising radiation was not related to differences in cell density, care was taken 
to ensure that cells were irradiated at comparable confluency, typically 70%.  
This pattern of p21 induction was reproduced in vivo. Briefly, nude mice were 
injected subcutaneously with 2.5x105 FAK -/- or FAK wt cells, xenografts were 
allowed to establish, and the animals were then irradiated with 5Gy whole body 
irradiation when tumours reached approximately 500mm3 by volume.  Mice were 
sacrificed at 0, 2hrs, 6hrs, and 24hrs post treatment (n=3 per group) and p21 
levels assessed by both western blotting of tumour lysates and 
immunohistochemistry staining of paraffin embedded tissue. The FAK -/- 
xenografts exhibited a clear increase in p21 protein levels as early as 2 hours 
post irradiation as shown by western blotting analysis (Figure 52A). In fact, the 
p21 levels were maximal at this point. Admittedly, one of the control samples 
appeared to be degraded (lane 3) which may have biased the experiment. 
However, p21 was also visibly increased by immunohistochemistry analysis, again 
most notably at 2 hours post irradiation (Figure 52B). Mean p21 positivity (based 
on scoring of 20 fields) was then analysed across all time points and this 
demonstrated a significant difference in the p21 levels in irradiated versus 
unirradiated animals (Kruskal-Wallis, p=0.038, n=3). Further, individual 
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comparison of the separate time points illustrated a statistically significant 
increase in p21 scoring compared with baseline levels (Mann Whitney, p=0.0404, 
n=3). The FAK wt xenografts, on the other hand, did not demonstrate any 
consistent increase in p21 levels at any of the time points examined by either 
means of analysis. Western blotting of FAK wt tumour lysates confirmed the 
presence of FAK, but there was no appreciable increase in p21 protein levels 
noted (Figure 53A). Representative p21 staining of paraffin embedded tissue at 
each time point is depicted in Figure 53B, again with no appreciable increase in 
p21 noted. A corresponding boxplot of the proportion of p21 positive cells per 
group is illustrated in Figure 53C. There was no significant increase in p21 
expression at 2hrs (p=0.6625), 6hrs (p=0.6625), or 24hrs (p=0.3827) (Mann 
Whitney, n=3). 
This data indicated that the regulation of p21 in response to ionising radiation 
was different between these cell lines and appeared to be critically dependent 
on the presence or absence or FAK. It also hinted at a possible mechanism for 
the difference in radiosensitivity between the FAK -/- and FAK wt cells, as p21 
has previously been linked with radioresistance. Most of the evidence in support 
of p21 as a mediator of radioresistance stems from work in human brain tumour 
cell lines. Overexpression of p21 was found to increase clonogenic survival in 
glioma cells (Kokunai and Tamaki 1999) while p21 knockdown using antisense 
oligonucleotides decreased clonogenic survival in a similar panel of cell lines 
(Kokunai, Urui et al. 2001). Interestingly, earlier research using the HCT-116 p21 
-/- colorectal cancer cell line had suggested that p21 deficient cells were more 
likely to be killed by apoptosis following ionising radiation than their p21 +/+ 
counterparts (Waldman, Lengauer et al. 1996; Waldman, Zhang et al. 1997). In 
fact, this ability of p21 to inhibit apoptosis has been cited as one of the main 
mechanisms by which p21 can induce radioresistance. However, p21 can also 
influence DNA repair and cell cycle kinetics, which adds to the complexity of this 
protein in the DNA damage response. This complexity may explain why p21 has 
conversely been associated with promoting sensitivity to chemotherapy and 
radiotherapy in certain situations. Our main priority, therefore, at this point was 
to determine if the increase in p21 levels in the FAK -/- cell line was indeed 
responsible for its more radioresistant phenotype.  
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Figure 51 - Ionising radiation results in p21 induction in FAK -/- cells but not FAK wt cells 
(A) FAK -/- and FAK wt cells were irradiated with 5Gy at 70% confluence and lysates prepared at 
the indicated time points. Immunoblotting was then performed with anti-p21 (upper), and anti-β-
actin (lower) antibodies. (B) RNA was extracted from subconfluent FAK -/- and FAK wt cell 
populations and converted to cDNA as previously described. A PCR reaction was then performed 
and 5µl of PCR product analysed on a 1.5% agarose gel (upper panel). β-actin loading is also 
shown (lower panel). (C) Protein extracts were prepared from subconfluent FAK -/- and FAK wt cell 
populations, separated by SDS-PAGE, transferred to nitrocellulose, and blotted with anti-p21 
(upper panel) and anti-β-actin (lower panel) antibodies. (D) Protein extracts were prepared from 
FAK -/- and FAK wt cell populations at the level of confluency indicated. Immunoblotting was then 
performed with anti-p21 (upper panel) and anti-β-actin (lower panel) antibodies. 
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Figure 52 - Ionising radiation results in p21 induction in FAK -/- xenografts 
(A) 2.5x105 FAK -/- cells were injected subcutaneously into the right flank of female nude mice. 
When xenografts reached approximately 500mm3, mice were irradiated with 5Gy and sacrificed at 
0, 2hrs, 6hrs, and 24hrs (n=3 per group). Half of the xenograft was fixed in formalin then embedded 
in paraffin and the other half was snap frozen in liquid nitrogen. Protein extracts were prepared 
from the frozen sections, separated by SDS-PAGE, transferred to nitrocellulose, and blotted with 
anti-FAK (upper), anti-p21 (middle), and anti-β-actin (lower) antibodies. (B) The paraffin embedded 
sections were stained with p21 and the proportion of p21 positive cells calculated per high powered 
field (20 fields per animal). Representative bright field images of p21 stained tissue at 0, 2hrs, 6hrs, 
and 24hrs post radiation are shown (scale bar, 0.1mm).  
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Figure 53 - Ionising radiation does not result in p21 induction in FAK wt xenografts 
(A) 2.5x105 FAK wt cells were injected subcutaneously into the right flank of female nude mice. 
When xenografts reached approximately 500mm3, mice were irradiated with 5Gy and sacrificed at 
0, 2hrs, 6hrs, and 24hrs (n=3 per group). Half of the xenograft was fixed in formalin then embedded 
in paraffin and the other half was snap frozen in liquid nitrogen. Protein extracts were prepared 
from the frozen sections, separated by SDS-PAGE, transferred to nitrocellulose, and blotted with 
anti-FAK (upper), anti-p21 (middle), and anti-β-actin (lower) antibodies. (B) The paraffin embedded 
sections were stained with p21 and the proportion of p21 positive cells calculated per high powered 
field (20 fields per animal). Representative bright field images of p21 stained tissue at 0, 2hrs, 6hrs, 
and 24hrs post radiation are shown (scale bar, 0.1mm).   
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6.2.3 p21 mediates radioresistance in FAK -/- cells. 
Since p21 has been associated with both resistance and sensitivity to DNA 
damaging agents, including ionising radiation, it was crucially important to 
ascertain whether the increase in p21 levels in the FAK -/- cell line was an 
incidental finding or a key mediator of radiation survival. Consequently, siRNA 
technology was utilised to achieve transient knockdown of p21 in a pooled 
population. Figure 54A and Figure 54B demonstrate western blotting for p21 in 
scrambled siRNA and p21 siRNA transfected pools and corresponding 
densitometry analysis indicating 90% p21 knockdown. Clonogenicity was then 
assessed at 0, 4, and 8Gy and comparison made between cell populations 
transfected with scrambled siRNA and p21 siRNA. Control cell populations which 
had been mock transfected were also assessed. As shown in Figure 54C, there 
was a significant difference in surviving fraction at 8Gy (p=0.0129) between the 
scrambled siRNA treated pools and the p21 siRNA treated pools, indicating that 
p21 did play a role in radioresistance in this cell line.  
p21 is known to initiate G1 arrest in response to ionising radiation in a variety of 
cell lines with wt p53. It is thought that in certain cell lines this ability of p21 
may promote radioresistance by allowing ample time for effective DNA repair. 
Hence, it was important to establish whether the difference in radiosensitivity 
was explained by altered cell cycle kinetics. FAK -/- and FAK wt cells were 
irradiated and samples collected for FACS analysis at the time points indicated 
in Figure 55. Radiation induced a temporary G2/M arrest at 8 – 12 hours 
followed by an accumulation of cells in G1 phase at 24 – 48 hours in both cell 
lines, as illustrated in Figure 55A, which displays the proportion of gated cells in 
each phase of the cell cycle (G1, S, and G2/M). The actual FACS plots from each 
time point are shown in Figure 55B. There was no obvious difference in cell 
cycle kinetics which would support the more radioresistant phenotype of the FAK 
-/- cell line. Although we demonstrated earlier that p21 levels increased with 
confluency (Figure 51D, page 173), indicating a role for this protein in density 
related cell cycle arrest, it appeared that p21 was not a major driver of cell 
cycle dynamics in response to radiation in these cells.  
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Figure 54 - p21 knockdown reduces radioresistance in FAK -/- cells 
(A) FAK -/- cells were transfected with 100nM siRNA (either a scrambled pool or p21 siRNA) at 
50% confluency as described in Methods section. Following incubation for 24 hours, protein 
extracts were prepared and immunoblotted with anti-p21 (upper) and anti-β-actin (lower) 
antibodies. (B) Densitometry comparing p21 levels in FAK -/- protein extracts treated with either a 
scrambled pool of siRNA or p21 siRNA was performed. The p21 protein levels were normalised to 
β-actin level and results shown are representative of one of three separate experiments. (C) FAK -
/- cells were mock transfected or transfected with 100nM of either a scrambled siRNA pool or p21 
siRNA at 50% confluency. After 24 hours the cell populations were trypsinised and diluted in 
growth medium to a final concentration that would permit single colony growth. 100 µl of this 
suspension was then added to each well of a 96 well plate. Following incubation for 6 hours to 
allow cell attachment the plates were irradiated with 0, 4, or 8Gy. The plates were set up in 
triplicate for each radiation dose. After 7 days the number of colonies per plate was counted and 
the surviving fraction calculated. The graphical representation shown represents the mean ± SEM 
from three separate experiments. Surviving fractions of p21 siRNA treated cells were compared 
with scrambled siRNA treated cells at each dose of radiation and statistical significance assessed 
by student’s unpaired t-test, * denotes p<0.05, n=9. 
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Figure 55 - p21 induction does not promote radioresistance in FAK -/- cells by increasing 
the length of cell cycle arrest in response to ionising radiation 
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Figure 55 - p21 induction does not promote radioresistance in FAK -/- cells by increasing 
the length of cell cycle arrest in response to ionising radiation (cont) 
(A) FAK -/- and FAK wt cells were irradiated with 5Gy at 70% confluence; at various time points 
samples were fixed in 70% ethanol, stained with propidium iodide and subjected to cell cycle 
analysis. The percentage of gated cells in each of the component phases (G1, S, and G2/M) of the 
cell cycle was evaluated at each time point. The graphs shown represent the mean ± SEM from 
three experiments. (B) Representative FACS plots from one of the experiments outlined above.  
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6.2.4 p21 induction following ionising radiation is regulated at 
transcriptional level in FAK -/- cells. 
Ionising radiation can alter the level of various cellular proteins by 
transcriptional and/or translational mechanisms. Following the observation that 
p21 levels increased in FAK -/- cells in response to ionising radiation, further 
studies were undertaken to determine whether this phenomenon was 
transcription-dependent or independent. RNA was therefore extracted from 
subconfluent populations of FAK -/- and FAK wt cells at various time points 
following 5Gy irradiation and qRT-PCR performed using endogenous p21 primers. 
A biphasic increase in p21 mRNA levels at 2 hours and 6 hours post radiation was 
seen in the FAK -/- cells whereas p21 mRNA levels remained stable in the FAK wt 
cell line over the full 24 hour period of investigation (Figure 56A).  
To determine whether radiation dose was significant, RNA was extracted from 
both cell lines 2 hours after a range of radiation doses (0, 2, 5, 10, 20, and 30Gy) 
and again analysed by qRT-PCR. This time point was selected as the maximum 
increase in p21 mRNA levels in FAK -/- cells in the experiment outlined above 
occurred  at  2hrs. Figure 56B  shows  that  p21 mRNA  levels increased  in  the   
FAK -/- cell line in a dose-dependent fashion from 2Gy to 10Gy with some fall-
off at doses in excess of 10Gy. Corresponding p21 protein levels were assessed 
by western blotting 2½ hours post irradiation (Figure 56C). The lowest dose of 
2Gy was sufficient to induce a detectable rise in p21 protein levels in FAK -/- 
cells and even higher levels were achieved with 10Gy. However, there was little 
difference in protein levels in cells stimulated by either 10Gy or 20Gy irradiation 
suggesting that p21 induction was dose dependent in FAK -/- cells in the range 
from 2Gy to 10Gy. Minimal protein response was detected following 30Gy, 
suggesting that either effective translation was not taking place or p21 was 
being rapidly degraded.  
Small increases in p21 mRNA levels were detected in the FAK wt cell line in 
response to the highest radiation doses of 20Gy and 30Gy (Figure 56B – right 
panels) but no p21 protein response was elicited in FAK wt cells at any of the 
examined radiation doses, including 20Gy and 30Gy (Figure 56C – right panels). 
Again, it was unclear on the basis of these results alone to differentiate between 
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ineffective translation and enhanced protein degradation at doses of or in excess 
of 20Gy. As it proved difficult to interpret the findings at these higher doses of 
radiation we opted to focus our studies mainly on doses of 10Gy or less.  Taken 
together, the findings here indicate that increased transcription was responsible, 
or at least partly responsible, for the increase in p21 protein levels in FAK -/- 
cells in response to clinically relevant doses of ionising radiation.     
6.2.5 p21 is regulated by p53 in FAK -/- cells. 
It has already been alluded to that p21 is a transcriptional target of p53. 
Although p21 is not exclusively regulated by p53, we suspected that p53 was 
driving p21 in FAK -/- cells as the surges in p21mRNA levels (Figure 56A) seemed 
to correlate with p53 stabilisation (Figure 35, page 131). As there is growing 
evidence linking FAK to p53, we wanted to determine whether p53 was a major 
regulator of p21 protein levels in these cells, as a FAK mediated effect on p53 
functionality or transcriptional activity could potentially explain the discrepancy 
in p21 induction. To this end, a pooled population of FAK -/- cells were 
transiently transfected with either scrambled siRNA or p53 siRNA and protein 
levels of both p53 and p21 measured after 24 hours. It proved difficult to 
quantify the reduction in p53 levels as the basal levels of this protein were very 
low, but a reduction in p21 levels of approximately 50% was recorded at 24 hours 
post transfection suggesting that p53 (at least partially) regulated the basal 
expression of p21 in these cells (Figures 57A and 57B). More importantly, when 
FAK -/- cells that had been transfected with p53 siRNA were irradiated with 5Gy, 
there was no significant increase in p21 levels up to 6 hours post treatment, in 
contrast with cells that had been transfected with scrambled siRNA which did 
show an elevation in p21 protein levels within 2 hours (Figure 57C).   
Here we have shown that p53 exerted a regulatory influence over both basal 
levels of p21 and the induction of p21 in response to ionising radiation in the FAK 
-/- cell line. These findings indicated that the role of p53 in these cells 
warranted further investigation. 
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Figure 56 - p21 induction following radiation is regulated at transcriptional level 
(A) RNA was extracted from subconfluent FAK -/- and FAK wt cell populations at various time 
points after 5Gy irradiation and converted to cDNA using Superscript II. The cDNA was diluted 1/5 
and 5µl added to 50µl SybrGreen master mix containing 1µM concentration of primer pair. qRT-
PCR analysis was then performed in triplicate based on a 96 well plate format. Fold increase in p21 
mRNA levels was calculated using the ddC(t) method with β-actin as a loading control. Graphical 
representation of combined mean ± SEM from three experiments is demonstrated. (B) RNA was 
extracted from subconfluent FAK -/- and FAK wt cell populations 2 hours after 0, 2, 5, 10, 20, and 
30Gy irradiation. cDNA was then generated and qRT-PCR for p21 performed as outlined above. 
(C) Protein extracts were prepared from FAK -/- and FAK wt cell populations 2½ hours after 
exposure to various doses of radiation as outlined. The extracts were separated by SDS-PAGE, 
transferred to nitrocellulose, and blotted with anti-p21 (upper) and anti-β-actin (lower) antibodies. 
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Figure 57 - p53 knockdown reduces basal p21 levels and prevents p21 induction following 
exposure to ionising radiation in FAK -/- cells 
(A) FAK -/- cells were transfected with 100nM siRNA (either scrambled pool or p53 siRNA) at 50% 
confluency. Following incubation for 24 hours, protein extracts were prepared and immunoblotted 
with anti-p53 (upper), anti-p21 (middle) and anti-β-actin (lower) antibodies. (B) Densitometry 
comparing p21 levels in FAK -/- protein extracts treated with either a scrambled pool of siRNA or 
p53 siRNA was performed. The p21 protein levels were normalised to β-actin and results shown 
are representative of one of three separate experiments. (C) FAK -/- cells at 50% confluence were 
transfected with either 100nM scrambled siRNA or 100nM p53 siRNA, incubated for 24 hours, then 
irradiated with 5Gy. Lysates were collected at the time points indicated and immunoblotted with 
anti-p53 (upper), anti-p21 (middle) and anti-β-actin (lower) antibodies. 
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6.2.6 p53 stabilisation in response to ionising radiation is 
regulated largely at post transcriptional level. 
Having established that p21 was regulated by p53 in FAK -/- cells, it was 
essential to pinpoint why p21 induction in response to radiation was a feature of 
FAK -/- cells and not FAK wt cells. As the presence or absence of FAK has been 
shown to influence total protein levels of p53 (Lim, Chen et al. 2008), it seemed 
pertinent to compare and contrast the ability of both cell lines to stabilise p53 in 
response to radiation. By measuring p53 protein levels on western blotting at 
various time points after 5Gy irradiation, it was clear that basal levels of p53 
were comparable (Figure 58A) and p53 was stabilised in both FAK -/- and FAK 
wt cell lines (Figure 58B). Although a similar pattern was seen in both cell lines 
initially, i.e. maximal levels of p53 at 2 hours post irradiation followed by a 
smaller increase at 6 hours, FAK -/- cells exhibited a further increase in p53 
protein levels at 24 hours.  
While the stabilisation of p53 in response to ionising radiation is principally at 
the post-translational level, radiation can induce transcription of p53 (Fu and 
Benchimol 1997; Takagi, Absalon et al. 2005). Interestingly, analysis of p53 
mRNA levels by qRT-PCR highlighted an increase in transcription of p53 only at 
the 24 hour time point in FAK -/- cells (Figure 58C). It appeared that the 
increases in p53 protein levels in response to ionising radiation were largely due 
to post-translational mechanisms in these cells, which is a typical finding, with 
the exception of the 24 hour time point in FAK -/- cells, the significance of 
which was unclear. 
6.2.7 p53 stabilisation is stress dependent not FAK dependent. 
We noted that p53 levels, although elevated in response to 5Gy irradiation, did 
not increase as significantly as other cell lines containing wt p53, for example 
the SCC 1.1 cell line. Exposing the FAK -/- and FAK wt cell lines to higher doses 
of radiation (up to 30Gy) led to further, albeit small, amplification at 2 hours 
post treatment (Figure 59). In contrast, the addition of cytotoxic agents, such 
as cisplatin or doxorubicin, effected massive accumulation of p53 levels, 
although this was dose and drug dependent (Figure 60). Topotecan, for 
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instance, did not induce p53 in either cell line. This was not particularly 
surprising as topoisomerase I inhibitors do not usually have this effect at the 
applied doses. The lack of response in either cell line following the addition of 
taxol was a little unexpected, however, as this drug is known to induce p53 in a 
range of cancer cell lines, albeit at high concentrations. It may be the case that 
concentrations in excess of 10µM would be required in order to produce any 
effect on p53 levels.  
With each of the stressors that did induce p53, namely ionising radiation, 
cisplatin, and doxorubicin, there was no visible difference in the levels of p53 
attained between the FAK -/- and FAK wt cells. This indicated that stabilisation 
of p53 was stress dependent rather than FAK dependent. Intriguingly, p21 
protein levels increased in both cell lines following exposure to both cisplatin 
and doxorubicin (Figure 60 – left panels). Admittedly, we have yet to investigate 
whether the drug induced elevation in p21 levels here were regulated at the 
transcriptional level by p53, but the disparity in p21 induction following 
radiation as opposed to chemotherapeutic agents led us to question whether this 
phenomenon was stress dependent as well as FAK dependent.   
It is noteworthy that cisplatin and doxorubicin operate via quite different 
mechanisms compared to ionising radiation. It would therefore be useful to 
repeat these studies with radiomimetic drugs such as etoposide or bleomycin 
which induce considerable levels of DSBs.  
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Figure 58 - p53 stabilisation in response to ionising radiation is predominantly regulated at 
post transcriptional level in both FAK -/- and FAK wt cells 
(A) Protein extracts were prepared from subconfluent FAK -/- and FAK wt cell populations, 
separated by SDS-PAGE, transferred to nitrocellulose, and blotted with anti-FAK, anti-p53 (upper 
panel) and anti-β-actin (lower panel) antibodies. (B) FAK -/- and FAK wt cells were irradiated with 
5Gy at 70% confluence and lysates prepared at the indicated time points. Immunoblotting was then 
performed with anti-p53 (upper), and anti-β-actin (lower) antibodies. (C) RNA was extracted from 
subconfluent FAK -/- and FAK wt cell populations at various time points after 5Gy irradiation, 
converted to cDNA, and qRT-PCR analysis was then performed using 1µM p53 primers as 
previously described. Fold increase in p53 mRNA levels was calculated using the ddC(t) method 
with β-actin as a loading control. The combined results from three separate experiments are 
shown. 
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Figure 59 - The level of p53 stabilisation in response to radiation is not FAK dependent 
Protein extracts were prepared from FAK -/- and FAK wt cell populations 2 hours after exposure to 
various doses of radiation (0 – 30Gy). The extracts were separated by SDS-PAGE, transferred to 
nitrocellulose, and blotted with anti-p53 (upper) and anti-β-actin (lower) antibodies. The last lane in 
each gel contains protein extracts from FAK -/- or FAK wt cells exposed to overnight treatment with 
0.1µM of actinomycin. 
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Figure 60 - The level of p53 stabilisation in response to cytotoxic agents is drug and dose 
dependent rather than FAK dependent                                                                        
Subconfluent populations of FAK -/- and FAK wt cells were exposed to various concentrations of 
the cytotoxic drugs indicated for 16 hours, at which point lysates were collected and 
immunoblotting performed for p53, p21, and β-actin. 
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6.2.8 ATM/ATR mediated phosphorylation of p53 (serine 15 and 
serine 20) in response to ionising radiation is not FAK 
dependent. 
The observation that p53 was stabilised in FAK wt cells at both 2 hours and 6 
hours post radiation with no corresponding increase in p21 suggested that FAK 
was somehow suppressing the transcriptional activity of p53 without directly 
affecting the total protein levels. Before assessing the global transcriptional 
function of p53, we considered the possibility that FAK may directly or indirectly 
influence the post translational modification of p53 in response to radiation and 
hence the conformation of the protein, as opposed to total protein level, which 
could perhaps have an effect on transcriptional activity. Following ionising 
radiation, a well described modification of p53 is the phosphorylation of key 
serine residues. We opted to focus on two of these serine residues, namely 
serine 15 and serine 20. The ATM and ATR kinases are activated within minutes 
of radiation and phosphorylate Chk1 and Chk2 kinases respectively, which in turn 
phosphorylate p53 at serine 20 (Chehab, Malikzay et al. 2000; Shieh, Ahn et al. 
2000). In addition, ATM can directly phosphorylate p53 at serine 15 (Canman, 
Lim et al. 1998).  
Accordingly, subconfluent FAK -/- and FAK wt cell populations were irradiated 
with 5Gy and lysates collected at various time points. Western blotting revealed 
an increase in phospho-Chk2-S68 at 15 minutes post radiation in addition to an 
increase in phospho-Chk1-S345 at 30 minutes post radiation in both cell lines. 
Similarly, increases in phospho-p53-S15 and phospho-p53-S20 were visible at 1 -2 
hours post radiation in both cell lines (Figure 61). It could therefore be 
concluded that there was no obvious disparity in ATM/ATR activation of the 
serine 15 and serine 20 sites which would explain the difference in p53 function.  
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Figure 61 - ATM/ATR mediated phosphorylation of p53 (serine 15 and serine 20) in response 
to ionising radiation is not FAK dependent 
Subconfluent populations of FAK -/- and FAK wt cells were irradiated with 5Gy and protein extracts 
were prepared at various time points. The extracts were then separated by SDS-PAGE, transferred 
to nitrocellulose, and blotted with the antibodies indicated. 
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6.2.9 Induction of the p53 target gene MDM2 is altered in FAK -/- 
versus FAK wt cells. 
The altered p21 transcriptional response pattern following exposure to ionising 
radiation led us to question whether this difference was restricted to p21 alone 
or if other p53 target genes were involved. We first examined MDM2 as this 
protein is known to increase following exposure to radiation. Also, the work by 
Lim et al. detailed a direct interaction between FAK and MDM2 as well as p53 
(Lim, Chen et al. 2008). Since MDM2 can target p53 for ubiquitination, it exerts 
powerful control over the levels of p53 in the cell. However, in view of the fact 
that p53 levels did not vary between FAK -/- and FAK wt cells (at least not in the 
first 12 hours after exposure to ionising radiation), we were not convinced that 
we would see any significant FAK dependent difference in MDM2 induction.  
Interestingly, qRT-PCR analysis showed that mRNA levels increased 4-fold in   
FAK -/- cells at 2 hours post 5Gy irradiation (Figure 62A). This corresponded 
with elevated protein levels (Figure 62B). FAK wt cells also demonstrated an 
increase in mRNA levels in response to the same dose of radiation, but this 
increase was less dramatic (2.5-fold as opposed to 4-fold) and occurred later, at 
4 hours rather than 2 hours (Figure 62A). An elevation in protein level was seen 
in the FAK wt cells at this later time point (Figure 62B). From these results it 
seemed unlikely that MDM2 was responsible for the discrepancy in p53 mediated 
p21 induction, but it was interesting to note that the increase in MDM2 at both 
the mRNA and protein level was lower and delayed in FAK wt cells compared 
with FAK -/- cells. 
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Figure 62 - Induction of MDM2 is altered in FAK -/- versus FAK wt cells 
(A) RNA was extracted from subconfluent FAK -/- and FAK wt cell populations at various time 
points after 5Gy irradiation and converted to cDNA. qRT-PCR analysis was then performed as 
previously described with 1µM MDM2 primers, using β-actin as a loading control. (B) FAK -/- and 
FAK wt cells were irradiated with 5Gy at 70 % confluence and lysates prepared at the indicated 
time points. Immunoblotting was then performed with anti-MDM2 (upper), and anti-β-actin (lower) 
antibodies.  
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6.2.10 Induction of p53 target genes involved in DNA repair is     
altered in FAK -/- versus FAK wt cells. 
p53 is traditionally thought to mediate radiosensitivity, but this is paradoxical in 
view of its role in inducing p21 which is often linked with radioresistance. 
Therefore, it is likely that in certain situations p53 may provide a cytoprotective 
role. With this in mind we set out to determine whether p53 induced 
transcription of genes in FAK -/- cells that may contribute to radioresistance, 
other than p21. As DNA repair is such an integral part of cellular radiation 
response, we examined mRNA levels in a number of p53 target genes that are 
known to be involved in repair following ionising radiation; gadd45, p53R2, 
Ddb2, and BRCA1. Although the results were not clear cut, a pattern emerged 
whereby mRNA levels for all but BRCA1 increased to a greater extent in the FAK 
-/- cells (Figure 63). Intriguingly, BRCA1 mRNA levels were moderately but 
consistently higher in the FAK wt cells.  
Despite the fact that the qRT-PCR results appeared to be inconsistent, we were 
able to show that DNA repair was more efficient in the FAK -/- cells by γH2AX 
immunofluorescence. Phosphorylation on the serine 139 site of the histone 
γH2AX occurs in response to ionising radiation (Rogakou, Pilch et al. 1998) and is 
generally considered to be a reliable surrogate of double strand break repair. 
Figure 64A depicts the percentage of nuclei containing <5 or ≥5 γH2AX foci at   
0 – 48 hours after a single dose of 5Gy irradiation.  Unsurprising, both FAK -/- 
and FAK wt populations demonstrated ≥5 γH2AX foci in virtually all cells 1 hour 
post irradiation. However, the FAK -/- cells had started to clear these foci within 
6 hours and reached baseline level within 24 hours, as opposed to the FAK wt 
cells which appeared to have a slower foci clearance rate. This is suggestive of 
more efficacious DNA repair abilities in the FAK deficient cells. Representative 
images of γH2AX immunofluorescence in FAK -/- cells (before and 1 hour after 
5Gy irradiation) are illustrated in Figure 64B. An interesting observation we 
made during this experiment is that the FAK -/- cells appeared to have generally 
higher levels of γH2AX foci under control conditions, with most cells displaying 
several foci and around 10-15% displaying ≥5 foci. The reasons for this are 
unclear but hint that these cells are either more genetically unstable than their 
FAK wt counterparts, or have generally enhanced DNA repair functions. 
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Figure 63 - Induction of p53 target genes involved in DNA repair is altered in FAK -/- versus 
FAK wt cells 
RNA was extracted from subconfluent FAK -/- and FAK wt cell populations at various time points 
after 5Gy irradiation. qRT-PCR analysis was then performed as previously described using primers 
directed against Ddb2 (A), gadd45 (B), p53R2 (C), and BRCA1 (D) with  β-actin as a loading 
control. 
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Figure 64 - FAK -/- cells are more efficient at DNA repair 
(A) FAK -/- and FAK wt cells were plated at low density on glass coverslips, incubated for 24 hours 
and irradiated with 5Gy. At various time points, the cells were fixed, permeabilised, stained with 
anti-phospho-γH2AX (serine 139) antibody and visualised under confocal microscopy. The number 
of foci per nucleus (<5 foci or ≥5 foci) was documented in at least 100 cells. Results shown are 
representative of one of two separate experiments. (B) Representative images of unirradiated and 
irradiated FAK -/- cells at 1 hour post 5Gy are shown, green – phospho-γH2AX and blue – DAPI 
(scale bar, 20µm), arrow in top right hand box pointing at a nucleus with <5 foci and broken arrow 
in bottom right hand box pointing at a nucleus with ≥5 foci. 
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6.2.11 Induction of p53 target genes involved in apoptosis is 
altered in FAK -/- versus FAK wt cells. 
p53 can downregulate as well as promote target gene transcription (Mack, 
Vartikar et al. 1993). It was therefore of interest to evaluate whether apoptosis 
was impaired in the FAK -/- cell line, particularly as p53 has long been linked to 
radiation induced apoptosis. We opted to study Bax and PUMA as both are well 
known p53 targets and have also been linked to radiation induced apoptosis 
(Garcia-Barros, Paris et al. 2003; Jeffers, Parganas et al. 2003; Yu, Wang et al. 
2003; Rotolo, Maj et al. 2008). As described earlier, RNA was extracted at 
various time points after 5Gy irradiation and analysed by qRT-PCR. FAK wt cell 
populations did not demonstrate any increase in mRNA or protein levels for 
either Bax or PUMA (Figure 65, A-D). However, PUMA mRNA levels were 
dramatically increased in FAK -/- cells at 2 hours, 6 hours, and 24 hours post 
radiation (Figure 65C). Corresponding western blots showed a gradual increase 
in PUMA-α levels (but not PUMA-β) over the 24 hours post irradiation (Figure 
65D). Interestingly, basal PUMA protein levels were higher in FAK -/- cells 
compared with FAK wt cells. Although Bax mRNA levels did show an 
approximately 2 fold increase in the FAK -/- cell population (Figure 65A), this 
was not associated with an increase at protein level (Figure 65B).  
The FAK -/- cell line was more radioresistant so it would appear slightly counter-
intuitive that apoptosis would be more marked in this cell line, although it must 
be noted that radiation induced apoptosis often plays a very small part of 
radiation induced cell death and does not necessarily reflect cellular 
radiosensitivity. Intriguingly, when we progressed to formally assess apoptosis by 
trying to examine the percentage of subG1 cells on FACS analysis at various time 
points following 5Gy, the levels were very low in both FAK -/- and FAK wt cells. 
In fact, it was difficult to detect any apoptosis by this method, with typical 
values of less than 1%. Representative FACS profiles are shown in Figure 66A. 
This data was corroborated by the absence of PARP cleavage on western blotting 
at various time points after 5Gy irradiation (Figure 66C). Increasing the dose of 
radiation up to a maximum of 30 Gy did not induce any PARP cleavage in either 
cell line (Figure 66D). Of note, 24 hours was selected for analysis as this 
allowed sufficient time for cells to be released from the temporary G2/M block 
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which occurs in response to radiation. In addition, PUMA-α protein levels were 
maximal at this time point in the previous experiment. As a positive control, we 
induced PARP cleavage with 0.5µM staurosporine (Figure 66B), indicating that 
these cells can undergo marked apoptotic cell death in response to certain 
triggers. Overall, these findings indicated that ionising radiation did not induce 
significant cell death by apoptosis in either FAK -/- or FAK wt cells and hinted 
that PUMA may have an additional or alternative cellular function here.  
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Figure 65 - Induction of p53 target genes involved in apoptosis is altered in FAK -/- versus 
FAK wt cells 
(A) RNA was extracted from subconfluent FAK -/- and FAK wt cell populations at various time 
points after 5Gy irradiation. qRT-PCR analysis was then performed as previously described using 
Bax primers with β-actin as a loading control. (B) FAK -/- and FAK wt cells were irradiated with 5Gy 
at 70% confluence and lysates prepared at the indicated time points. Immunoblotting was then 
performed with anti-Bax (upper) and anti-β-actin (lower) antibodies. (C) RNA was extracted from 
subconfluent FAK -/- and FAK wt cell populations at various time points after 5Gy irradiation. qRT-
PCR analysis was then performed using PUMA primers with β-actin as a loading control. (D) FAK   
-/- and FAK wt cells were irradiated with 5Gy at 70% confluence and lysates prepared at the 
indicated time points. Immunoblotting was then performed with anti-PUMA α/β (upper) and anti-β-
actin (lower) antibodies.  
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Figure 66 - Ionising radiation does not induce significant apoptosis in FAK -/- or FAK wt 
cells 
(A) 1x106 FAK -/- and FAK wt cells were irradiated with 5Gy at 70% confluence, fixed in 70% 
ethanol, stained with propidium iodide and cell cycle profiles obtained by FACS analysis. 
Representative images are shown (FAK -/- on the left and FAK wt on the right) at 0 and 24 hours. 
(B) Subconfluent populations of FAK -/- and FAK wt cells were irradiated with 5Gy and protein 
extracts were prepared at 0, 6, 12, 24, and 48 hours. Immunoblotting was then performed with anti 
–cleaved PARP (upper) and anti-β-actin (lower) antibodies. (C) Subconfluent populations of FAK    
-/- and FAK wt cells were irradiated with increasing doses of radiation and protein extracts 
prepared at 24 hours. Immunoblotting was then performed with anti–cleaved PARP (upper) and 
anti-β-actin (lower) antibodies. (D) FAK -/- and FAK wt cells were treated overnight with 0.5µM 
staurosporine. Lysates were then prepared and immunoblotting performed with anti–cleaved PARP 
(upper) and anti-β-actin (lower) antibodies. 
(A)
(C)
0 hrs
24 hrs
FAK -/- FAK wt
FAK wt
cPARP
β-actin
cPARP
β-actin
0        6        12       24      48     hrs 0        6        12       24      48     hrs
FAK -/-
cPARP
β-actin
cPARP
β-actin
0       2       5       10       20      30   Gy 0       2       5       10       20      30   Gy 
105
75
50
35
105
75
50
35
105
75
50
35
105
75
50
35
(B)
(D)
FAK wtFAK -/-
cPARP
β-actin
FAK -/-
0        0.5      µM  staurosporine
105
75
50
35
Chapter 6  202 
6.2.12 FAK does not interact directly with p53 or prevent 
nuclear localisation and/or accumulation of p53 in response 
to ionising radiation. 
It has been reported that FAK binds to p53 in the cytoplasm before shuttling into 
the nucleus (Lim, Chen et al. 2008). In certain cancer cell lines with wt p53, 
particularly breast cancer and neuroblastoma cells, the p53 protein is not fully 
functional as it is sequestrated in the cytoplasm (Moll, Riou et al. 1992; Moll, 
LaQuaglia et al. 1995). We therefore wondered whether FAK was binding p53 
and preventing its accumulation in the nucleus, which would explain the relative 
lack of transcriptional activity as nuclear localisation is necessary to achieve full 
transcriptional functionality. Immunofluorescence studies, however, refuted 
this. Accumulation of p53 in the nucleus was visible in the majority of cells at 2 
hours post 5Gy irradiation in both FAK -/- and FAK populations (Figure 67). In 
addition, we did not find any evidence that FAK translocated to either the 
cytoplasm or nucleus following irradiation (data not shown).  
To confirm that FAK did not directly interact with p53, we proceeded to 
immunoprecipitation studies. FAK wt lysates were collected 2 hours after 5Gy 
irradiation or mock irradiation and immunoprecipitated with a FAK antibody. As 
expected, Src binding was visible on western blotting in the FAK wt  mock 
irradiated and irradiated immunoprecipitates, but there was no interaction with 
p53 (Figure 68A). As a negative control, irradiated FAK wt lysate was 
immunoprecipitated with a histidine antibody. Paired lysates were probed for 
FAK, Src and p53 to ensure equal loading (Figure 68B). 
 
 
 
 
 
Chapter 6  203 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 67 - FAK does not prevent nuclear accumulation of p53 in response to ionising 
radiation 
FAK -/- and FAK wt cells were plated at low density on glass coverslips and subjected to 5Gy 
irradiation after 24 hour incubation. At 0 and 2 hours the cells were fixed, permeabilised, stained 
with anti-p53 antibody, and visualised under fluorescent confocal microscopy. Representative 
images from 1 of 3 experiments are shown, green – p53 and blue – DAPI, arrows represent 
nuclear accumulation of p53 (N) (scale bar, 50µm). 
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Figure 68 - FAK and p53 do not directly interact in response to ionising radiation 
(A) FAK wt cells were irradiated at 70 – 80% confluency and lysates prepared at 0 and 2 hours. 
1mg of protein was immunoprecipated with an anti-FAK agarose conjugated antibody at 4oC 
overnight. The IPs were separated by SDS-PAGE and immunoblotted with anti-FAK, anti-Src, and 
anti-p53 antibodies. As a negative control, irradiated FAK wt cell lysates were also 
immunoprecipitated with an anti-histidine agarose conjugated antibody. (B) 20µg of protein lysate 
was separately immunoblotted with anti-FAK, anti-Src, anti-p53, and anti-β-actin antibodies. 
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6.2.13 FAK kinase inhibition with a small molecule inhibitor 
induces p21 protein levels in response to ionising radiation. 
We have acquired evidence that the presence or absence of FAK influenced the 
function of p53 in this cell system. In addition, our data suggested that the 
FAK/p53 interaction was indirect. It is well recognised that FAK has kinase-
dependent as well as kinase-independent functions. To assess whether the 
kinase domain was integral to this phenomenon, we treated FAK wt cells with a 
FAK kinase inhibitor (PF-562,271) at a range of doses (0, 0.1µM, 0.2µM, and 
0.5µM) for 2 hours prior to irradiation. Lysates were collected for 
immunoblotting analysis at 0, 2, 4, and 6 hours after 5Gy. There was no 
difference in the level of p53 induction at any of the applied concentrations but 
p21 levels were visibly increased 2 hours after radiation in 0.5µM PF-562,271 
treated cells. Figure 69 demonstrates p53 and p21 levels in response to 5Gy 
irradiation in vehicle treated FAK wt cells (left) and  0.5µM PF-562,271 treated 
FAK wt cells (right).   
These results were surprising as the current literature indicates that the FAK– 
p53 functional interaction is mediated by the scaffolding function of FAK and is 
not kinase–dependent. In order to confirm our findings, we plan to evaluate the 
ability of FAK kinase defective mutants to affect the function of p53 by using 
p21 induction in response to radiation as readout of p53 activity. We also plan to 
evaluate the radiosensitivity of these mutants and, in addition, incorporate the 
FAK kinase inhibitor into clonogenic assays with FAK wt cells and assess whether 
this reproduces the radiation survival curve of FAK -/- cells.  
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Figure 69 - p21 is induced in FAK wt cells in response to ionising radiation in the presence 
of a FAK kinase inhibitor 
FAK wt cell populations at 70% confluence were incubated for 2 hours with either PF-562,271 
(0.1µM, 0.2µM, and 0.5µM) or 0.1% DMSO then irradiated with 5Gy. Protein extracts were 
prepared at 0, 2, 4, and 6 hours and immunoblotting performed with anti-p53, anti-p21, and anti-β-
actin antibodies. Representative immunoblots from 0.1% DMSO (left) and 0.5M drug treated (right) 
cell populations are shown.  
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6.3 Discussion 
The evidence to date suggests that knockdown of FAK protein levels increases 
radiosensitivity (Cordes, Frick et al. 2007). Although the authors were unable to 
pinpoint a clear mechanism, there are several theoretical reasons that could 
potentially explain this phenomenon. These include the effects of FAK on cell 
cycle, cell survival, and adhesion signalling. However, results in our cell system 
clearly show that the absence of FAK has a detrimental effect on 
radiosensitivity. An explanation for this discrepancy might be that this 
phenomenon is entirely cell line dependent. The cell lines examined by Cordes 
et al originated from human pancreatic adenocarcinomas, whereas the cell 
lines of interest in this case were derived from a murine squamous cell 
carcinoma of the skin. Aside from the possibility that there may be crucial 
disparities in the function of FAK in humans versus mice, it is likely that FAK has 
different properties in cancer cells depending on both the tissue of origin and 
cell type of origin. It is also likely that FAK has different properties depending on 
the underlying molecular aberrations present within the cell. Notably, the 
pancreatic cancer cell lines outlined above have mutant p53 whereas the cell 
lines under evaluation here have wt p53. The potential relevance of p53 will be 
discussed in detail later. 
A key issue that needs to be addressed, however, is that the complete absence 
of FAK may be a very different biological entity compared to reduced levels of 
FAK. It is possible that genetic deletion generates a particularly resistant 
phenotype which may not be fully recapitulated by simply lowering levels of FAK 
in the cell. It would therefore be crucial to repeat the radiosensitivity 
experiments in FAK +/+ cells using siRNA to knockdown the levels of FAK and 
compare with a paired FAK -/- population. We are currently developing paired 
FAK +/+ and FAK -/- cell lines from the isolated single cell clones and aim to 
explore this avenue of research. 
Regardless of whether this is a cell line dependent phenomenon, we have shown 
that the presence or absence FAK does influence radiation survival in this cell 
system; specifically FAK deletion promotes increased radioresistance. 
Furthermore, we determined that radioresistance is mediated, or at least partly 
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mediated by p21. Interestingly, this could not be explained by a difference in 
cell cycle kinetics. Since the radiosensitivity pattern of a cell line is governed by 
many factors, we acknowledged that it was possible other elements were at play 
here. As p21 is driven by p53 in this system, and p53 is deemed to be a critical 
mediator of radiation survival, it seemed reasonable to consider the possibility 
that p53 could be influencing radiation survival via both p21 dependent and p21 
independent mechanisms. One of the areas we focussed on was the 
transcriptional control of p53 target genes involved in DNA repair as the ability 
of a cell to repair damage can greatly influence radiosensitivity, as evidenced by 
various genetic syndromes such as ataxia telangectasia and Nimegen breakage 
syndrome. Although there was a general trend, specifically FAK -/- cells 
demonstrated higher levels of transcript for 3 out of 4 genes tested, these genes 
are primarily involved in single strand break repair. While single strand breaks 
undoubtedly do occur after exposure to ionising radiation, it is generally 
accepted that the ability to repair double strand breaks is crucial to cell survival 
after such an insult. Careful review of the literature reveals an abundance of 
data linking the transcriptional function of p53 to single strand break repair but 
the evidence connecting the transcriptional activity of p53 to double strand 
repair is rather limited (reviewed by (Gatz and Wiesmuller 2006)). Interestingly, 
BRCA1, which is involved in double strand repair (Scully, Chen et al. 1997; 
Moynahan, Chiu et al. 1999), was transcribed to a slightly higher level in the FAK 
wt population. However, it would be important to examine whether this 
corresponds to an increase in protein level. Also, BRCA1 is not necessarily a 
straightforward p53 target gene and, conversely, BRCA1 has been shown to 
influence p53 stabilisation (MacLachlan, Takimoto et al. 2002). Nevertheless, 
this may represent a genuine increase and BRCA1 may be a critical mediator of 
DNA repair in FAK wt cells.  
 Although we were unable to definitively link p53 transcriptional activity to 
double stranded DNA repair in FAK -/- cells, it was clear from observing the rate 
of γ-H2AX foci that this process is more efficient in FAK -/- cells compared with 
FAK wt cells. Whether this is mediated by p21 which probably has a role in DNA 
repair (reviewed by (Abbas and Dutta 2009)), or through p53 target genes that 
we did not examine, or even unrelated to p53 is unknown. However, there are 
several possibilities that ought to be considered. Firstly, p53 has recently been 
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shown to play a direct role in cellular metabolism. Through the induction of 
target genes such as TIGAR, p53 can alter the way in which a cell utilises glucose 
(Bensaad, Tsuruta et al. 2006). This is important because if cells are diverted 
into a pentose phosphate shunt, this may encourage the synthesis of nucleotides 
and other products that might be important for the repair of DNA lesions. 
Incidentally, a further by-product of this pathway is an increase in glutathione 
levels which can promote scavenging of reactive oxygen species (and 
theoretically lessen the effects of ionising radiation). It may be significant that 
p53R2, one of the target genes we examined, appears to be involved in 
regulating nucleotide pools within damaged cells (Tanaka, Arakawa et al. 2000). 
We have carried out some preliminary qRT-PCR studies with Gpx-1, a p53 target 
gene that is known to be involved in metabolism, and we found that this was 
upregulated only in FAK -/- cells (data not shown). While Gpx-1 has not been 
formally linked with resistance to ionising radiation, overexpression of the 
protein has been associated with resistance to UV irradiation (Baliga, Wang et al. 
2007). Secondly, mounting evidence links non-transcriptional activities of p53 to 
double strand DNA repair. Essentially, p53 can bind directly to damaged DNA  
and institute repair mechanisms directly (Ko and Prives 1996; Levine 1997; 
Albrechtsen, Dornreiter et al. 1999). The role of FAK (if any) in inhibiting this 
process is open to debate. 
Similarly,   p53   transcription-dependent   and   transcription-independent 
mechanisms have been described in apoptosis (Moll, Wolff et al. 2005). One key 
difference is that the transcription-independent function of p53 in this case is 
related to its localisation in the cytoplasm and / or  mitochondria as opposed to 
the nucleus (Mihara and Moll 2003; Chipuk, Kuwana et al. 2004; Leu, Dumont et 
al. 2004). Radiation can induce significant p53 dependent apoptosis in vitro, for 
example, in cells of haemopoetic origin (Lorimore, Goodhead et al. 1995) and in 
vivo in tissues such as spleen, gut and thymus (Clarke, Purdie et al. 1993; Lowe, 
Schmitt et al. 1993; Clarke, Gledhill et al. 1994; Komarova, Christov et al. 
2000), but this is not necessarily the case in cancer cell lines. Indeed, we found 
that trying to quantify apoptosis was not particularly valuable in this system as 
the level of apoptotic cell death induced by ionising radiation was exceedingly 
low. Studying the induction of Bax and PUMA, however, again highlighted the 
significant difference in the control of p53 target genes in FAK -/- versus FAK wt 
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cells. Surprisingly, although PUMA-α protein levels increased in the FAK -/- cell 
line, this did not result in any detectable increase in apoptosis. While PUMA has 
been undisputedly linked to p53 dependent apoptosis, including specifically 
radiation induced apoptosis (Jeffers, Parganas et al. 2003; Yu, Wang et al. 
2003), most research studies do not specify which of the four isoforms (α, β, γ, 
δ) is under investigation so it is difficult to delineate the specific functions of 
each protein. There is now some preliminary evidence which suggests that 
PUMA-α is both p53 dependent (Jiang, Wei et al. 2006; Sole, Hernandez-
Guillamon et al. 2008) and required for apoptotic response (Jiang, Wei et al. 
2006; Sole, Hernandez-Guillamon et al. 2008), but whether this is cell line 
dependent has yet to established. Another critical point is that PUMA induced 
apoptosis requires co-operation between nuclear and cytoplasmic proteins 
(Chipuk, Bouchier-Hayes et al. 2005) and for some reason this interaction may be 
defective in FAK -/- cells. Of course, it may simply be the case that PUMA has 
another function here.  
Taken together, the results up to this point highlight several important issues. 
Firstly, p53 appears to be mediating radioresistance through p21 dependent (and 
possibly p21 independent) mechanisms. Secondly, we believe that the loss of 
FAK promotes the pro-survival function of p53 in response to ionising radiation in 
these cells. Admittedly, a critical experiment would be to perform clonogenicity 
assays in the context of p53 knockdown but we did not have sufficient time. 
However, we were able to demonstrate that p21 knockdown reduces 
radioresistance in FAK -/- cells, and that p21 is in turn driven by p53 
transcription, in these same cells. This combined data gives credence to our 
above proposal that FAK mediated effects on p53 are responsible for the 
variations in radiosensitivity that we see in FAK -/- compared with FAK wt cells. 
As discussed in Chapter 5, wt p53 is typically associated with radiosensitivity 
rather than radioresistance but this is by no means definitive and there is data 
which challenges this view. One theory which would support a role for functional 
wt p53 in mediating radioresistance is that low levels of p53 induction tend to 
activate genes associated with cell cycle whereas high levels of p53 typically 
lead to apoptosis (reviewed by (Chen, Ko et al. 1996; Weinberg, Veprintsev et 
al. 2005)). This may explain the relative radioresistance of certain glioblastoma 
cell lines, some of which show a selective impairment of the apoptotic functions 
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of wt p53, while retaining the potential to mediate p53 responses relevant for 
DNA repair and control of cell cycle (Shu, Kim et al. 1998). Obviously, this would 
depend on how “stressful” ionising radiation is to the cell. Certainly in our cell 
system radiation did not effect dramatic levels of p53 stabilisation, as opposed 
to certain chemotherapeutic agents, and perhaps this is not surprising as ionising 
radiation is a transient insult unlike the sustained high level stress imposed by 
prolonged exposure to cytotoxics. To counter this, the precise role of cell cycle 
arrest and radiosensitivity has yet to be clarified and p53 is not solely 
responsible for checkpoint activation in response to radiation. Indeed, we were 
unable to illustrate any difference in cell cycle between FAK -/- and FAK wt 
cells. Further evidence against this hypothesis stems from in vivo work where 
researchers have been able to show that p53 target gene induction is tissue 
dependent and does not critically hinge on the level of p53 (MacCallum, Hupp et 
al. 1996; Bouvard, Zaitchouk et al. 2000; Komarova, Christov et al. 2000; Fei, 
Bernhard et al. 2002).  
As increasing information is obtained pertaining to the activation and function of 
p53 in response to stress, it is becoming clear that this process is highly complex 
and dependent on many factors including cell type, cell environment, and both 
the nature and duration of stress (reviewed by (Vousden and Lu 2002; Murray-
Zmijewski, Slee et al. 2008; Vousden and Prives 2009)). For that reason, it is 
difficult to make generalisations on the role of p53 in radiosensitivity but it 
seems that maintenance, or at least partial maintenance, of the pro-survival 
functions of wt p53 might be an important factor contributing to the survival of 
certain cancer cells in response to ionising radiation and /or other cellular 
stress. Whether this is an acquired property during the process of cancer cell 
evolution or a manifestation of the predetermined developmental pattern of a 
specific tissue or distinct cell types within a tissue has yet to be determined. A 
greater understanding of this phenomenon is vital, especially as there is 
currently interest in augmenting or restoring the function of wt p53; in certain 
situations this may prove to be detrimental. 
In light of recent publications, it was important to characterise the relationship 
between FAK and p53 in these cells, and in particular determine whether this 
relationship was direct or indirect and kinase-dependent or independent. As  
nuclear localisation of p53 is necessary for full transcriptional activity, we 
Chapter 6  212 
anticipated that FAK may directly (or indirectly) prevent nuclear accumulation 
of p53 in response to ionising radiation, but this was not the case. Further to 
this, we have shown, in contrast to a recent study (Lim, Chen et al. 2008), that 
FAK does not translocate to either the cytoplasm or nucleus and it does not 
directly bind to p53. We do not dispute the mounting evidence that a p53 
binding site exists on FAK (Golubovskaya, Kaur et al. 2004; Golubovskaya, Finch 
et al. 2005; Golubovskaya and Cance 2007) or vice versa (Golubovskaya, Finch et 
al. 2008), and, as there is accumulating data to suggest that p53 exists in various 
pools within the cell, it would not be inconceivable for binding between p53 and 
FAK to occur. Nonetheless, in this particular cell line, any FAK/p53 functional 
interaction in this context is indirect. We accept that this may be stress 
dependent and it would be interesting to see if FAK does directly cooperate with 
p53 under different cellular stresses. 
Although the presence or absence of FAK does not influence either basal levels 
of p53 or stabilisation of p53, at the total protein level, in response to radiation 
in these cells (with the exception of the 24 hour time point), we did wonder 
whether FAK indirectly influences the phosphorylation status of p53, particularly 
as various post translational modifications can affect the transcriptional activity 
of p53. There are many residues on p53 which are phosphorylated in response to 
DNA damage but it proved difficult to obtain sufficiently robust phospho-specific 
antibodies directed at mouse p53. We were able to examine the serine 15 and 
serine 20 sites, however, which constitute two of the most significant 
phosphorylation sites on p53 following DNA damage, specifically ionising 
radiation. Significantly, there was no difference in phosphorylation levels 
between FAK -/- and FAK wt cells at these sites in response to irradiation. p53 is 
further regulated at the post translational level by multiple additional 
mechanisms, for example, acetylation, sumolyation, neddylation, methylation, 
and ubiquitination. It is difficult on the basis of current evidence to link FAK to 
any of these mechanisms, with the exception of ubiquitination. FAK has been 
shown to form a scaffold with p53 and Mdm2 and promote Mdm2 mediated 
degradation of p53 (Lim, Chen et al. 2008). We did not formally assess this but 
the slower rate of Mdm2 increase after radiation in FAK wt cells, coupled with 
relatively similar levels of p53 mRNA and protein in both cell lines would perhaps   
argue against increased degradation. 
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As FAK does not appear to alter the localisation or level of p53, there must be 
another explanation for the differential transcription pattern of p53 target genes 
in response to ionising radiation. We outlined earlier that the selective 
functioning of p53 in response to stress is dependent on cell line factors as well 
as the type of stress. However, it is becoming increasingly realised that the 
function of p53 is also dependent on cofactors, proteins that interact with p53 
and influence both its transcription-dependent and transcription-independent 
activities. While some cooperate directly with p53 to influence target gene 
activity by binding to the DNA-binding domain, such as the evolutionary 
conserved ASPP family (reviewed by (Sullivan and Lu 2007)), more recently other 
modifiers have been identified which indirectly affect p53 function by regulating 
the proteins that are directly involved in its activation and repression, for 
example p300/CBP (reviewed by (Lee and Mapp 2010)). Although recent work 
suggests that there is a direct interaction between FAK and p53 (Lim, Chen et al. 
2008), an indirect mechanism has previously been described. FAK is known to 
associate with the FAK-interacting protein (FIP200) which can bind p53 and 
enhance its half-life (Abbi, Ueda et al. 2002). We have yet to examine whether 
FIP200 is significant here but, as this protein tends to alter the levels of p53 as 
opposed to selective functioning, this may not be a particularly productive line 
of investigation.  The possible link between FAK and p53 cofactors involved in 
selective functioning, however, opens up a novel area of research. As a 
signalling molecule, FAK would be well placed to exert an effect over many 
cellular proteins, some of which may interact with p53. We suspect that the 
kinase function of FAK is integral to this phenomenon, but accept that we only 
have limited evidence in support of this at present. Notably, Src signalling has 
been linked both directly to p53 (Wang, Zheng et al. 2009) and indirectly via the 
ASPP family (personal communication – Karen Vousden). While this information 
may strengthen our hypothesis that adhesion signalling can affect the function of 
p53, we then have to question whether our findings are Src dependent rather 
than FAK dependent. In fact, we intend to investigate the significance of Src in 
our system. 
While there is no direct evidence in the literature which connects the kinase 
activity of FAK to p53, this has not yet been examined by other research groups 
in the context of ionising radiation. It has already been shown that FAK activity 
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can be upregulated by radiation (Beinke, Van. Beuningen et al. 2003). While this 
may represent indirect activation (e.g. via EGFR), it is possible that FAK may be 
directly activated by radiation through the production of highly reactive oxygen 
species by radiation. Certainly, FAK tyrosine phosphorylation can be induced by 
reactive oxygen species generated by alternative means such as hydrogen 
peroxide (Sonoda, Watanabe et al. 1999; Meriem, ValÉrie et al. 2000). As 
previously discussed, the effect of ionising radiation on the cell is quite different 
from that of other stresses such as cytotoxic chemotherapy. Thus, the type of 
damage induced by radiation may preferentially activate certain kinase 
functions of FAK. Just as the effects of p53 on the cell are stress dependent, it 
may well be the case that the effects of FAK are also stress dependent. Based on 
our preliminary data and the published results to date, the precise nature of the 
FAK – p53 functional interaction may vary not only from cell line to cell line, but 
may be direct or indirect and kinase–related or unrelated depending on the 
nature and severity of stress.  
Much effort was spent trying to establish exactly how any FAK–p53 functional 
interaction operates in these cells and further clarification is still required.  One 
probing question that persisted throughout the course of this work, however, 
was why should the presence of FAK in the cell dampen down the pro-survival 
function of p53? Although FAK does not strictly function as an oncogene, much of 
the evidence in the literature points toward upregulation of FAK levels and/or 
activity in association with the cancer phenotype. Further, FAK has been directly 
linked to carcinogenesis in the mouse skin cancer model (McLean, Brown et al. 
2001; McLean, Komiyama et al. 2004) and, more recently, other carcinogenesis 
models such as breast cancer (Provenzano, Inman et al. 2008; Luo, Fan et al. 
2009). However, it is important to note that high levels of FAK expression and 
activity need not always be associated with be a more aggressive phenotype. 
Reduced FAK activity, for example, has also been shown to promote motility, 
invasion and metastases in the in vitro and in vivo settings (Lu, Jiang et al. 2001; 
Yano, Mazaki et al. 2004). This suggests that FAK may have tumour suppressor as 
well as tumour promoter properties. While the evidence for the former is rather 
limited at present, intriguing data is emerging from conditional FAK knockout 
experiments in the mouse hepatobiliary system. Loss of FAK appears to 
accelerate carcinogenesis in the pancreas and liver on a background of 
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constitutive K-Ras activation (personal communication – Owen Sansom). It is 
therefore not unreasonable to speculate that FAK may possess a tumour 
suppressor type function in our cell system. This function may have evolved in 
order to keep the pro-survival activity of p53 in check. Why this property of FAK 
should emerge specifically in response to ionising radiation is rather puzzling and 
requires further investigation. 
One of our initial aims was to evaluate the role of FAK in radiosensitivity in vivo. 
As the effects of radiation can be more or less pronounced in vivo compared 
with in vitro, we wanted to establish whether any of the effects attributed to 
FAK would translate in a more clinically relevant setting. This is especially 
important as the functions of FAK appear to be very context dependent, as 
exemplified by the requirement of FAK for growth in an anchorage-independent 
environment while it is redundant for growth on cell culture plastic. Setting up 
this experiment was incredibly technically challenging due to various underlying 
biological factors. The cell lines were very radioresistant and we were limited by 
the dose of radiation we could use as whole body irradiation is poorly tolerated. 
Doses in excess of 5Gy in nude mice result in fatal haematological and 
gastrointestinal toxicity. Also, the xenografts became necrotic at around 1cm in 
diameter and did not reach the maximum diameter of 1.7cm permitted by the 
Home Office.  
Despite these limitations, we were able to show the absence of FAK was 
associated with reduced tumour growth inhibition in response to radiation. 
Furthermore, the pattern of p21 induction suggested that similar mechanisms 
were invoked in vitro and in vivo. We intend to do further studies to assess 
whether any additional mechanisms contribute to radioresistance in vivo. One 
area of interest is the potential difference in vascularity between FAK -/- and 
FAK wt xenografts. A defective vascular system could create a hypoxic 
environment which may have important implications on radiation survival. 
It could be argued that studying the response to radiation in xenografts is still 
rather artificial. For this reason, we did consider irradiating 
K14CreERT2FAKflox/flox mice bearing tumours but this was precluded by the long 
latency period necessary for topical carcinogenesis. In retrospect, this may have 
been problematic as, based on our experience with both the SCC 1.1 and SCC 7.1 
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xenografts, the application of 4-OHT is unlikely to have induced sufficient  FAK 
deletion in carcinomas. Even if 4-OHT treatment had been successful, the results 
would have proved difficult to interpret in view of heterogeneity between 
tumours and even within the different cellular components of the same tumour.  
Although we have yet to ascertain whether or not genetic deletion of FAK would 
result in similar effects in response to radiation in another cancer cell line, we 
strongly suspect that the underlying heterogeneous nature of cancer cells and 
the multiple roles of FAK within the cell suggest that the outcome is likely to be 
tissue and / or cell line specific. The interplay between FAK and p53 and how 
this axis is programmed to respond to stress is likely to be a critical factor, at 
least in cells with wt p53. Attempting to predict the effect of FAK on 
radiosensitivity in the context of a p53 null or mutant p53 background is more 
difficult, not least because it is unclear exactly how mutant p53 proteins can 
influence radiation survival. Also, the relationship between FAK and mutant p53 
is even less well described. Whether FAK can directly or indirectly impinge on 
the transcription-dependent or transcription-independent functions of mutant 
p53 proteins and whether this in turn depends on the specific mutation or 
conformation of p53 is largely unexplored.  
Interestingly, there is some preliminary evidence to suggest that cancer cells 
with mutant p53 have higher levels of FAK due to uncontrolled transcription 
(Golubovskaya, Finch et al. 2008). The precise function of FAK in such cells is 
unclear but if high levels of FAK are contributing to cell survival then FAK 
knockdown under these circumstances could be beneficial. It is noteworthy that 
Liu et al. found that treatment with the FAK kinase inhibitor TAE226 induced 
apoptosis in mutant p53 containing cells and not in wt p53 containing cells (Liu, 
LaFortune et al. 2007), although it must be pointed out that this drug also 
inhibits the growth factor receptor IGF-1R and it cannot be assumed that its 
effects are exclusively FAK mediated. It is also difficult to dissect whether any 
of the possible FAK mediated effects on survival are related to p53 or not. 
Unfortunately the Cordes group were unable to pinpoint the exact mechanism 
responsible for increased radiosensitivity following FAK knockdown in the 
pancreatic cancer cell lines they evaluated. Notably, the combination of FAK 
siRNA and radiation induced slightly different effects on cell cycle dynamics and  
cell signalling / cell survival proteins such as Akt in each cell line, again 
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demonstrating the range of tumour cell heterogeneity. Indeed, it may well be 
relevant that each cell line possesses a different p53 mutation.  
6.4 Summary 
This work has demonstrated that loss of FAK has a detrimental effect on 
radiation survival in this cell line. We have shown that this effect is mediated by 
transcriptional regulation of p21, which is driven by p53, and we believe that wt 
p53 is acting as a radioprotectant in this system. Why FAK should repress the 
pro-survival function of p53 is unclear, but this data indicates that inhibition of 
FAK may not always be advantageous in the clinical setting and contributes to a 
small body of literature highlighting a close interaction between FAK and p53. 
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7 Concluding Remarks and Future Perspectives 
7.1 Concluding Remarks 
Radiotherapy remains one of the principal anti-cancer modalities and is the 
treatment of choice in a variety of solid epithelial tumours. For many years, it 
was accepted that radiotherapy exerted its effect by indirect DNA damage 
secondary to free radical formation and the field of radiation biology remained 
relatively quiescent. Meanwhile, massive technological advances in medical 
imaging and radiation physics were driving the discipline of clinical oncology 
forward. The advent of 3D, and now 4D, treatment planning means that 
radiotherapy is better directed at the target, and safer, than ever before. In 
recent years, however, it has become increasingly apparent that cancer cells can 
evade radiation–induced cell death. The reasons for this are complex. At the 
cellular level, the ability of cancer cells to repair damaged DNA, and the 
activation of growth factor receptor mediated survival pathways in response to 
ionising radiation, appear to be critical. However, the tumour microenvironment 
also has a significant effect on radiosensitivity. This is often related to tumour 
oxygenation, which is dependent on the efficiency and stability of the supporting 
vasculature, but it is likely that other factors are also involved, and there is 
much more to learn. The inherent radioresistance present in certain cancer cells 
contributes to treatment failure and probably explains why dose escalation 
studies in radiotherapy practice are not always successful. Hence, there is a 
great need to gain a better understanding of the complex processes that govern 
radioresistance. This will help to identify certain cellular or tumour 
characteristics that could be selectively targeted in order to improve the 
efficacy of radiation treatment.  
To this end, a number of putative novel signal transduction targets have already 
been identified. Amongst the most advanced is EGFR. There is evidence that 
inhibiting EGFR signalling can enhance the effectiveness of radiation in head and 
neck cancer (Bonner, Harari et al. 2009). However, this is not standard practice 
as this combination has yet to show superiority over chemoradiotherapy in a 
clinical trial. Nonetheless, the Bonner study indicated that targeted agents could 
feasibly be combined with a radical course of radiotherapy, paving the way for 
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further evaluation of EGFR inhibitors (and other targeted agents) in combination 
with radiation in a wide range of tumour types.  
FAK is a non-receptor tyrosine kinase that is located in focal adhesions and 
therefore plays an integral role in transmitting signals from growth factor 
receptors and integrins to the nucleus. As ionising radiation can stimulate cell 
survival through both growth factor receptor and integrin signalling pathways, 
we hypothesised that FAK may be an important mediator of radioresistance. We 
aimed to test this hypothesis by developing a novel cancer cell line with 
inducible fak deletion. 
Using a conditional mouse model which was already well established in this 
laboratory (McLean, Komiyama et al. 2004), we were able to generate SCC cell 
lines from mouse skin (SCC 1.1 and SCC 7.1) and successfully delete fak from one 
of these cell lines (SCC 7.1). The precise reason why we were unable to produce 
a FAK -/- cell line in SCC 1.1 cells is unknown, but we did consider whether this 
was related to the presence of wt p53. Although it is likely that Cre expression 
and/or function was suboptimal in this cell line, we suspected that SCC 1.1 cells 
may have undergone growth arrest or cell death in the complete absence of FAK, 
due to activation of p53, therefore precluding the proliferation of a stable 
knockout. This is obviously conjecture as the growth arrest/cell death inducing 
abilities of high dose 4-OHT made it difficult to interpret the results of FACS 
analysis. The reasoning behind this conjecture was based, in part, on an 
emerging body of data outlining a key functional interaction between FAK and 
p53. In fact, the significance of p53 and the possible interplay between FAK and 
p53 in these derived cell lines are recurring themes throughout this thesis, 
although this was not what we had set out to test. 
p53 was important in the SCC 7.1 cell line for a number of reasons. Firstly, the 
FAK -/- cell line contained functional wt p53, demonstrating that, at least in 
certain cancer cells, the complete absence of FAK does not promote 
uncontrolled activation of p53 and resultant growth arrest or cell death. This 
suggests a different “wiring” or “functional inter-dependency” between normal 
MEFs (Ilic, Furuta et al. 1995) and the cancer cells we derived here. Secondly, 
the observation that the SCC 7.1 FAK +/+ parental cell line was composed of a 
mixture of cell populations with either wt p53 or mutant p53 (L254R), and that 
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these populations had different cellular characteristics, made it clear that a 
direct comparison could not be performed between SCC 7.1 FAK +/+ cells and 
SCC 7.1 FAK -/- cells. Thirdly, it is likely that the poorly described L254R p53 
mutant protein has gain of function properties, including increased proliferative 
capacity in vitro and the ability to invade in vivo. Admittedly, these 
characteristics may be related to other mutations and we have yet to confirm 
that mutant p53 alone is the cause of these effects. 
Although in the short term it was disappointing that we could not immediately 
proceed to clonogenic assays in the SCC 7.1 FAK +/+ and FAK -/- cell lines, it was 
of the utmost importance to create a system that would provide the most 
accurate representation of any potential FAK mediated effects on clonogenicity. 
We achieved this by introducing a FAK wt construct into the FAK -/- clone, 
ensuring that FAK wt was both correctly localised and expressed at a similar 
level to endogenous FAK. In doing so, we were then able to evaluate the role of 
FAK in radiation survival in an advanced, invasive squamous cell carcinoma cell 
line under highly controlled and reproducible conditions. 
Much to our surprise, and in contrast to published literature to date based on 
human pancreatic cancer cells (Cordes, Frick et al. 2007), the absence of FAK in 
our SCC cell lines was associated with a more radioresistant phenotype. This 
result raises questions of course about reduction of FAK levels versus deletion of 
FAK and the possibility of different roles for FAK in humans versus mice which 
have yet to be addressed. It seems more likely, however, that FAK will play 
different roles in cell survival depending on the particular cell of interest and 
the various mutations and/or molecular aberrations it has acquired during the 
process of carcinogenesis. Indeed, we believe that p53 status is likely to be 
critical. However, we acknowledge that in certain cell lines or tissues, gene 
products other than FAK or p53 may be more important in determining cell fate 
in response to ionising radiation or other cellular stresses.  
The reason why we believed that p53 status was critical in determining radiation 
survival in the SCC 7.1 FAK -/- versus FAK wt cell lines was based on the ability 
of p53 to transcriptionally activate p21 following a radiation insult in the 
absence of FAK. Accordingly, p21 knockdown led to a significant increase in 
radiosensitivity in FAK -/- cells. As the cellular response to ionising radiation is 
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complex, factors unrelated to p21 are probably also involved. Nonetheless, this 
data suggested that wt p53 promoted cell survival in response to radiation. It 
also indicated that FAK somehow inhibited the pro-survival function of p53 in 
these cancer cells. While wt p53 is traditionally characterised by its tumour 
suppressor functions, including a more radiosensitive phenotype, this ability of 
p53 is very much cell line and context dependent. The fact that our SCC cell line 
had survived transfer from the original mouse tumour to the cell culture 
environment, followed by repeated passage and high dose 4-OHT treatment 
without acquiring a p53 mutation, implies that we had selected out a 
particularly aggressive wt p53 cell line.    
Similarly, while FAK typically has tumour promoting properties, emerging data 
highlights that in certain cellular systems FAK acts as a tumour suppressor 
(personal communication – Owen Sansom). Hence, it seems that both FAK and 
p53 can play very different roles depending on the precise cellular context. It is 
reasonable to conclude that in our SCC cell line FAK suppresses radiation 
induced survival mediated by wt p53.  
There are several important questions that stem from this. Firstly, what is the 
major mechanism for cell death in the FAK containing cells exposed to radiation? 
We did not demonstrate any increase in apoptosis in FAK wt cells compared with 
FAK -/- cells at any of the time points examined. However, as we have already 
pointed out apoptosis propensity does not always reflect cellular 
radiosensitivity, and from our experience radiation induced apoptosis is difficult 
to detect in many cancer cell lines in the laboratory setting. The possibility of 
enhanced cell death by alternate events, such as mitotic catastrophe, should be 
considered. Secondly, why does the radiation enhancing role of FAK appear to be 
stress dependent? Intriguingly, we have yet to demonstrate a similar effect in 
response to cytotoxic chemotherapy. This may be specifically related to the 
property of ionising radiation to induce DSBs. FAK may somehow sense that these 
are particularly damaging to the cell and prevent p53 from activating survival 
mechanisms through p21 (and other target genes / pathways). However, FAK has 
not been directly implicated in the DNA damage/response pathway. While FAK 
activity can be stimulated directly in response to reactive oxygen species (which 
are the cause of DSBs), it is unclear whether this alone could explain the 
phenomenon, especially as cytotoxic agents can also induce free radical 
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formation. At this point, we can only speculate why FAK has different functions 
in response to different stresses in these cancer cells. 
Despite increasing evidence highlighting a direct functional interaction between 
FAK and p53 in both normal and cancer cells, we were unable to demonstrate 
this in the SCC 7.1 cell line. On the contrary, our results were indicative of an 
indirect FAK/p53 functional interaction. Moreover, preliminary data based on 
the use of a small molecule inhibitor in the FAK wt cells suggests that the kinase 
activity of FAK is important. This is also in direct opposition to most of the 
published work to date, with the most convincing evidence produced by Lim et 
al. clearly delineating the requirement of the FAK FERM domain in establishing a 
structural connection between FAK and p53 (Lim, Chen et al. 2008). This 
discrepancy may be explained by cell line dependent factors. It is certainly 
reasonable to speculate that the FAK/p53 axis may vary from cell line to cell 
line. However, we have considered the possibility that the indirect relationship 
between FAK and p53 in our cells may be specific to ionising radiation (and/or 
other cellular stresses). It may be the case that FAK does directly influence the 
function of p53 in SCC 7.1 cells in response to other cellular stresses.  
To summarise, in the SCC 7.1 cell line, p53 is stabilised in response to ionising 
radiation within a few hours. This occurs regardless of FAK status. In the absence 
of FAK, upregulation of p53 leads to transcriptional activation of p21 which 
increases the ability of the cell to survive the radiation insult. Increased survival 
is not secondary to effects on cell cycle, but may instead be related to the DNA 
repair function of p21. It is likely that additional p53 transcription-dependent or 
independent pathways also have a part to play. In the presence of FAK, p53 is 
still stabilised in response to radiation. However, we believe that FAK signalling 
suppresses these p53 mediated survival mechanisms. Any FAK/p53 functional 
interaction in this context is indirect and mediated by an unknown pathway, the 
end result of which may be the recruitment and/or activation of a cellular 
protein(s) that can selectively control p53 transcriptional function.  A schematic 
diagram of this hypothesis is shown in Figure 70. Interestingly, evaluation of the 
radiomodulating properties of other non-receptor tyrosine kinases such as Src 
and ILK has revealed that the interaction of these proteins with EGFR appears to 
be critical. While we did not specifically investigate this possibility, it is worth  
noting that the SCC 7.1 cell line expresses very low levels of EGFR and we did 
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not find any obvious differences in the activation of downstream signalling 
pathways as assessed by immunoblotting for phospho-ERK and phospho-Akt 
between FAK -/- and FAK wt cell populations in response to ionising radiation 
(data not shown). However, our SCC 7.1 cells do express high levels of other 
receptor tyrosine kinases such as the Ret oncoprotein, and Ret interacts with 
FAK (personal communication – Emma Sandilands). This could be an area for 
further study. Also, it may be that FAK can influence the translocation of EGFR 
to the nucleus, and hence its DNA repair abilities, but is possible that we have 
discovered a protein kinase-dependent effect on radiosensitivity that is 
completely distinct from EGFR. 
In addition, we have shown for the first time that FAK can influence radiation 
survival in vivo as well as in vitro.  This was a particularly pertinent experiment 
to do in view of the potentially different roles for FAK depending on the cellular 
context. Indeed,  we demonstrated that FAK was imperative for proliferation in 
a 3D but not a 2D environment in our SCC cells. In this case, FAK is constitutively 
active and FAK kinase activity drives growth and proliferation in the absence of 
adhesion signalling. We believe that loss of FAK (specifically loss of FAK kinase 
activity) delays the onset of xenograft formation, but this deficit is soon 
overcome by the supporting infrastructure provided by the host animal. Hence, 
when xenografts have established and FAK is no longer critical for performing an 
anchorage-independent type function, it may be able to resume similar roles 
that it plays in vitro. Notably, an increase in p21 was seen in FAK   -/- xenografts 
but not FAK wt xenografts, indicating that similar FAK mediated mechanisms are 
provoked in vitro and in vivo. However, there are a number of characteristics 
specific to the in vivo setting, such as tumour oxygenation and angiogenesis, 
that may have contributed to the overall outcome and which require further 
investigation.  
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Figure 70 - FAK mediated effects on radiosensitivity 
In response to ionising radiation, FAK may be activated indirectly by growth factor receptor or 
integrin signalling. However, FAK may also be phosphorylated by reactive oxygen species. p53 is 
able to detect cellular stress induced by radiation and accumulates in the nucleus. FAK does not 
interact directly with p53, but through an unknown mechanism (which may involve recruitment of a 
p53 co-factor via a signalling pathway) FAK inhibits transcription of p21 and other p53 target genes 
that promote cell survival. There may be additional mechanisms that contribute to reduced 
clonogenic survival; these may be p53 transcription-independent or even p53-independent. 
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Interestingly, work has just been published assessing the role of the FAK 
inhibitor TAE226 as a radiosensitising agent in head and neck cancer cell lines 
(Hehlgans, Lange et al. 2009). The authors found that radiosensitivity was 
increased in a 3D (laminin-rich ECM) but not a 2D environment. While these 
results may corroborate our preliminary data suggesting that the kinase activity 
of FAK has an important role in mediating radiation survival, we do wonder 
whether TAE226 was applied too early in the experiment, i.e. when FAK kinase 
activity was necessary to stimulate colony formation. Even more intriguingly, 
two of the three pancreatic cancer cell lines evaluated by Cordes et al. (Cordes, 
Frick et al. 2007) were also examined in this study and TAE226 did not 
radiosensitise either of these cell lines in 2D or 3D, indicating that reduced FAK 
levels as opposed to reduced FAK activity was the critical factor in promoting 
radiosensitivity in the Cordes study.  
Thus, just as the cellular response to ionising radiation is complex, the 
relationship between FAK and radiosensitivity is also complex. The effects of 
FAK on radiation survival appear to vary from cell line to cell line. It is likely 
that either the scaffolding function of FAK or the kinase activity of FAK may be 
important depending on the cell line of interest and the various roles that FAK 
plays in each particular cell line. We believe that the functional interaction 
between FAK and p53 is also critical, at least in cell lines with wt p53 where p53 
strongly influences the outcome of ionising radiation via predetermined pro-
survival or pro-death pathways. As we have already outlined, trying to predict 
the effect of the FAK/p53 axis on radiosensitivity in cells with mutant p53 is 
much more difficult. Hopefully, future radiation studies in a wide panel of cell 
lines with varying p53 status will help to dissect out the roles of FAK and p53 in 
the highly intricate cellular response to ionising radiation. This highlights the 
need for greater understanding of the underlying critical factors and mechanisms 
before embarking on trials of FAK inhibitors along with radiotherapy in clinical 
trials. 
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7.2 Future Perspectives 
The work presented in this thesis represents a thorough investigation into the 
role of FAK in mediating radiosensitivity in vitro and in vivo using mouse 
squamous cell carcinoma cell lines. In addition, it has prompted a wide range of 
potential research questions. In this final section we will focus on the most 
pertinent topics for future study: 
1.  Dissecting out the general complexities of the FAK/p53 interaction and its     
role in mediating radiosensitivity in a heterogeneous set of cancers with defined 
molecular properties 
2.  Evaluating whether the FAK mediated effects on p53 and radiosensitivity in 
the SCC cells we derived are Src-dependent 
3.  Investigating the role of autophagy in radiation induced survival in our SCC 
FAK -/- and FAK wt cells  
4.  Exploring the role of FAK in normal tissue radiosensitivity 
7.2.1 Dissecting out the general complexities of the FAK/p53 
interaction and its role in mediating radiosensitivity 
One particular topic that requires further clarification is the precise relationship 
between FAK and p53 in our SCC cells. We have shown that any FAK/p53 
functional interaction in response to ionising radiation in these cells is indirect. 
While we think that the catalytic activity of FAK is a prerequisite, more 
definitive evidence is needed. Firstly, we plan to incorporate the small molecule 
inhibitor PF-562,271 into clonogenic assays and evaluate whether FAK kinase 
inhibition in combination with radiation reproduces the radioresistant phenotype 
of FAK -/- cells. Secondly, we aim to compare and contrast the radiation survival 
of cell lines expressing FAK kinase mutants, and also assess the ability of these 
cells to induce p21 in response to radiation. Indeed, we have already generated 
FAK KD mutants as described in Chapter 5. Further, we have also generated FAK-
Y397F and FAK–YF4-Y9F kinase mutants and expressed these in the FAK deficient 
SCC 7.1 cells. In the former, Src is unable to bind due to mutation of the Y397 
Chapter 7  228 
site, and this in turn inhibits full FAK catalytic activity. In the latter, all of the 
Src–dependent phosphorylation sites on FAK have been mutated from tyrosine to 
phenylalanine and so FAK cannot be phosphorylated by Src. This also inhibits full 
FAK catalytic activity. The advantage of this work is that it may also reveal 
whether or not Src is critical for any FAK mediated effects on p53, and the 
signalling determinants in FAK that controls its effects.  
Clearly, one of the major differences between our work and the Cordes study  
(Cordes, Frick et al. 2007) is the presence of wt p53 in the mouse SCC cells 
versus mutant p53 in the pancreatic cancer cell lines. We had hoped to address 
this by developing FAK -/- cell lines from the isolated mutant p53 single cell 
clones (A10 and H7) by the addition of high dose 4-OHT and comparing 
radiosensitivity in FAK +/+ versus FAK -/- cells in the context of a mutant p53 
background. Despite much effort, this endeavour has not yet proved successful. 
In fact, it may be necessary to generate new single cell clones from an early 
passage SCC 7.1 population and repeat the 4-OHT selection process. An 
alternative approach would be to return to the original mouse model and 
incorporate various p53 mutations into this system in addition to deleting fak. 
New SCC cell lines with altered p53 genetic backgrounds could then be 
propagated by the topical carcinogenesis protocol we described earlier. In this 
way, we could examine a number of common “hotspot” p53 mutations, including 
R172H and R270H, and their contribution to radiosensitivity in the presence or 
absence of FAK. Ideally, we would also incorporate a reporter gene such as lacZ 
into this model, as this would allow visualisation of Cre in the derived cell lines. 
One problem with this method is the likelihood of the various SCC cell lines to 
have amassed different mutations during the process of carcinogenesis and in 
some of these cell lines it is quite possible that p53 will not significantly affect 
radiation survival. This makes standardisation and direct comparison between 
cell lines difficult. One way to circumvent this might be to conditionally delete 
out p53 as well as FAK and thus create a p53 null SCC cell line. A variety of p53 
mutant constructs could then be transfected into the p53 -/- cells and the 
behaviour of these mutant proteins compared in FAK +/+ and FAK -/- cells. It 
may even be possible to insert wt p53 into the p53 -/- cells, although the 
presence of wt p53 in p53 knockout cells is often only tolerated for a short 
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period of time and therefore this approach may prove difficult due to the 
prolonged duration of a clonogenic assay. 
7.2.2 Evaluating whether the FAK mediated effects on p53 and 
radiosensitivity are Src-dependent 
It can be difficult to separate out the effects of FAK on the cancer phenotype 
from those of Src. In fact, until the work by McLean et al. demonstrated a 
causative role for FAK in carcinogenesis (McLean, Komiyama et al. 2004), it was 
suggested that any apparent cancer related properties of FAK may be due to Src. 
We aim to evaluate whether Src is driving the radiation enhancing function of 
FAK in the SCC 7.1 cell line. As outlined above, assessing the FAK kinase mutants 
which have lost either the Src binding site or the Src-dependent phosphorylation 
sites on FAK will provide very useful information. In addition, we intend to study 
the effect of Src knockdown using siRNA and/or a Src kinase inhibitor such as 
dasatinib on p21 induction and clonogenicity in the SCC 7.1 FAK wt cell line. It 
would also be reasonable to delete Src in the conditional mouse model as 
opposed to FAK and investigate the radiosensitivity of Src +/+ and Src -/- cell 
lines. However, it is important to point out that analysis may be confounded due 
to functional redundancy between Src family kinases – such that Fyn and Yes will 
still be present when Src is knocked out. 
7.2.3 Investigating the role of autophagy in radiation induced 
survival in FAK -/- and FAK wt cancer cells 
We have reiterated several times that the cellular response to radiation is 
complex. Although we were able to show that activation of p53 led to 
transcriptional upregulation of p21 in FAK -/- cells following exposure to 
radiation, we accepted that this mechanism may only partly explain the 
radioresistant phenotype of this cell line. One cell protective mechanism that 
has provoked increasing levels of interest over the past few years is autophagy. 
This process is not yet fully understood and there is data suggesting that 
autophagy may either promote radiosensitivity (Paglin, Hollister et al. 2001; Zois 
and Koukourakis 2009) or radioresistance (Moretti, Cha et al. 2007; Apel, Herr et 
al. 2008; Lomonaco, Finniss et al. 2009). We are currently exploring whether 
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autophagy is an important means of cell survival in response to ionising radiation 
in the SCC 7.1 cell line.  
The specific reasoning behind this possibility stems from very recent work in this 
laboratory demonstrating increased autophagy in the SCC 7.1 FAK -/- cell line 
(Sandilands, Serrels et al., submitted). Intriguingly, this phenomenon appears to 
be mediated via Src. It was first noted that although the SCC 7.1 FAK -/- and FAK 
wt cells displayed similar levels of Src, activated Src was present at a lower 
level in the FAK -/- cells (Figure 71A). Furthermore, localisation studies 
revealed that the absence of FAK caused a dramatic relocation of Src from focal 
adhesions to distinct intracellular punctate structures (Figure 71B) which were 
shown to represent autophagosomes (Figure 71C). Treatment with an autophagy 
inhibitor restored normal Src localisation and, more importantly, led to 
increased cell death through apoptosis in FAK -/- cells (personal communication 
– Emma Sandilands). Collectively, this data describes a novel form of autophagy 
by which active Src is selectively targeted from focal adhesions to 
autophagosomes, and on for degradation, thus explaining the overall loss of 
active Src from the cell after perturbation of integrin signalling caused by FAK 
deletion. Physiologically, this is needed for these cancer cells to evade cell 
death in the absence of FAK.  
Preliminary investigations are underway to determine whether protein 
expression levels and/or localisation of key autophagy regulators, such as LC3, 
beclin-1 and ATG7, are altered in response to ionising radiation in the SCC 7.1 
FAK -/- and FAK wt cell lines. The definitive experiment, of course, would be to 
inhibit autophagy in combination with radiation in the FAK -/- and FAK wt cell 
lines and evaluate the effect on clonogenicity. The options include the 
commonly used autophagy inhibitor 3MA which has the disadvantage of 
interrupting a large range of intracellular proteins and may not be particularly 
specific or alternatively using siRNA to knockdown autophagy regulators such as 
ATG7.  
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Figure 71 - Active Src is trafficked to autophagosomes in the absence of FAK 
(A) Western blot analysis for FAK, Src and activated Src in FAK -/- and FAK wt cells. β-actin 
loading is also shown. (B) Immunofluorescence analysis demonstrating localisation of FAK and 
activated Src in FAK -/- and FAK wt cells, FAK – red and pSrc-Y416 – green, arrows demonstrating 
punctuate distribution of activated Src in FAK -/- cells (scale bar, 20µm). (C) Cells were fixed and 
stained for pSrc-Y416 (red) and LC3B (green), complete arrows represent co-localisation at focal 
adhesions while broken arrows in zoomed image show co-localisation in puncta. Experiment 
courtesy of E Sandilands. 
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7.2.4 Exploring the role of FAK in normal tissue radiosensitivity 
Our results demonstrated a negative effect on radiosensitivity following fak 
deletion in a squamous cell carcinoma cell line. This has provided a new insight 
into the role of FAK in cellular radiation survival and the relationship between 
FAK and p53. Should future work confirm that manipulating FAK levels and / or 
activity in combination with radiation is advantageous in certain cell lines 
and/or tumour types, there are a number of important questions that would 
need to be addressed before considering progression into the clinical phase of 
investigation. For instance, which patients would be most likely to benefit and 
would this depend on tumour type alone? If not, would patient selection be 
based at the molecular level and if so, what molecular signature would predict 
response? Is it likely to be as straightforward as p53 status given the contrasting 
pro-survival and pro-death functions of the wt p53 protein depending on cell line 
and context, coupled with the vast number of potential p53 mutations and their 
diverse (and often largely unknown) properties? There are also issues regarding 
the best form of pharmacological approach – would this entail the use of a 
protein-protein interaction inhibitor which is complex to develop or a small 
molecule tyrosine kinase inhibitor, several of which are already in existence, and 
would this depend on the treatment context? Also, are FAK inhibitors safe in the 
long term or will they induce dormancy, allowing late reactivation of tumour cell 
activity? 
Finally, how will altered FAK levels affect normal tissue response to radiation? It 
is slightly concerning that Ashton et al. have just reported that FAK is necessary 
for intestinal regeneration following irradiation of mouse gut (Ashton, Morton et 
al. 2010). However, their findings were based on a background of genetic 
deletion and perhaps low levels of FAK protein as opposed to FAK deletion would 
be sufficient to prevent this. Interestingly, it has been proposed that cells with a 
high turnover may be more susceptible to FAK inhibition due to the role of FAK 
in focal adhesion turnover. If the gut is definitely intolerant of low FAK levels 
and/or activity, then it may be necessary to focus combination regimens at 
other sites. Towards the end of this project, we did some work looking at 
whether FAK mediates radiation survival in fibroblasts, using FAK +/+ and FAK    
-/- MEFs. Preliminary data indicates that the presence or absence of FAK has no 
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effect on radiosensitivity in these cells (Figure 72). This suggests that some 
normal tissues may not be compromised by FAK inhibition or FAK loss in the 
context of radiation induced DNA damage. However, it is important to point out 
that the MEFs are deficient in p53. Hence, the possibility of a completely 
different outcome in vivo in the presence of wt p53 must be considered, 
although this is difficult to test.  
Also, the FAK -/- MEFs have upregulation of Pyk2 (this was not evident in our SCC 
cells) and in the MEFs it is possible that Pyk2 may compensate for the loss of 
FAK. Currently, there is no data in the literature regarding Pyk2 and cellular 
radiation response. Intriguingly, it has just recently been reported that Pyk2 can 
facilitate cell survival in FAK-/- / p21-/- MEFs by translocation to the nucleus 
and limiting levels of p53 in a FERM domain–dependent manner (Lim, Miller et al. 
2010). While this highlights some important similarities in the function of FAK 
and Pyk2, obviously a Pyk2 mediated effect on p53 would not explain our 
radiation findings in the MEFs based on their p53 null background.  It may be the 
case that Pyk2 (and FAK) have significant p53-independent influences on cell 
survival that have yet to be fully explored.  
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Figure 72 - FAK is not an important mediator of radiosensitivity in MEFs 
(A) Western blot analysis of FAK and Pyk2 protein levels in MEFs. (B) FAK +/+ and FAK -/- MEFs 
were irradiated (0, 2Gy, 4Gy and 6Gy), immediately trypsinised and seeded into 60mm dishes at a 
density that would permit colony growth of 50–150 colonies per plate. After seven days the plates 
were fixed in methanol and stained with crystal violet. The numbers of colonies per plate were 
counted under low power microscopy and surviving fraction calculated at each dose of radiation. 
Results shown represent mean ± SEM from two combined experiments.  
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Final Comment 
I have now returned to clinical practice and in my future career as a clinical 
oncologist I look forward to contributing to the development of radiotherapy 
practice. Whilst there are ever increasing technological advances in radiotherapy 
planning and delivery (even in the four years I spent out of practice), the 
research work that I described here has made me much more aware of the 
complexity that underpins the biological effects of radiation at the cellular 
level. Understanding this complexity and being cogniscent of the potential 
context specificity of the various putative novel radiosensitising targets is crucial 
if radiotherapy is to be successfully combined with targeted therapies. It is likely 
that the effects of targeted agents in combination with radiation will be tumour 
type specific, or may even be dependent on patient-specific response factors. 
This highlights the need for further and extensive basic laboratory research in 
order to develop informative biomarkers of response and/or predictive assays, 
such that the optimal combined treatment could be offered to each individual 
patient.  
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Appendix 1 – Development of 83320 murine pancreatic cancer cell line      
(A) Targeting expression of p53 (R172H) and K-Ras (G12D) to the mouse pancreas results in the 
formation of invasive carcinomas (Hingorani, Wang et al. 2005). (B) A cell line was derived from a 
mouse pancreatic tumour – 83320; a phase contrast image is shown. (C) This cell line 
demonstrated high levels of nuclear p53 on immunofluorescence in keeping with an accumulating 
mutation of p53. (D) Sequencing analysis was carried out on the p53 DNA binding domain in 
mouse keratinocytes (left) and 83320 cells (right). This revealed a G-A base change at codon 172 
in 83320 cells in keeping with the presence of R172H mutation. 
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171              172                173
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